US20220256823A1 - Compositions and methods for characterizing a microbiome - Google Patents
Compositions and methods for characterizing a microbiome Download PDFInfo
- Publication number
- US20220256823A1 US20220256823A1 US17/673,581 US202217673581A US2022256823A1 US 20220256823 A1 US20220256823 A1 US 20220256823A1 US 202217673581 A US202217673581 A US 202217673581A US 2022256823 A1 US2022256823 A1 US 2022256823A1
- Authority
- US
- United States
- Prior art keywords
- disease
- elegans
- condition
- microbiome
- microbial strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims description 73
- 244000005700 microbiome Species 0.000 title abstract description 151
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 252
- 230000000813 microbial effect Effects 0.000 claims abstract description 214
- 201000010099 disease Diseases 0.000 claims abstract description 204
- 208000035475 disorder Diseases 0.000 claims abstract description 48
- 208000024827 Alzheimer disease Diseases 0.000 claims description 76
- 238000011282 treatment Methods 0.000 claims description 35
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 32
- 230000037361 pathway Effects 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 230000004770 neurodegeneration Effects 0.000 claims description 21
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 20
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 20
- 241001509489 Terrisporobacter glycolicus Species 0.000 claims description 11
- 241000711810 Coprococcus sp. Species 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 10
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 241000589216 Komagataeibacter hansenii Species 0.000 claims description 10
- 241000592795 Paenibacillus sp. Species 0.000 claims description 10
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 241000093740 Acidaminococcus sp. Species 0.000 claims description 9
- 244000063299 Bacillus subtilis Species 0.000 claims description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 9
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- 241000193171 Clostridium butyricum Species 0.000 claims description 9
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 9
- 241001331543 Veillonella sp. Species 0.000 claims description 9
- 230000002950 deficient Effects 0.000 claims description 9
- 241000131482 Bifidobacterium sp. Species 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 abstract description 105
- 241000282414 Homo sapiens Species 0.000 description 113
- 241001465754 Metazoa Species 0.000 description 90
- 239000005090 green fluorescent protein Substances 0.000 description 61
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 36
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 36
- 102000013498 tau Proteins Human genes 0.000 description 34
- 108010026424 tau Proteins Proteins 0.000 description 34
- -1 Acp Chemical compound 0.000 description 33
- 206010033799 Paralysis Diseases 0.000 description 29
- 239000000523 sample Substances 0.000 description 29
- 241000124008 Mammalia Species 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 22
- 235000013305 food Nutrition 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 101710095339 Apolipoprotein E Proteins 0.000 description 18
- 102100029470 Apolipoprotein E Human genes 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 150000003384 small molecules Chemical class 0.000 description 14
- 101100368940 Caenorhabditis elegans tbb-2 gene Proteins 0.000 description 13
- 241001167795 Escherichia coli OP50 Species 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 244000005702 human microbiome Species 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 101100011377 Caenorhabditis elegans egl-9 gene Proteins 0.000 description 11
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000013074 reference sample Substances 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 8
- 241000605862 Porphyromonas gingivalis Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 102000057063 human MAPT Human genes 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 241001240954 Escherichia albertii Species 0.000 description 7
- 241000588720 Escherichia fergusonii Species 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 108090000848 Ubiquitin Proteins 0.000 description 7
- 102000044159 Ubiquitin Human genes 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 229960000074 biopharmaceutical Drugs 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 150000005829 chemical entities Chemical class 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000010196 hermaphroditism Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000013011 mating Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000002407 ATP formation Effects 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 5
- 101100422780 Caenorhabditis elegans sur-5 gene Proteins 0.000 description 5
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 5
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 5
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000588749 Klebsiella oxytoca Species 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000244206 Nematoda Species 0.000 description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 5
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 5
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 230000003959 neuroinflammation Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000017448 oviposition Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 101150114748 unc-119 gene Proteins 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 4
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 4
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 235000021436 nutraceutical agent Nutrition 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 101150037123 APOE gene Proteins 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000588813 Alcaligenes faecalis Species 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 241000244203 Caenorhabditis elegans Species 0.000 description 3
- 101100528916 Caenorhabditis elegans rol-6 gene Proteins 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 3
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 241000282324 Felis Species 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 241001288016 Streptococcus gallolyticus Species 0.000 description 3
- 208000034799 Tauopathies Diseases 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229940005347 alcaligenes faecalis Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000007960 cellular response to stress Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SMWADGDVGCZIGK-AXDSSHIGSA-N (2s)-5-phenylpyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)CCC1C1=CC=CC=C1 SMWADGDVGCZIGK-AXDSSHIGSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 241000588626 Acinetobacter baumannii Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101800001718 Amyloid-beta protein Proteins 0.000 description 2
- 241001584951 Anaerostipes hadrus Species 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000123777 Blautia obeum Species 0.000 description 2
- 101100372902 Caenorhabditis elegans vha-6 gene Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000588919 Citrobacter freundii Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241001531275 Faecalitalea cylindroides Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241001134569 Flavonifractor plautii Species 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 241000032681 Gluconacetobacter Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000186399 Holdemanella biformis Species 0.000 description 2
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 2
- 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 2
- 241001674997 Hungatella hathewayi Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 2
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101001087410 Mus musculus Tyrosine-protein phosphatase non-receptor type 18 Proteins 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000193465 Paeniclostridium sordellii Species 0.000 description 2
- 102100022033 Presenilin-1 Human genes 0.000 description 2
- 102100022036 Presenilin-2 Human genes 0.000 description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 241000203719 Rothia dentocariosa Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 102100025639 Sortilin-related receptor Human genes 0.000 description 2
- 101710126735 Sortilin-related receptor Proteins 0.000 description 2
- 241000192087 Staphylococcus hominis Species 0.000 description 2
- 241001501869 Streptococcus pasteurianus Species 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- 241000194051 Streptococcus vestibularis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241001531188 [Eubacterium] rectale Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000007792 alzheimer disease pathology Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000002715 bioenergetic effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000007418 data mining Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000010235 enterohepatic circulation Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000010448 genetic screening Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000652 hormesis Toxicity 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 230000006951 hyperphosphorylation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241001430193 Absiella dolichum Species 0.000 description 1
- 241001531194 Absiella tortuosum Species 0.000 description 1
- 241000193451 Acetoanaerobium sticklandii Species 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241000915445 Acetobacterium tundrae Species 0.000 description 1
- 241001584692 Acetomicrobium hydrogeniformans Species 0.000 description 1
- 241000581735 Achromobacter aegrifaciens Species 0.000 description 1
- 241000581742 Achromobacter insuavis Species 0.000 description 1
- 241001250076 Achromobacter piechaudii Species 0.000 description 1
- 241001673062 Achromobacter xylosoxidans Species 0.000 description 1
- 241000604451 Acidaminococcus Species 0.000 description 1
- 241000604450 Acidaminococcus fermentans Species 0.000 description 1
- 241001116699 Acidaminococcus intestini Species 0.000 description 1
- 241000122230 Acinetobacter junii Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241001147825 Actinomyces sp. Species 0.000 description 1
- 241000549949 Agathobaculum butyriciproducens Species 0.000 description 1
- 241001531272 Agathobaculum desmolans Species 0.000 description 1
- 241000606806 Aggregatibacter segnis Species 0.000 description 1
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 241001580959 Alistipes finegoldii Species 0.000 description 1
- 241000801627 Alistipes indistinctus Species 0.000 description 1
- 241000030713 Alistipes onderdonkii Species 0.000 description 1
- 241001135230 Alistipes putredinis Species 0.000 description 1
- 241000030716 Alistipes shahii Species 0.000 description 1
- 241001258672 Allisonella histaminiformans Species 0.000 description 1
- 241001288806 Alloprevotella tannerae Species 0.000 description 1
- 206010072599 Amyloid related imaging abnormalities Diseases 0.000 description 1
- 241001464907 Anaerococcus hydrogenalis Species 0.000 description 1
- 241000530054 Anaerococcus octavius Species 0.000 description 1
- 241001464890 Anaerococcus prevotii Species 0.000 description 1
- 241001464898 Anaerococcus tetradius Species 0.000 description 1
- 241001464864 Anaerococcus vaginalis Species 0.000 description 1
- 241000193457 Anaerocolumna aminovalerica Species 0.000 description 1
- 241001446754 Anaerocolumna xylanovorans Species 0.000 description 1
- 241000511622 Anaerofilum agile Species 0.000 description 1
- 241001580965 Anaerofustis stercorihominis Species 0.000 description 1
- 241000081343 Anaerosporobacter mobilis Species 0.000 description 1
- 241001227086 Anaerostipes Species 0.000 description 1
- 241000100356 Anaerostipes rhamnosivorans Species 0.000 description 1
- 241000319947 Anaerotignum lactatifermentans Species 0.000 description 1
- 241001136167 Anaerotignum propionicum Species 0.000 description 1
- 241000428313 Anaerotruncus colihominis Species 0.000 description 1
- 241001558987 Anaerovorax odorimutans Species 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 241001135164 Arcobacter butzleri Species 0.000 description 1
- 241000882105 Asaccharobacter celatus Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193838 Atopobium parvulum Species 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000906059 Bacillus pseudomycoides Species 0.000 description 1
- 241000012248 Bacillus toyonensis Species 0.000 description 1
- 241000790486 Bacillus wiedmannii Species 0.000 description 1
- 241000217846 Bacteroides caccae Species 0.000 description 1
- 241001032450 Bacteroides cellulosilyticus Species 0.000 description 1
- 241000801600 Bacteroides clarus Species 0.000 description 1
- 241001220439 Bacteroides coprocola Species 0.000 description 1
- 241000545821 Bacteroides coprophilus Species 0.000 description 1
- 241001105998 Bacteroides dorei Species 0.000 description 1
- 241001135322 Bacteroides eggerthii Species 0.000 description 1
- 241000956551 Bacteroides faecis Species 0.000 description 1
- 241000402140 Bacteroides finegoldii Species 0.000 description 1
- 241000801629 Bacteroides fluxus Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000047484 Bacteroides intestinalis Species 0.000 description 1
- 241001122266 Bacteroides nordii Species 0.000 description 1
- 241000801630 Bacteroides oleiciplenus Species 0.000 description 1
- 241001135228 Bacteroides ovatus Species 0.000 description 1
- 241001220441 Bacteroides plebeius Species 0.000 description 1
- 241000168636 Bacteroides salanitronis Species 0.000 description 1
- 241001122267 Bacteroides salyersiae Species 0.000 description 1
- 241000204294 Bacteroides stercoris Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606219 Bacteroides uniformis Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 241000115153 Bacteroides xylanisolvens Species 0.000 description 1
- 241000260432 Barnesiella intestinihominis Species 0.000 description 1
- 241000567117 Bartonella clarridgeiae Species 0.000 description 1
- 241000785907 Bartonella quintana str. Toulouse Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186014 Bifidobacterium angulatum Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241000186022 Bifidobacterium coryneforme Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241000529097 Bifidobacterium faecale Species 0.000 description 1
- 241001312346 Bifidobacterium gallicum Species 0.000 description 1
- 241000186147 Bifidobacterium longum subsp. suis Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 241001495172 Bilophila wadsworthia Species 0.000 description 1
- 241000206827 Bittarella massiliensis Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 241000335561 Blautia faecis Species 0.000 description 1
- 241001449840 Blautia glucerasea Species 0.000 description 1
- 241000194002 Blautia hansenii Species 0.000 description 1
- 241000520742 Blautia hydrogenotrophica Species 0.000 description 1
- 241000028537 Blautia luti Species 0.000 description 1
- 241001464894 Blautia producta Species 0.000 description 1
- 241001051189 Blautia schinkii Species 0.000 description 1
- 241000335560 Blautia stercoris Species 0.000 description 1
- 241001038648 Blautia wexlerae Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000589174 Bradyrhizobium japonicum Species 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 241001646647 Burkholderia ambifaria Species 0.000 description 1
- 241000371430 Burkholderia cenocepacia Species 0.000 description 1
- 241000589638 Burkholderia glumae Species 0.000 description 1
- 241000020731 Burkholderia multivorans Species 0.000 description 1
- 241000134107 Burkholderia plantarii Species 0.000 description 1
- 241001539336 Butyricicoccus faecihominis Species 0.000 description 1
- 241000301580 Butyricicoccus pullicaecorum Species 0.000 description 1
- 241001264133 Butyricimonas faecihominis Species 0.000 description 1
- 241001264107 Butyricimonas paravirosa Species 0.000 description 1
- 241000132393 Butyricimonas virosa Species 0.000 description 1
- 241000193174 Butyrivibrio crossotus Species 0.000 description 1
- 102100027557 Calcipressin-1 Human genes 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589873 Campylobacter concisus Species 0.000 description 1
- 241000589985 Campylobacter curvus Species 0.000 description 1
- 241000606208 Campylobacter gracilis Species 0.000 description 1
- 241001290832 Campylobacter hominis Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000589992 Campylobacter showae Species 0.000 description 1
- 241001135528 Campylobacter upsaliensis Species 0.000 description 1
- 241001234025 Candidatus Dorea massiliensis Species 0.000 description 1
- 241001234035 Candidatus Stoquefichus massiliensis Species 0.000 description 1
- 241000190888 Capnocytophaga gingivalis Species 0.000 description 1
- 241000190882 Capnocytophaga sputigena Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000207206 Cardiobacterium Species 0.000 description 1
- 241000207210 Cardiobacterium hominis Species 0.000 description 1
- 241001443867 Catenibacterium mitsuokai Species 0.000 description 1
- 241000159549 Catonella morbi Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000043249 Cedecea lapagei Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001494522 Citrobacter amalonaticus Species 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 241000920610 Citrobacter youngae Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000186542 Clostridium baratii Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241001147706 Clostridium sardiniense Species 0.000 description 1
- 241000744741 Clostridium saudiense Species 0.000 description 1
- 241000193470 Clostridium sporogenes Species 0.000 description 1
- 241000186528 Clostridium tertium Species 0.000 description 1
- 241000192020 Clostridium ventriculi Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241001262170 Collinsella aerofaciens Species 0.000 description 1
- 241001330547 Collinsella intestinalis Species 0.000 description 1
- 241001330548 Collinsella stercoris Species 0.000 description 1
- 241000801626 Collinsella tanakaei Species 0.000 description 1
- 241001443880 Coprobacillus cateniformis Species 0.000 description 1
- 241001592881 Coprobacter fastidiosus Species 0.000 description 1
- 241000220677 Coprococcus catus Species 0.000 description 1
- 241000949098 Coprococcus comes Species 0.000 description 1
- 241001464949 Coprococcus eutactus Species 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241000158508 Corynebacterium amycolatum Species 0.000 description 1
- 241000158496 Corynebacterium matruchotii Species 0.000 description 1
- 241001518270 Corynebacterium pseudogenitalium Species 0.000 description 1
- 241001518263 Corynebacterium tuberculostearicum Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241001464974 Cutibacterium avidum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 241000579714 Deinococcus grandis Species 0.000 description 1
- 241000192091 Deinococcus radiodurans Species 0.000 description 1
- 241001508479 Dermabacter hominis Species 0.000 description 1
- 241001189626 Desulfovibrio legallii Species 0.000 description 1
- 241000604463 Desulfovibrio piger Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241001624700 Dialister invisus Species 0.000 description 1
- 241000982523 Dialister micraerophilus Species 0.000 description 1
- 241000260433 Dialister succinatiphilus Species 0.000 description 1
- 241000995910 Dielma fastidiosa Species 0.000 description 1
- 241001531200 Dorea formicigenerans Species 0.000 description 1
- 241000016537 Dorea longicatena Species 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000365095 Dysgonomonas mossii Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241001657508 Eggerthella lenta Species 0.000 description 1
- 241000988238 Eggerthella sinensis Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000291067 Enhydrobacter aerosaccus Species 0.000 description 1
- 241000881810 Enterobacter asburiae Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241001217893 Enterobacter ludwigii Species 0.000 description 1
- 241000962426 Enterobacter xiangfangensis Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000580502 Enterococcus asini Species 0.000 description 1
- 241001468179 Enterococcus avium Species 0.000 description 1
- 241001522957 Enterococcus casseliflavus Species 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 241000194030 Enterococcus gallinarum Species 0.000 description 1
- 241000520134 Enterococcus mundtii Species 0.000 description 1
- 241001235138 Enterococcus raffinosus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 1
- 241000711946 Erysipelotrichaceae bacterium Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000520740 Eubacterium callanderi Species 0.000 description 1
- 241000186398 Eubacterium limosum Species 0.000 description 1
- 241000186401 Eubacterium oxidoreducens Species 0.000 description 1
- 241001531190 Eubacterium ramulus Species 0.000 description 1
- 241000143590 Eubacterium ruminantium Species 0.000 description 1
- 241001531192 Eubacterium ventriosum Species 0.000 description 1
- 241001531182 Eubacterium xylanophilum Species 0.000 description 1
- 241000670472 Exiguobacterium mexicanum Species 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 241001531274 Faecalicatena contorta Species 0.000 description 1
- 241000186589 Faecalicatena orotica Species 0.000 description 1
- 241000194000 Faecalicoccus pleomorphus Species 0.000 description 1
- 241000192016 Finegoldia magna Species 0.000 description 1
- 241000755562 Flintibacter butyricus Species 0.000 description 1
- 206010049238 Food aversion Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 241001365051 Fusicatenibacter saccharivorans Species 0.000 description 1
- 241000605908 Fusobacterium gonidiaformans Species 0.000 description 1
- 241000605956 Fusobacterium mortiferum Species 0.000 description 1
- 241000605991 Fusobacterium ulcerans Species 0.000 description 1
- 241000605975 Fusobacterium varium Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 241000193814 Gemella haemolysans Species 0.000 description 1
- 241001657446 Gemella sanguinis Species 0.000 description 1
- 241001223495 Gemmiger formicilis Species 0.000 description 1
- 241000589236 Gluconobacter Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 241001486261 Gordonibacter pamelaeae Species 0.000 description 1
- 241000201858 Granulicatella adiacens Species 0.000 description 1
- 241000607259 Grimontia hollisae Species 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 241000752432 Harryflintia acetispora Species 0.000 description 1
- 241001503513 Helicobacter bilis Species 0.000 description 1
- 241000557057 Helicobacter bizzozeronii Species 0.000 description 1
- 241000543133 Helicobacter canadensis Species 0.000 description 1
- 241000590014 Helicobacter cinaedi Species 0.000 description 1
- 241001495141 Helicobacter pullorum Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000027130 Helicobacter winghamensis Species 0.000 description 1
- 241000862470 Holdemania filiformis Species 0.000 description 1
- 241000956013 Holdemania massiliensis Species 0.000 description 1
- 101000580357 Homo sapiens Calcipressin-1 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 241001523756 Hungatella effluvii Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 241000946243 Intestinimonas butyriciproducens Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241000589012 Kingella oralis Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241001534204 Klebsiella pneumoniae subsp. rhinoscleromatis Species 0.000 description 1
- 241000348358 Klebsiella quasipneumoniae subsp. quasipneumoniae Species 0.000 description 1
- 241001014264 Klebsiella variicola Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 241001180676 Lachnoanaerobaculum saburreum Species 0.000 description 1
- 241001233594 Lachnobacterium bovis Species 0.000 description 1
- 241001134640 Lachnospira multipara Species 0.000 description 1
- 241001134642 Lachnospira pectinoschiza Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241001647783 Lactobacillus amylolyticus Species 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000316282 Lactobacillus antri Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186842 Lactobacillus coryniformis Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001060359 Lactobacillus delbrueckii subsp. indicus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186839 Lactobacillus fructivorans Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186685 Lactobacillus hilgardii Species 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000394636 Lactobacillus mucosae Species 0.000 description 1
- 241000186784 Lactobacillus oris Species 0.000 description 1
- 241000183331 Lactobacillus paracasei subsp. tolerans Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 244000164595 Lactobacillus plantarum subsp plantarum Species 0.000 description 1
- 235000012523 Lactobacillus plantarum subsp plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241001438705 Lactobacillus rogosae Species 0.000 description 1
- 241000186870 Lactobacillus ruminis Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000316280 Lactobacillus ultunensis Species 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 241000500213 Lactococcus formosensis Species 0.000 description 1
- 241000194040 Lactococcus garvieae Species 0.000 description 1
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 1
- 241000123728 Leptotrichia buccalis Species 0.000 description 1
- 241000029588 Leptotrichia hofstadii Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 241000186806 Listeria grayi Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241001140861 Longicatena caecimuris Species 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000425724 Marvinbryantia formatexigens Species 0.000 description 1
- 241000096799 Megamonas funiformis Species 0.000 description 1
- 241000550893 Megamonas rupellensis Species 0.000 description 1
- 241000604448 Megasphaera elsdenii Species 0.000 description 1
- 241000440950 Megasphaera indica Species 0.000 description 1
- 241001116693 Megasphaera micronuciformis Species 0.000 description 1
- 241000769329 Megasphaera paucivorans Species 0.000 description 1
- 241000202985 Methanobrevibacter smithii Species 0.000 description 1
- 241001064129 Methanomassiliicoccus luminyensis Species 0.000 description 1
- 241000204676 Methanosphaera stadtmanae Species 0.000 description 1
- 241001430258 Methylobacterium radiotolerans Species 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241001123604 Mitsuokella jalaludinii Species 0.000 description 1
- 241000509622 Mitsuokella multacida Species 0.000 description 1
- 241000203732 Mobiluncus mulieris Species 0.000 description 1
- 241001494429 Mogibacterium timidum Species 0.000 description 1
- 241001670206 Mogibacterium vescum Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241001052646 Morganella morganii subsp. morganii Species 0.000 description 1
- 241000373884 Murdochiella asaccharolytica Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241001508003 Mycobacterium abscessus Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588654 Neisseria cinerea Species 0.000 description 1
- 241000588651 Neisseria flavescens Species 0.000 description 1
- 241000588674 Neisseria macacae Species 0.000 description 1
- 241000588659 Neisseria mucosa Species 0.000 description 1
- 241000588645 Neisseria sicca Species 0.000 description 1
- 241001136170 Neisseria subflava Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000605156 Nitrobacter hamburgensis Species 0.000 description 1
- 241000605154 Nitrobacter winogradskyi Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000801628 Odoribacter laneus Species 0.000 description 1
- 241001135232 Odoribacter splanchnicus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000990071 Olsenella profusa Species 0.000 description 1
- 241000973582 Olsenella scatoligenes Species 0.000 description 1
- 241000927555 Olsenella uli Species 0.000 description 1
- 241000675114 Oribacterium sinus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001467886 Oscillibacter ruminantium Species 0.000 description 1
- 241001042460 Oscillibacter valericigenes Species 0.000 description 1
- 241000266823 Oscillospira guilliermondii Species 0.000 description 1
- 241000605936 Oxalobacter formigenes Species 0.000 description 1
- 241000708785 Paenibacillus barengoltzii Species 0.000 description 1
- 241000189604 Paenibacillus jamilae Species 0.000 description 1
- 241000706216 Paenibacillus kribbensis Species 0.000 description 1
- 241000220897 Paenibacillus riograndensis Species 0.000 description 1
- 241000179796 Paenisporosarcina Species 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 241000030714 Parabacteroides goldsteinii Species 0.000 description 1
- 241001216709 Parabacteroides gordonii Species 0.000 description 1
- 241000543747 Parabacteroides johnsonii Species 0.000 description 1
- 241000204306 Parabacteroides merdae Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000374256 Peptoniphilus duerdenii Species 0.000 description 1
- 241000937481 Peptoniphilus grossensis Species 0.000 description 1
- 241000530062 Peptoniphilus harei Species 0.000 description 1
- 241001464878 Peptoniphilus indolicus Species 0.000 description 1
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241001464924 Phascolarctobacterium faecium Species 0.000 description 1
- 241000801571 Phascolarctobacterium succinatutens Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001135211 Porphyromonas asaccharolytica Species 0.000 description 1
- 241001135213 Porphyromonas endodontalis Species 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 241001135215 Prevotella bivia Species 0.000 description 1
- 241001135217 Prevotella buccae Species 0.000 description 1
- 241000385060 Prevotella copri Species 0.000 description 1
- 241001135219 Prevotella disiens Species 0.000 description 1
- 241001141018 Prevotella marshii Species 0.000 description 1
- 241001135223 Prevotella melaninogenica Species 0.000 description 1
- 241001135225 Prevotella nigrescens Species 0.000 description 1
- 241000864367 Prevotella pallens Species 0.000 description 1
- 241000331195 Prevotella salivae Species 0.000 description 1
- 241001430102 Prevotella stercorea Species 0.000 description 1
- 241000530934 Prevotella timonensis Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241001472782 Proteus penneri Species 0.000 description 1
- 241000576783 Providencia alcalifaciens Species 0.000 description 1
- 241000588777 Providencia rettgeri Species 0.000 description 1
- 241000043392 Providencia rustigianii Species 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- 241001528479 Pseudoflavonifractor capillosus Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000529919 Ralstonia sp. Species 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000187561 Rhodococcus erythropolis Species 0.000 description 1
- 241001052237 Robinsoniella peoriensis Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 241000605944 Roseburia cecicola Species 0.000 description 1
- 241000872831 Roseburia faecis Species 0.000 description 1
- 241000872832 Roseburia hominis Species 0.000 description 1
- 241000398180 Roseburia intestinalis Species 0.000 description 1
- 241001394655 Roseburia inulinivorans Species 0.000 description 1
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 1
- 241000192029 Ruminococcus albus Species 0.000 description 1
- 241000123753 Ruminococcus bromii Species 0.000 description 1
- 241000123754 Ruminococcus callidus Species 0.000 description 1
- 241000291327 Ruminococcus faecis Species 0.000 description 1
- 241000202356 Ruminococcus lactaris Species 0.000 description 1
- 241000190045 Ruthenibacterium lactatiformans Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241001601862 Sellimonas intestinalis Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 241000607766 Shigella boydii Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241001374825 Slackia faecicanis Species 0.000 description 1
- 241001191217 Slackia isoflavoniconvertens Species 0.000 description 1
- 241000801625 Slackia piriformis Species 0.000 description 1
- 241001464874 Solobacterium moorei Species 0.000 description 1
- 241000246348 Sporosarcina sp. Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001147695 Staphylococcus caprae Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 1
- 241000192086 Staphylococcus warneri Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241000172191 Streptococcus anginosus subsp. whileyi Species 0.000 description 1
- 241000176094 Streptococcus australis Species 0.000 description 1
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 1
- 241000193992 Streptococcus downei Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241001147754 Streptococcus gordonii str. Challis Species 0.000 description 1
- 241001473878 Streptococcus infantarius Species 0.000 description 1
- 241000960363 Streptococcus infantis Species 0.000 description 1
- 241000194046 Streptococcus intermedius Species 0.000 description 1
- 241001308339 Streptococcus lactarius Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241001617354 Streptococcus lutetiensis Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193991 Streptococcus parasanguinis Species 0.000 description 1
- 241000377364 Streptococcus rubneri Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241001580973 Subdoligranulum variabile Species 0.000 description 1
- 241000801622 Succinatimonas hippei Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000096798 Sutterella parvirubra Species 0.000 description 1
- 241000644554 Sutterella stercoricanis Species 0.000 description 1
- 241000123713 Sutterella wadsworthensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001678097 Turicibacter sanguinis Species 0.000 description 1
- 241001147795 Tyzzerella nexilis Species 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000935255 Ureaplasma parvum Species 0.000 description 1
- 241001126386 Vagococcus penaei Species 0.000 description 1
- 241001085082 Varibaculum cambriense Species 0.000 description 1
- 241001533207 Veillonella atypica Species 0.000 description 1
- 241001533204 Veillonella dispar Species 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- 241001341704 Veillonella rogosae Species 0.000 description 1
- 241001592639 Veillonella tobetsuensis Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241001148070 Vibrio furnissii Species 0.000 description 1
- 241000607253 Vibrio mimicus Species 0.000 description 1
- 241000703751 Victivallis vadensis Species 0.000 description 1
- 241000975185 Weissella cibaria Species 0.000 description 1
- 241000186675 Weissella confusa Species 0.000 description 1
- 241000192133 Weissella paramesenteroides Species 0.000 description 1
- 241000607735 Xenorhabdus nematophila Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 241000514948 [Bacteroides] pectinophilus Species 0.000 description 1
- 241001509492 [Clostridium] aerotolerans Species 0.000 description 1
- 241001118737 [Clostridium] aldenense Species 0.000 description 1
- 241000193458 [Clostridium] aminophilum Species 0.000 description 1
- 241001350461 [Clostridium] amygdalinum Species 0.000 description 1
- 241000342876 [Clostridium] asparagiforme Species 0.000 description 1
- 241001118742 [Clostridium] citroniae Species 0.000 description 1
- 241000854263 [Clostridium] clariflavum Species 0.000 description 1
- 241000186561 [Clostridium] clostridioforme Species 0.000 description 1
- 241000985257 [Clostridium] cocleatum Species 0.000 description 1
- 241001509494 [Clostridium] colinum Species 0.000 description 1
- 241000696045 [Clostridium] glycyrrhizinilyticum Species 0.000 description 1
- 241001531305 [Clostridium] herbivorans Species 0.000 description 1
- 241000030487 [Clostridium] hiranonis Species 0.000 description 1
- 241000030493 [Clostridium] hylemonae Species 0.000 description 1
- 241000193462 [Clostridium] innocuum Species 0.000 description 1
- 241001098250 [Clostridium] lavalense Species 0.000 description 1
- 241000186569 [Clostridium] leptum Species 0.000 description 1
- 241001621904 [Clostridium] methoxybenzovorans Species 0.000 description 1
- 241001656805 [Clostridium] methylpentosum Species 0.000 description 1
- 241001147792 [Clostridium] polysaccharolyticum Species 0.000 description 1
- 241001509315 [Clostridium] rectum Species 0.000 description 1
- 241000685809 [Clostridium] saccharogumia Species 0.000 description 1
- 241001656794 [Clostridium] saccharolyticum Species 0.000 description 1
- 241001147801 [Clostridium] scindens Species 0.000 description 1
- 241001147717 [Clostridium] sphenoides Species 0.000 description 1
- 241001147796 [Clostridium] spiroforme Species 0.000 description 1
- 241001351214 [Clostridium] straminisolvens Species 0.000 description 1
- 241000193450 [Clostridium] symbiosum Species 0.000 description 1
- 241001147712 [Clostridium] xylanolyticum Species 0.000 description 1
- 241001531273 [Eubacterium] eligens Species 0.000 description 1
- 241001531197 [Eubacterium] hallii Species 0.000 description 1
- 241000557616 [Eubacterium] infirmum Species 0.000 description 1
- 241001531189 [Eubacterium] siraeum Species 0.000 description 1
- 241001282046 [Eubacterium] sulci Species 0.000 description 1
- 241001531183 [Eubacterium] yurii Species 0.000 description 1
- 241000974570 [Propionibacterium] namnetense Species 0.000 description 1
- 241001464867 [Ruminococcus] gnavus Species 0.000 description 1
- 241001464870 [Ruminococcus] torques Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940044726 anaerococcus tetradius Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229940092527 bartonella clarridgeiae Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229940055009 propionibacterium avidum Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000021491 salty snack Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000001963 scanning near-field photolithography Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0335—Genetically modified worms
- A01K67/0336—Genetically modified Nematodes, e.g. Caenorhabditis elegans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/70—Invertebrates
- A01K2227/703—Worms, e.g. Caenorhabdities elegans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
- G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
- G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
Definitions
- Caenorhabditis elegans is a bacteriovorus nematode that is about 1 mm in length and lives in temperate soil environments.
- C. elegans can provide and/or represent surprisingly useful systems for assessing one or more features of a microbial preparation (e.g., of a microbiome sample).
- the present disclosure describes technologies that can be useful for assessing microbiome samples to identify or characterize effects and/or modulation of microbial strains of such microbiome samples on certain diseases or conditions.
- such technologies can be useful to discern strain-level differences in a particular patient or patient population.
- the present disclosure also provides technologies that can be useful to assess the nature of the microbial strains in patient-specific samples and thus provide patient-specific information on how individual patients' microbiomes differentially affect their health conditions.
- technologies provided herein can be useful to identify diseases or conditions to which a patient might be susceptible, based on the nature of the microbial strains in patient-specific samples.
- technologies provided herein can be useful to identify microbial strains in patients that are beneficial, e.g., to protect patients from or confer resistance to certain diseases or conditions.
- technologies described herein are useful as diagnostic tools for screening microbiome samples (e.g., human microbiome samples) for disease modifiers (e.g., microbial strains that affect a disease or condition).
- transgenic C. elegans whole-animal model systems to identify or screen for microbiome strains (e.g., present in human microbiome) that can modulate or affect pathogenesis and/or development of a neurodegenerative disease or condition (e.g., Alzheimer's disease).
- microbiome strains e.g., present in human microbiome
- a neurodegenerative disease or condition e.g., Alzheimer's disease
- neurodegenerative diseases such as Alzheimer's disease as exemplified, but also relating to various other diseases or conditions that may be associated with microbiomes, such as, but not limited to Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, type II diabetes, obesity, hyperglycemia, glucose intolerance, insulin resistance (i.e., hyperinsulinemia, metabolic syndrome, syndrome X), hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia (e.g., dyslipidemia), hypertriglyceridemia, cardiovascular disease, atherosclerosis, peripheral vascular disease, kidney disease, ketoacidosis, thrombotic disorders, nephropathy, diabetic neuropathy, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, glaucoma, sexual dysfunction, dermatopathy, dyspepsia, hypoglycemia
- systems comprising a plurality of C. elegans cultures, wherein each culture comprises a transgenic C. elegans strain that models a disease or condition (e.g., a mammalian disease or condition).
- a plurality of C. elegans cultures may comprise at least 5 or more (including, e.g., at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50 or more) C. elegans cultures.
- one or more of C. elegans cultures in a provided system includes a transgenic C. elegans strain that models a disease or condition present in a target subject.
- one or more of C. elegans cultures in a provided system may include a transgenic C. elegans strain that models a mammalian disease or condition (e.g., a human disease or condition).
- An exemplary human disease or condition to be modeled by C. elegans strains may include a neurodegenerative disease or disorder (e.g., Alzheimer's disease).
- elegans strains may include a disease or condition associated with an altered or defective HIF-1 pathway (e.g. may comprise a cellular stress response).
- the disease or condition to be modeled by C. elegans may be an ocular neovascular disease or disorder (e.g., diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma).
- one or more of C. elegans cultures in a provided system may include a transgenic C.
- elegans that models a non-human mammalian disease or conditions, e.g., a canine, a feline, an equine, a bovine, an ovine, a caprine, or a porcine disease or condition.
- a non-human mammalian disease or conditions e.g., a canine, a feline, an equine, a bovine, an ovine, a caprine, or a porcine disease or condition.
- transgenic C. elegans strains provided in a system described herein may comprise a transgene comprising a characteristic sequence element associated with a target disease or condition (e.g., a mammalian disease or condition).
- a characteristic sequence element that is associated with a disease or condition e.g., a mammalian disease or condition
- a foreign gene e.g., a mammalian gene
- a DNA regulatory element e.g., a mammalian DNA regulatory element
- RNA regulatory element e.g., a mammalian RNA regulatory element
- DNA regulatory elements that are associated with a disease or condition may be or comprise enhancers, promoters, silencers, insulators, locus control regions, and combination thereof.
- RNA regulatory elements such as, e.g., untranslated regions, introns, splice sites, and combinations thereof, which are associated with a disease or condition (e.g., a mammalian disease or condition), may be used in accordance with the present disclosure.
- transgenic C. elegans strains in a provided system may comprise a transgene comprising a reporter gene.
- a reporter gene may include, but are not limited to, fluorescent, phosphorescent, and/or bioluminescent proteins.
- At least two or more of such cultures may each comprise a transgenic C. elegans strain that models the same disease or condition (e.g., a mammalian disease or condition). In some such embodiments, at least two or more of such cultures may each comprise a transgenic C. elegans strain that models a different biochemical or molecular pathway associated with the same disease or condition (e.g., a mammalian disease or condition). In some embodiments involving C. elegans cultures, all of such cultures may each comprise the same transgenic C. elegans strains that model the same disease or condition (e.g., a mammalian disease or condition).
- At least two or more of such cultures may each comprise a transgenic C. elegans strain that models a different disease or condition (e.g., a mammalian disease or condition).
- a transgenic C. elegans strain that models a different disease or condition (e.g., a mammalian disease or condition).
- one or more C. elegans cultures in such a system comprise microbes of a mammalian microbiome (e.g., a human microbiome).
- each of such C. elegans cultures may include microbes of a mammalian microbiome (e.g., a human microbiome).
- microbes cultures in such a system can comprise microbes of a canine, a feline, an equine, a bovine, an ovine, a caprine, or a porcine microbiome.
- Microbiomes used in accordance with the present disclosure may be obtained or derived from target anatomical locations of mammalian subjects. Examples of such microbiomes may include, but are not limited to cutaneous microbiomes, oral microbiomes, nasal microbiomes, gastrointestinal microbiomes, brain microbiomes, pulmonary microbiomes, and/or urogenital microbiomes.
- microbes in each C. elegans culture can comprise one or more microbial strains. In some embodiments, microbes in each culture can comprise a single microbial strain.
- one or more of C. elegans cultures can comprise a therapeutic or nutraceutical agent.
- a method is for screening a microbiome of an individual (e.g., a mammal, e.g., a human) to determine if a microbial strain or a combination of microbial strains affects a mammalian disease or disorder.
- a method is for diagnosing an individual (e.g., a mammal, e.g., a human) based on one or more microbial strains in a microbiome of the individual.
- a method is for monitoring a disease or condition progression in an individual (e.g., a mammal, e.g., a human) based on one or more microbial strains in a microbiome of the individual.
- a is provided method comprising adding microbes obtained from a mammalian microbiome to each of C. elegans cultures of a system described herein.
- microbes in each C. elegans culture can comprise one or more microbial strains.
- microbes in each such culture can comprise a single microbial strain.
- Microbiomes used in methods described herein may be obtained or derived from target anatomical locations of mammalian subjects. Examples of such microbiomes may include, but are not limited to cutaneous microbiomes, oral microbiomes, nasal microbiomes, gastrointestinal microbiomes, brain microbiomes, pulmonary microbiomes, and/or urogenital microbiomes.
- a method may comprise adding a plurality of microbial strains of a mammalian microbiome to a plurality of C. elegans cultures, wherein a different microbial strain is added to each C. elegans culture, and wherein each culture comprises the same transgenic C. elegans strain, and the transgenic C. elegans strain models a mammalian disease or condition.
- one or more of C. elegans cultures can comprise a therapeutic or nutraceutical agent.
- a method described can further comprise adding a therapeutic or nutraceutical agent to one or more of C. elegans cultures.
- a method described herein can further comprise determining one or more parameter values of a transgenic C. elegans strain in each of C. elegans cultures.
- such parameter(s) of a transgenic C. elegans is/are associated with a mammalian disease or condition that such a transgenic C. elegans strain models.
- Exemplary such parameters of transgenic C. elegans may include biological functions or phenotypes and/or levels and/or activity of molecules (e.g., small molecules, proteins, polypeptide, or transcripts) that are associated with a mammalian disease or condition.
- a method may further comprise: (a) determining, before adding a microbial strain to a C. elegans culture, one or more parameter values of the transgenic C. elegans strain in such a culture, (b) determining, after adding the microbial strain to the C. elegans culture, the same one or more parameter values of the transgenic C. elegans strain in such a culture, and (c) comparing the one or more parameter values determined before adding the microbial strain with the one or more parameter values determined after adding the microbial strain.
- a transgenic C. elegans strain involved in systems and methods described herein models a human disease or condition.
- An exemplary human disease or condition that a transgenic C. elegans strain model is Alzheimer's disease.
- a disease or condition (e.g. human disease or condition) that a transgenic C. elegans strain models may include a disease or condition associated with an altered or defective HIF-1 pathway (e.g. may comprise a cellular stress response).
- elegans strain models may be an ocular neovascular disease or disorder (e.g., diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma).
- a disease or condition that a transgenic C. elegans strain models is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
- one aspect provides a method, which comprises (a) adding a microbial strain to a C. elegans culture comprising a transgenic C. elegans strain that models Alzheimer's disease, and (b) determining whether the microbial strain affects one or more parameters of the transgenic C. elegans strain, wherein such one or more parameters are associated with Alzheimer's disease.
- a transgenic C. elegans strain may comprise a transgene encoding a human ssApoE4 protein, a human A ⁇ 1-42 polypeptide, or a human pseudophosphorylated tau protein.
- such a method further comprises: (a) determining, before adding a microbial strain to a C. elegans culture, one or more parameter values of the transgenic C. elegans strain in such a culture, (b) determining, after adding the microbial strain to the C. elegans culture, the same one or more parameter values of the transgenic C. elegans strain in such a culture, and (c) comparing the one or more parameter values determined before adding the microbial strain with the one or more parameter values determined after adding the microbial strain.
- Exemplary such one or more parameters include, but are not limited to, (i) a level of C.
- elegans paralysis (ii) a level of amyloid plaques; (iii) a level of tau filaments; (iv) a level of neuroinflammation; (v) a level of proteasomal function; and/or (vi) a combination thereof.
- the present disclosure provides a method of characterizing a microbial strain of a human biome, comprising: (a) adding the microbial strain to a C. elegans culture comprising a transgenic C. elegans strain that models a disease or condition associated with an altered or defective HIF-1 pathway, and (b) determining whether the microbial strain affects one or more parameters of the transgenic C. elegans strain, wherein the one or more parameters are associated with an altered or defective HIF-1 pathway.
- a transgenic C. elegans strain may comprise a transgene encoding a human prolyl hydroxylase EGLN, a human HIF transcription factor, or a human HIF ⁇ protein.
- such a method further comprises: (a) determining, before adding the microbial strain to a C. elegans culture, one or more parameter values of the transgenic C. elegans strain in the culture, (b) determining, after adding the microbial strain to the C. elegans culture, the same one or more parameter values of the transgenic C. elegans strain in the culture, and (c) comparing the one or more parameter values determined before adding the microbial strain with the one or more parameter values determined after adding the microbial strain.
- Exemplary such one or more parameters include, but are not limited to, (i) a level of neuroinflammation; (ii) a level of proteasomal function; (iii) a level of C. elegans egg-laying rate; and/or (iv) a combination thereof.
- a transgenic C. elegans strain that expresses two or more of (i) a human ssApoE4, (ii) a human A ⁇ 1-42, (iii) a human pseudophosphorylated tau, and (iv) a UbV-GFP proteasomal marker is also within the scope of the present disclosure.
- the present disclosure also describes uses of provided transgenic C. elegans strains, systems, and/or methods to screen a mammalian microbiome for microbial strains that affect a mammalian disease or condition. Also, within the scope of the present disclosure includes uses of provided C. elegans , systems, and/or methods to characterize the effect a microbial strain of a mammalian microbiome has on a mammalian disease or condition. For example, a human microbiome can be screened/characterized using technologies provided herein in accordance with the present disclosure.
- compositions comprising one or more microbial strains.
- a composition provided herein comprises one or more microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein.
- a composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein.
- composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains listed in TABLE 8 below.
- a composition provided herein comprises Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, Acidaminococcus sp., or a combination thereof.
- a combination comprises at least two of, at least three of, at least four of, at least five of, at least six of, at least seven of, at least eight of, at least nine of, or all of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis , and Acidaminococcus sp.
- a composition is a pharmaceutical composition. In some embodiments, a composition is an ingestible item.
- the present disclosure describes, among other things, methods comprising administering a composition described herein.
- a method of treating a disease or condition in a subject comprising administering to a subject in need a composition as described herein.
- a disease or condition is a neurodegenerative disease or disorder.
- a disease or condition is Alzheimer's disease.
- a disease or condition may be associated with an altered or defective HIF-1 pathway.
- a disease or condition may be an ocular neovascular disease or disorder.
- a disease or condition is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma. The present disclosure describes, among other things, uses of compositions described herein.
- a use of a composition as described herein is in the treatment of a disease or condition in a subject.
- a disease or condition is a neurodegenerative disease or disorder.
- a disease or condition is Alzheimer's disease.
- a disease or condition may be associated with an altered or defective HIF-1 pathway.
- a disease or condition may be an ocular neovascular disease or disorder.
- a disease or condition is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
- administration typically refers to the administration of a composition to a subject or system to achieve delivery of an agent to the subject or system.
- the agent is, or is included in, the composition; in some embodiments, the agent is generated through metabolism of the composition or one or more components thereof.
- routes may, in appropriate circumstances, be utilized for administration to a subject, for example a human.
- administration may be ocular, oral, parenteral, topical, etc.
- administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g. intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc.
- bronchial e.g., by bronchial instillation
- buccal which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.
- enteral intra-arterial, intradermal, intragas
- administration is oral administration.
- administration may involve only a single dose.
- administration may involve application of a fixed number of doses.
- administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and/or periodic (e.g., individual doses separated by a common period of time) dosing.
- administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time.
- Administration of cells can be by any appropriate route that results in delivery to a desired location in a subject where at least a portion of the delivered cells or components of the cells remain viable.
- a period of viability of cells after administration to a subject can be as short as a few hours, e.g., twenty-four hours, to a few days, to as long as several years, i.e., long-term engraftment.
- administration comprises delivery of a bacterial extract or preparation comprising one or more bacterial metabolites and/or byproducts but lacking fully viable bacterial cells.
- an analog refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an “analog” shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways.
- an analog is a substance that can be generated from the reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance. In some embodiments, an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.
- Comparable refers to two or more agents, entities, situations, sets of conditions, subjects, etc., that may not be identical to one another but that are sufficiently similar to permit comparison therebetween so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed.
- comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features.
- Conservative refers to instances when describing a conservative amino acid substitution, including a substitution of an amino acid residue by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of interest of a protein, for example, the ability of a receptor to bind to a ligand.
- Examples of groups of amino acids that have side chains with similar chemical properties include: aliphatic side chains such as glycine (Gly, G), alanine (Ala, A), valine (Val, V), leucine (Leu, L), and isoleucine (Ile, I); aliphatic-hydroxyl side chains such as serine (Ser, S) and threonine (Thr, T); amide-containing side chains such as asparagine (Asn, N) and glutamine (Gln, Q); aromatic side chains such as phenylalanine (Phe, F), tyrosine (Tyr, Y), and tryptophan (Trp, W); basic side chains such as lysine (Lys, K), arginine (Arg, R), and histidine (His, H); acidic side chains such as aspartic acid (Asp, D) and glutamic acid (Glu, E); and sulfur-containing side chains such as cysteine (Cys, C) and
- Conservative amino acids substitution groups include, for example, valine/leucine/isoleucine (Val/Leu/Ile, V/L/I), phenylalanine/tyrosine (Phe/Tyr, F/Y), lysine/arginine (Lys/Arg, K/R), alanine/valine (Ala/Val, A/V), glutamate/aspartate (Glu/Asp, E/D), and asparagine/glutamine (Asn/Gln, N/Q).
- a conservative amino acid substitution can be a substitution of any native residue in a protein with alanine, as used in, for example, alanine scanning mutagenesis.
- a conservative substitution is made that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet, G. H. et al., 1992, Science 256:1443-1445, which is incorporated herein by reference in its entirety.
- a substitution is a moderately conservative substitution wherein the substitution has a nonnegative value in the PAM250 log-likelihood matrix.
- Control refers to the art-understood meaning of a “control” being a standard against which results are compared. Typically, controls are used to augment integrity in experiments by isolating variables in order to make a conclusion about such variables.
- a control is a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparator.
- a “control” also includes a “control animal.”
- a “control animal” may have a modification as described herein, a modification that is different as described herein, or no modification (i.e., a wild-type animal).
- a “test” i.e., a variable being tested) is applied.
- a control is a historical control (i.e., of a test or assay performed previously, or an amount or result that is previously known).
- a control is or comprises a printed or otherwise saved record.
- a control may be a positive control or a negative control.
- Determining, measuring, evaluating, assessing, assaying and analyzing are used interchangeably herein to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assaying may be relative or absolute. “Assaying for the presence of” can be determining the amount of something present and/or determining whether or not it is present or absent.
- Dosage form may be used to refer to a physically discrete unit of an agent (e.g., a therapeutic agent) for administration to a subject.
- agent e.g., a therapeutic agent
- each such unit contains a predetermined quantity of agent.
- such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen).
- a therapeutic dosing regimen i.e., a therapeutic dosing regimen.
- the total amount of a therapeutic composition or agent administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.
- Dosing regimen may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time.
- a given agent has a recommended dosing regimen, which may involve one or more doses.
- a dosing regimen comprises a plurality of doses each of which is separated in time from other doses.
- individual doses are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses.
- all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population.
- Engineered refers to the aspect of having been manipulated by the hand of man.
- a cell or organism is considered to be “engineered” if it has been manipulated so that its genetic information is altered (e.g., new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or deletion mutation, or by mating protocols).
- new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or deletion mutation, or by mating protocols.
- progeny of an engineered polynucleotide or cell are typically still referred to as “engineered” even though the actual manipulation was performed on a prior entity.
- Excipient refers to an inactive (e.g., non-therapeutic) agent that may be included in a pharmaceutical composition, for example to provide or contribute to a desired consistency or stabilizing effect.
- suitable pharmaceutical excipients may include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- a “functional” biological molecule is a biological molecule in a form in which it exhibits a property and/or activity by which it is characterized.
- a biological molecule may have two functions (i.e., bifunctional) or many functions (i.e., multifunctional).
- Gene refers to a DNA sequence in a chromosome that codes for a product (e.g., an RNA product and/or a polypeptide product).
- a gene includes coding sequence (i.e., sequence that encodes a particular product).
- a gene includes non-coding sequence.
- a gene may include both coding (e.g., exonic) and non-coding (e.g., intronic) sequence.
- a gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences that, for example, may control or impact one or more aspects of gene expression (e.g., cell-type-specific expression, inducible expression, etc.).
- regulatory sequences e.g., promoters, enhancers, etc.
- intron sequences e.g., cell-type-specific expression, inducible expression, etc.
- an appropriate reference measurement may be or comprise a measurement in a particular system (e.g., in a single individual) under otherwise comparable conditions absent presence of (e.g., prior to and/or after) a particular agent or treatment, or in presence of an appropriate comparable reference agent.
- an appropriate reference measurement may be or comprise a measurement in comparable system known or expected to respond in a particular way, in presence of the relevant agent or treatment.
- an appropriate reference is a negative reference; in some embodiments, an appropriate reference is a positive reference.
- Isolated refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man.
- an isolated substance or entity may be enriched; in some embodiments, an isolated substance or entity may be pure.
- isolated substances and/or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated.
- isolated agents are about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure.
- a substance is “pure” if it is substantially free of other components.
- a substance may still be considered “enriched”, “isolated” or even “pure”, after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, percent isolation or purity of the substance is calculated without including such carriers or excipients.
- carriers or excipients e.g., buffer, solvent, water, etc.
- percent isolation or purity of the substance is calculated without including such carriers or excipients.
- composition refers to a composition in which an active agent is formulated together with one or more pharmaceutically acceptable carriers.
- the active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population.
- a pharmaceutical composition may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue, capsules, powders, etc.
- an active agent may be or comprise a cell or population of cells (e.g., a culture, for example of an EES microbe); in some embodiments, an active agent may be or comprise an extract or component of a cell or population (e.g., culture) of cells.
- an active agent may be or comprise an isolated, purified, or pure compound. In some embodiments, an active agent may have been synthesized in vitro (e.g., via chemical and/or enzymatic synthesis). In some embodiments, an active agent may be or comprise a natural product (whether isolated from its natural source or synthesized in vitro).
- composition as disclosed herein, means that the carrier, diluent, or excipient is compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
- pharmaceutically acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
- a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be is “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ring
- prevention refers to a delay of onset, and/or reduction in frequency and/or severity of one or more symptoms of a particular disease, disorder or condition. In some embodiments, prevention is assessed on a population basis such that an agent is considered to “prevent” a particular disease, disorder or condition if a statistically significant decrease in the development, frequency, and/or intensity of one or more symptoms of the disease, disorder or condition is observed in a population susceptible to the disease, disorder, or condition. In some embodiments, prevention may be considered complete, for example, when onset of a disease, disorder or condition has been delayed for a predefined period of time.
- Reference As used herein describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and/or comparison to a particular possible reference or control. In some embodiments, a reference is a negative control reference; in some embodiments, a reference is a positive control reference.
- risk of a disease, disorder, and/or condition refers to a likelihood that a particular individual will develop the disease, disorder, and/or condition. In some embodiments, risk is expressed as a percentage. In some embodiments, risk is from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or up to 100%. In some embodiments risk is expressed as a risk relative to a risk associated with a reference sample or group of reference samples. In some embodiments, a reference sample or group of reference samples have a known risk of a disease, disorder, condition and/or event. In some embodiments a reference sample or group of reference samples are from individuals comparable to a particular individual. In some embodiments, relative risk is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.
- sample typically refers to an aliquot of material obtained or derived from a source of interest.
- a source of interest is a biological or environmental source.
- a source of interest may be or comprise a cell or an organism, such as a microbe, a plant, or an animal (e.g., a human).
- a source of interest is or comprises biological tissue or fluid.
- a biological tissue or fluid may be or comprise amniotic fluid, aqueous humor, ascites, bile, bone marrow, blood, breast milk, cerebrospinal fluid, cerumen, chyle, chime, ejaculate, endolymph, exudate, feces, gastric acid, gastric juice, lymph, mucus, pericardial fluid, perilymph, peritoneal fluid, pleural fluid, pus, rheum, saliva, sebum, semen, serum, smegma, sputum, synovial fluid, sweat, tears, urine, vaginal secretions, vitreous humour, vomit, and/or combinations or component(s) thereof.
- a biological fluid may be or comprise an intracellular fluid, an extracellular fluid, an intravascular fluid (blood plasma), an interstitial fluid, a lymphatic fluid, and/or a transcellular fluid.
- a biological fluid may be or comprise a plant exudate.
- a biological tissue or sample may be obtained, for example, by aspirate, biopsy (e.g., fine needle or tissue biopsy), swab (e.g., oral, nasal, skin, or vaginal swab), scraping, surgery, washing or lavage (e.g., bronchioalveolar, ductal, nasal, ocular, oral, uterine, vaginal, or other washing or lavage).
- a biological sample is or comprises cells obtained from an individual.
- a sample is a “primary sample” obtained directly from a source of interest by any appropriate means.
- the term “sample” refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane.
- processing e.g., by removing one or more components of and/or by adding one or more agents to
- a primary sample e.g., filtering using a semi-permeable membrane.
- Such a “processed sample” may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to one or more techniques such as amplification or reverse transcription of nucleic acid, isolation and/or purification of certain components, etc.
- Small molecule refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons. In general, small molecules may have a molecular weight of less than 3,000 Daltons (Da). Small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).
- 3,000 Da e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about
- a subject refers to an individual to which a provided treatment is administered.
- a subject is animal.
- a subject is a mammal, e.g., a mammal that experiences or is susceptible to a disease, disorder, or condition as described herein.
- an animal is a vertebrate, e.g., a mammal, such as a non-human primate, (particularly a higher primate), a sheep, a dog, a rodent (e.g. a mouse or rat), a guinea pig, a goat, a pig, a cat, a rabbit, or a cow.
- an animal is a non-mammal animal, such as a chicken, an amphibian, a reptile, or an invertebrate model C. elegans .
- a subject is a human.
- a patient is suffering from or susceptible to one or more diseases, disorders or conditions as described herein.
- a patient displays one or more symptoms of a one or more diseases, disorders or conditions as described herein.
- a patient has been diagnosed with one or more diseases, disorders or conditions as described herein.
- the subject is receiving or has received certain therapy to diagnose and/or to treat a disease, disorder, or condition.
- the subject is an experimental animal or animal substitute as a disease model.
- Substantially refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest.
- One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result.
- the term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
- Therapeutic regimen refers to a dosing regimen whose administration across a relevant population may be correlated with a desired or beneficial therapeutic outcome.
- Therapeutically effective amount is meant an amount that produces the desired effect for which it is administered.
- the term refers to an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and/or condition.
- a therapeutically effective amount is one that reduces the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition.
- a therapeutically effective amount does not in fact require successful treatment be achieved in a particular individual.
- a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment.
- reference to a therapeutically effective amount may be a reference to an amount as measured in one or more specific tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.).
- tissue e.g., a tissue affected by the disease, disorder or condition
- fluids e.g., blood, saliva, serum, sweat, tears, urine, etc.
- a therapeutically effective amount of a particular agent or therapy may be formulated and/or administered in a single dose.
- a therapeutically effective agent may be formulated and/or administered in a plurality of doses, for example, as part of a dosing regimen.
- treatment refers to any administration of a therapy that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition.
- such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition.
- such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.
- treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
- FIG. 1 shows data evidencing that APOE4 protein enhances the A ⁇ -induced paralysis phenotype in C. elegans.
- C. elegans animals having the indicated genotypes were administered an E. coli OP50 standard laboratory strain. Animals were monitored from day 1 adulthood every alternative day until all were paralyzed. For each assay, at least 20 animals were recorded. Data from three independent trials are presented in a plot. For each data point, mean ⁇ s.d is presented in the graph.
- FIG. 2 shows data evidencing that expression of A ⁇ 3-42 conjugated to green fluorescent protein (GFP) and human ssAPOE4 significantly increased the number of aggregates.
- C. elegans animals having the indicated genotypes were administered an E. coli OP50 standard laboratory strain.
- GFP aggregates in the anterior region of the animal were counted when the animals reached adulthood. For each assay, at least 17 animals were recorded. For each data point, mean ⁇ s.d is presented in a bar graph.
- animals expressing A ⁇ 3-42 and ssApoE4 had significantly increased GFP aggregates as analyzed using Student's t-test, P ⁇ 0.0001.
- FIG. 3 shows data evidencing that UbV-GFP is stabilized in animals expressing both human ssAPOE4 and human tau352(PHP).
- C. elegans animals having the indicated genotypes were administered with the E. coli OP50 standard laboratory strain. The number of animals expressing GFP in the gut were counted when the animals reached adulthood. For each assay, at least 30 animals were recorded. Data from three independent trials are presented in a bar graph. For each data point, mean ⁇ s.d is presented in the graph.
- animals expressing ssAPOE4 and tau352(PHP) had significantly increased UbV-GFP expression as analyzed using Student's t-test, P ⁇ 0.0001.
- FIG. 4 includes data evidencing that certain microbial strains of a microbiome increase A ⁇ mediated paralysis.
- C. elegans animals having the indicated genotypes were administered with either E. coli OP50 standard laboratory strain or individual microbiome strains. Number of paralyzed animals were recorded on day 4 of adulthood. Data from three independent trials are presented in a bar graph. For each data point, mean ⁇ s.d is presented in the graph. Table 1 includes the raw data with number of animals analyzed for each condition.
- FIG. 5 includes data evidencing certain microbial strains of a microbiome modulate A ⁇ 3-42::GFP aggregation.
- C. elegans animals having the indicated genotypes were administered with either E. coli op50 standard laboratory strain or individual microbiome strains.
- the number of GFP aggregates in the anterior region of the animal were counted when the animals reached adulthood.
- GFP aggregates in three animals were counted for each condition. For each data point, mean ⁇ s.d is presented in the graph.
- FIG. 6 includes data showing that certain microbial strains altered ATP production.
- FIG. 7 includes a schematic of the exemplary HIF pathways.
- identification, assessment, or characterization can occur with or without chemical entities and/or biologics (e.g., antibodies).
- C. elegans is a bacteriovorus nematode that is fed on E. coli diet in the laboratory.
- C. elegans can provide reliable, effective, and efficient genotypic and phenotypic models for a number of mammalian diseases and conditions, including various human diseases and conditions, such as aging, diabetes, neurodegenerative disorders, metabolic diseases, and cancer.
- the present disclosure provides the insight that C. elegans models of mammalian diseases and conditions can be used to rapidly screen human microbiome for microbial strains that are affecting such mammalian diseases and conditions. It is improbable to conduct such studies in standard mammalian cell culture assays or animal models.
- C. elegans may not include some of the complexities of mammalian systems, C. elegans models share features with mammalian systems, have quick response times, and are less expensive to produce and maintain than mammalian model systems. Accordingly, C. elegans models of mammalian diseases and conditions provide a powerful front line for examining the impacts microbial strains of mammalian biomes have on mammalian diseases and conditions and present a useful tool to prioritize lead microbial strains that impact specific and sensitive conserved therapeutic targets.
- Microbial strains of samples from a healthy patient or a patient having a disease or condition can be cultured using standard microbiological techniques. These microbial strains can be fed to a transgenic C. elegans strain carrying a mammalian (e.g., human) disease marker, a mammalian (e.g., human) disease gene mutation, or a combination thereof. Microbial strains can be fed to a transgenic C. elegans strain either individually or in combination. In some cases, an individual microbial strain or a combination of microbial strains can be fed to transgenic C.
- elegans strains that have a mammalian (e.g., human) disease marker, a mammalian (e.g., human) disease gene mutation, or a combination thereof in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies).
- a mammalian disease marker e.g., human
- a mammalian disease gene mutation e.g., human disease gene mutation
- chemical entities e.g., small molecules, e.g., drugs
- biologics e.g., monoclonal antibodies
- the present disclosure recognizes that multiple outcomes can arise from feeding an individual microbial strain or a combination of microbial strains can be fed to transgenic C. elegans strains that have a mammalian (e.g., human) disease marker, a mammalian (e.g., human) disease gene mutation, or a combination thereof in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies).
- chemical entities e.g., small molecules, e.g., drugs
- biologics e.g., monoclonal antibodies
- methods described here could be used to identify, define, assess, and/or detect individual microbial strains or combinations of microbial strains from a mammalian microbiome that decrease the severity of a mammalian disease or condition phenotype in C. elegans .
- methods described here could be used to identify, define, assess, and/or detect individual microbial strains or combinations of microbial strains from a mammalian microbiome that have no effect of a mammalian disease or condition phenotype in C. elegans .
- the present disclosure recognizes that each of these outcomes provides valuable information.
- individual microbial strains or combinations of microbial strains from a mammalian microbiome that increase the severity of a mammalian disease or condition phenotype in C. elegans can be potential early diagnostic biomarkers for a mammalian disease or condition.
- such individual microbial strains or combinations of microbial strains are correlated with a high occurrence or increased severity of the disease or condition in mammals (e.g., human). If such a correlation has not been previously found, transgenic C. elegans and methods of using transgenic C.
- elegans described herein could be used to rapidly screen and/or assess one or more microbial strains in a mammalian microbiome using genetic screening or chemical extraction or genomic data mining methods to identify the potential “toxic” metabolites or components of microbiome involved in an increase in disease severity or incidence. These identified microbial strains and/or components of a mammalian microbiome could be also used for developing diagnostics. Also, identification and/or characterization of “toxic” microbial strains or microbiome components could be used for developing modulators or therapeutics that could target microbial strains, microbiome components or biosynthetic pathways that produce them.
- the present disclosure recognizes that individual microbial strains or combinations of microbial strains from a mammalian microbiome that decrease the severity of a mammalian disease or condition phenotype in C. elegans can correlate with disease severity in human patients.
- such individual microbial strains or combinations of microbial strains are correlated with a low occurrence or decreased severity of the disease or condition in mammals (e.g., human). If such a correlation has not been previously found, transgenic C. elegans and methods of using transgenic C.
- elegans described herein could be used to rapidly screen and/or assess one or more microbial strains in a mammalian microbiome using genetic screening or chemical extraction or genomic data mining methods to identify the potential “beneficial” microbial strains, microbiome components, or metabolites involved in an decrease in disease severity or incidence. These identified microbial strains and/or components of a mammalian microbiome could be also used for developing diagnostics. Also, identification and/or characterization of “beneficial” microbial strains or microbiome components could be used as modulators or therapeutics for disease.
- individual microbial strains or combinations of microbial strains from a mammalian microbiome can be also fed in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof to a transgenic C. elegans strain to identify potential biological or signaling or cellular target genes or pathways.
- chemical entities e.g., small molecules, e.g., drugs
- biologics e.g., monoclonal antibodies
- Biological or signaling or cellular target genes or pathways can include, but are not limited to, inflammation, insulin receptor, cell death, mitochondria, endoplasmic reticulum, proteasome, lipogenesis, and detoxification.
- individual microbial strains or combinations of microbial strains from a mammalian microbiome can be fed in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof to C. elegans strain to identify a set of signaling or target genes or pathways (e.g., a comprehensive set) that could modulate or optimize functions of a particular subcellular organelle relevant for a particular disease.
- chemical entities e.g., small molecules, e.g., drugs
- biologics e.g., monoclonal antibodies
- Biological targets for improving mitochondrial function include: biogenesis, bioenergetics, hormesis, and/or repair.
- transgenic C. elegans disease models and/or methods of using C. elegans disease models described herein it is possible to identify individual or combinatorial microbiome species and/or combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof that could modify or improve or alter either mitochondrial biogenesis, bioenergetics, hormesis or repair or combinations thereof.
- chemical entities e.g., small molecules, e.g., drugs
- biologics e.g., monoclonal antibodies
- microbial strains or combinations of microbial strains from a mammalian microbiome and/or chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof that able to target multiple pathways to, e.g., achieve optimal mitochondrial function.
- chemical entities e.g., small molecules, e.g., drugs
- biologics e.g., monoclonal antibodies
- C. elegans The free-living nematode C. elegans has been used extensively as a model system. C. elegans are inexpensive to cultivate, easy to physically manipulate, and has a multitude of genetic and molecular tools available for study. C. elegans are simple multicellular organisms: adults contain approximately 1,000 somatic cells yet have a variety of tissue types such as muscles, nerves, and intestinal cells. C. elegans have a short generation time, which allows for rapid experimentation. C. elegans generally progress from egg to larva to fertile adult in 3 days at room temperature. A single adult C. elegans can have between 300 and 1,000 progenies, which allows for a significant number of animals to be used and then quickly replenished in a relatively short amount of time.
- C. elegans Due to the sexual dimorphism, C. elegans are useful for genetics. Self-fertilizing hermaphrodites can be maintained as homozygous mutations without the need for mating and males can be used for genetic crosses. C. elegans are transparent at every stage of their life cycle, which provides the ability to see inside the organism. This permits the observation of cellular events. It also permits the use of phosphorescent, luminescent, and fluorescent reporters. Manipulation of protein expression in C. elegans can also be performed using RNA-mediated interference (RNAi), which can allow for rapid assessment of gene function. Another advantage of using C. elegans a model system is the ability to freeze and recover the animals, thereby allowing long-term storage.
- RNAi RNA-mediated interference
- C. elegans can be genetically modified using a number of techniques to generate transgenic C. elegans strains.
- the sexual dimorphism of C. elegans allows for genetic manipulations to be performed with relative ease and according to know procedures. For example, if a strain needs to be propagated, single hermaphrodites can be used to self-fertilize and generate a population of offspring. Even if a mutation renders an animal unable to mate, it remains possible for a hermaphrodite to produce progeny.
- Another aspect of C. elegans reproduction that makes C. elegans an effective genetic tool is the animal's ability to cross males with hermaphrodites.
- mating experiments allow genetic markers such as mutations causing visible phenotypes to be placed together in a single organism along with an unknown mutation in order to facilitate mapping of that mutation.
- Hermaphrodites make only a limited number of sperm and can typically have approximately 300 self progeny. Mating increases the number of offspring produced by a single hermaphrodite to approximately 1,000 due to the addition of the male-produced sperm.
- the relatively large number of progeny coupled with the short life span of C. elegans allows for rapid and inexpensive analyses to be performed on the animals.
- C. elegans can be genetically modified via injection of transgenes.
- Microinjection is an effective method for creating transgenic animals and for introducing various types of molecules directly to cells.
- one approach is to inject DNA into a distal arm of a C. elegans gonad.
- a distal germline of C. elegans contains a central core of cytoplasm that is shared by many germ cell nuclei. Therefore, DNA injected into a distal arm of a C. elegans gonad can be delivered to many progeny.
- Microinjection directly into oocyte nuclei can induce chromosomal integration of transgenes, but this technique can be more difficult to perform.
- C. elegans can also incorporate genetic material that is fed to them.
- C. elegans are relatively simple to culture.
- C. elegans can be cultivated in either liquid culture or on the Nematode Growth Medium (NGM) agar plates in the presence of bacteria. It is possible to grow the animals in a chemically defined medium without the addition of bacteria, which can be useful because the components of a medium can be altered in order to study the nutrient or other chemical requirements of the animals.
- C. elegans are grown on the agar plates.
- C. elegans can be grown on Nematode Growth Medium (NGM) agar plates. Bacteria can be spread on the NGM plates as a food source for the animals. For example, OP50, a leaky E. coli uracil auxotroph can be used.
- OP50 will grow slowly and provide nutrients for the animals without overgrowing them. Once the animals have eaten all of the food on a plate they will burrow into the agar and can be maintained on the “starved” plate for weeks at a time in a 15° C. incubator.
- the animals can be transferred to an agar plate with fresh bacteria by either cutting and moving a small block of agar from the starved plate with a sterile instrument such as a micropipette tip, or washing the worms off the surface of the plate with sterile water, or by picking one or more individuals onto a fresh plate, which will cause the C. elegans to reemerge. At any time, C. elegans can be cryogenically preserved.
- C. elegans can be cryogenically preserved.
- elegans prefer to grow between 15° C. and 25° C., but the temperature can vary depending on the strain of C. elegans and conditions being tested.
- a C. elegans culture can be cultured at a temperature of at least 5° C., at least 10° C., at least 15° C., at least 20° C., at least 25° C., at least 30° C., at least 35° C., or at least 40° C.
- elegans culture can be cultured at a temperature of at most 65° C., at most 60° C., at most 55° C., at most 50° C., at most 55° C., at most 40° C., at most 35° C., at most 30° C., at most 25° C., or at most 20° C.
- Standard protocols for C. elegans manipulation and culture are known, e.g., as described by Stiernagle T. Maintenance of C. elegans . Wormbook, ed. The C. elegans Research Community, WormBook. (Feb. 11, 2006), which is incorporated herein by reference.
- the present disclosure provides systems and methods for assessing, characterizing, and identifying one or more microbial strains of a microbiome. Such systems and methods can be useful for assessing, characterizing, and identifying one or more microbial strains that affect the health of humans, livestock, and/or pets. In some embodiments, assessing, characterizing, and identifying one or more microbial strains from a microbiome of a snake, lizard, fish, or bird. In some embodiments, assessing, characterizing, and identifying one or more microbial strains from a mammalian microbiome.
- a mammalian microbiome can be a canine, a feline, an equine, a bovine, an ovine, a caprine, or a porcine microbiome.
- a microbiome used in a system or method described herein will correspond with the disease or condition modeled by a transgenic C. elegans used in the system or method. For example, if a transgenic C. elegans models a human disease, a human microbiome will be assessed, characterized, or identified.
- a microbiome can be isolated from any system or tissue of an organism that supports microbial growth.
- a microbiome can be a cutaneous microbiome, an oral microbiome, a nasal microbiome, a gastrointestinal microbiome, a brain microbiome, a pulmonary microbiome, or a urogenital microbiome.
- a list of exemplary microbial strains found in a gastrointestinal microbiome is included below in TABLE 8.
- a microbiome sample can be obtained by various ways known in the art. For example, a cutaneous, oral, nasal, pulmonary, or urogenital microbiome sample could be obtained using a swab or tissue scrapping.
- a gastrointestinal microbiome could be sampled from feces.
- a cutaneous microbiome, an oral microbiome, a nasal microbiome, a gastrointestinal microbiome, a brain microbiome, a pulmonary microbiome, or a urogenital microbiome sample could be obtained via a biopsy.
- a microbiome is a microbiome of a healthy individual or an individual who does not suffer from or is not at risk of developing a particular disease or disorder. In some embodiments, a microbiome is a microbiome of an individual that suffers from or is at risk of developing a particular disease or disorder. In some embodiments, a microbiome is a microbiome of an individual who is known to suffer from a particular disease or disorder. In some embodiments, a human microbiome is a microbiome of a human with an unknown risk for one or more diseases or conditions.
- a microbiome is a reference microbiome.
- a reference microbiome can be a microbiome of a healthy individual or an individual who does not suffer from or is not at risk of developing a particular disease or disorder.
- a reference microbiome may be from the same individual as a microbiome to be assessed or characterized, but was obtained at a different time.
- a reference microbiome may be from the same individual as a microbiome to be assessed or characterized, but was obtained from a different system or tissue.
- an individual microbial strain or a combination of microbial strains may be assessed, characterized, or identified in a different relative amount than such strain or strains are found in a microbiome.
- a single strain may be assessed, characterized, or identified using transgenic C. elegans or methods using transgenic C. elegans described herein, even though it is naturally present in a microbiome with other microbial strains.
- two microbial strains may be assessed, characterized, or identified together transgenic C. elegans or methods using transgenic C. elegans described herein, even though they are naturally present in a microbiome with additional microbial strains.
- An extract, component, or compound of a microbial strain may also be assessed, characterized, or identified using transgenic C. elegans or methods using transgenic C. elegans described herein.
- an extract, component, or compound of a microbial strain that has been determined to affect a transgenic C. elegans model of a disease or condition may be assessed, characterized, or identified. Assessing, characterizing or identifying an extract, component, or compound of a microbial strain that affect a transgenic C. elegans model of a disease or condition may provide additional information about potential biomarkers, targets, or protective agents in a microbiome.
- a variety of technologies are known in the art that can be used to prepare extracts of microbial strains, and/or to isolate extracts, components, or compounds therefrom, or to process (e.g., to isolate and/or purify one or more components or compounds from).
- processes e.g., to isolate and/or purify one or more components or compounds from.
- technologies may include, for example, one or more of organic extraction, vacuum concentration, chromatography, and so on.
- C. elegans can be used to identify, characterize, or assess microbial strain(s) of a mammalian microbiome by contacting the microbial strain(s) (e.g., feeding the microbial strain(s) to, administering to) transgenic C. elegans that model a mammalian disease or condition.
- the microbial strain(s) e.g., feeding the microbial strain(s) to, administering to
- transgenic C. elegans that model a mammalian disease or condition.
- parameters of the transgenic C. elegans can be observed, measured, or assessed in different samples that have been contacted with the microbial strain or combination of microbial strains.
- transgenic C. elegans can be observed, measured, or assessed to determine whether a microbial strain or combination of microbial strains affects a transgenic C. elegans that model a mammalian disease or condition.
- transgenic C. elegans behaviors e.g., mating, feeding, food aversion, or locomotion
- genetic mutations e.g., the presence of SNPs, deletions, additions, inversions, or repeats in DNA
- transcript levels e.g., protein levels, metabolite levels, lipid levels, carbohydrate levels
- protein (e.g., enzyme) activity levels can be observed, measured, or assessed to determine whether a microbial strain or combination of microbial strains affects a transgenic C. elegans that model a mammalian disease or condition.
- a first sample is a reference sample.
- a reference sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed), e.g., OP50.
- a reference sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) a microbial strain or combination of microbial strains from a microbiome of a healthy individual.
- a reference sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) a microbial strain or combination of microbial strains from a microbiome of an individual obtained at a first time point.
- a second sample can be a test sample.
- a test sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) an individual microbial strain or a combination of microbial strains from a mammalian microbiome, e.g., a human microbiome.
- a human microbiome is a microbiome of a human suffering from or at risk of a disease or condition.
- a human microbiome is a microbiome of a human with an unknown risk for one or more diseases or conditions.
- a test sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) a microbial strain or combination of microbial strains from a microbiome of an individual obtained at a second time point.
- methods described herein comprise comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample. In some embodiments, by comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample, it can be determined that an individual microbial strain or a combination of microbial strains from a microbiome increase the severity or incidence of a disease or condition phenotype modeled by the cultured transgenic C. elegans .
- comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample it can be determined that an individual microbial strain or a combination of microbial strains from a microbiome decrease the severity or incidence of a disease or condition phenotype modeled by the cultured transgenic C. elegans .
- by comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample it can be determined that an individual microbial strain or a combination of microbial strains from a microbiome have no effect on the severity or incidence of a disease or condition phenotype modeled by the cultured transgenic C. elegans.
- Transgenic C. elegans and methods using transgenic C. elegans provided herein can be useful in assessing, characterizing, or identifying microbial strains of a microbiome that affect a mammalian disease or condition.
- the present disclosure also provides the recognition that transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to define and/or characterize a microbial signature associated with a disease or condition. Further, the present disclosure provides the recognition that transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to define and/or characterize a microbial signature associated with one or more features of a disease or condition (e.g., severity, responsiveness to therapy, etc.).
- the microbial strains, as well as their relative amounts could be used as a signature to identify individuals who are at risk of developing an increased severity of the disease or disorder.
- the microbial strains, as well as their relative amounts could be used as a signature to identify when that individual is at risk of developing an increased severity of the disease or disorder.
- transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to diagnose an individual with a disease or condition.
- transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to diagnose an individual with a disease or condition.
- a microbial signature associated with a disease or condition determined through the use of transgenic C. elegans and methods using transgenic C. elegans provided herein an individual can be diagnosed early and/or identified as an individual at risk.
- transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to monitor progression of a disease or condition in an individual. For example, if microbial strains determined to increase the severity of a disease or condition decrease in relative amount within a microbiome, it may indicate that the disease or condition is being attenuated, e.g., by treatment or immune response.
- transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to tailor treatments (e.g., therapies, nutraceuticals, and/or probiotics) to an individual patient.
- transgenic C. elegans and methods using transgenic C. elegans provided herein can provide “personalized” therapy.
- microbial strains within an individual can be assessed, characterized, or identified to determine if they have an effect on a disease or disorder. Based on the results, the individual can be treated with one or more microbial strains to adjust the microbial strains (and/or component or compound thereof) in their microbiome.
- this will affect the disease or condition the individual is suffering from or at risk of developing. For example, if an individual is determined to have a relatively low amount of one or more microbial strains that have been determined to decrease the severity of a disease or condition, administration of the one or more microbial strains that have been determined to decrease the severity of a disease or condition to the individual (or an extract, component, or compound thereof) may attenuate the severity of the individual's disease or condition.
- compositions comprising individual microbial strains or combinations of microbial strains.
- a composition comprises individual microbial strains or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein.
- a composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein.
- composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains listed in TABLE 8 below.
- a composition provided herein comprises Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, Acidaminococcus sp., or a combination thereof.
- a combination comprises at least two of, at least three of, at least four of, at least five of, at least six of, at least seven of, at least eight of, at least nine of, or all of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis , and Acidaminococcus sp.
- an individual microbial strain or combinations of microbial strains from a mammalian microbiome that have been killed may include cells that are viable or alive.
- one or more microbial strains comprise a viable or living individual microbial strain or combinations of microbial strains, e.g., from a mammalian microbiome.
- one or more microbial strains comprise a viable or living individual microbial strain or combinations of microbial strains, e.g., from a mammalian microbiome, as described herein comprises and/or is formulated through use of one or more cell cultures and/or supernatants or pellets thereof, and/or a powder formed therefrom.
- compositions for use in accordance with the present disclosure are pharmaceutical compositions, e.g., for administration (e.g., oral administration) to a mammal (e.g., a human).
- Pharmaceutical compositions typically include an active agent (e.g., individual microbial strains or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof), and a pharmaceutically acceptable carrier.
- active agent e.g., individual microbial strains or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof
- a pharmaceutically acceptable carrier include, for instance saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- a pharmaceutical composition for use in accordance with the present disclosure may include and/or may be administered in conjunction with, one or more supplementary active compounds; in certain embodiments, such supplementary active agents can include ginger, curcumin, probiotics (e.g, probiotic strains of one or more of the following genera: Lactobacillus, Bifidobacterium, Saccharomyces, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus , and/or Escherichia coli (see Fijan, Int J Environ Res Public Health.
- probiotics e.g, probiotic strains of one or more of the following genera: Lactobacillus, Bifidobacterium, Saccharomyces, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus , and/or Escherichia coli (see Fijan, Int J Environ Res Public Health.
- prebiotics nondigestible food ingredients that help support growth of probiotic bacteria, e.g., fructans such as fructooligosaccharides (FOS) and inulins, galactans such as galactooligosaccharides (GOS), dietary fibers such as resistant starch, pectin, beta-glucans, and xylooligosaccharides (Hutkins et al., Curr Opin Biotechnol. 2016 February; 37: 1-7, which is incorporated herein by reference) and combinations thereof.
- FOS fructooligosaccharides
- GOS galactans
- dietary fibers such as resistant starch, pectin, beta-glucans, and xylooligosaccharides
- compositions are typically formulated to be compatible with its intended route of administration.
- routes of administration include oral administration.
- Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, N.Y.).
- Oral compositions generally include an inert diluent or an edible carrier.
- an oral formulation may be or comprise a syrup, a liquid, a tablet, a troche, a gummy, a capsule, e.g., gelatin capsules, a powder, a gel, a film, etc.
- a pharmaceutical composition can contain, e.g., any one or more of the following inactive ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- compositions can be taken as-is or sprinkled onto or mixed into a food or liquid (such as water).
- a composition that may be administered to mammals as described herein may be or comprise an ingestible item (e.g., a food or drink) that comprises (e.g., is supplemented) with an individual microbial strain or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof.
- a food can be or comprise one or more of bars, candies, baked goods, cereals, salty snacks, pastas, chocolates, and other solid foods, as well as liquid or semi-solid foods including yogurt, soups and stews, and beverages such as smoothies, shakes, juices, and other carbonated or non-carbonated beverages.
- foods are prepared by a subject by mixing in individual microbial strains or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof.
- compositions can be included in a kit, container, pack, or dispenser, together with instructions for administration or for use in a method described herein.
- a composition e.g., a pharmaceutical composition
- technologies for preparing compositions and/or preparations, and/or for preparing (and particularly for preparing pharmaceutical compositions) may include one or more steps of assessing or characterizing a compound, preparation, or composition, e.g., as part of quality control.
- an assayed material does not meet pre-determined specifications for the relevant assessment, it is discarded.
- such assayed material does meet the pre-determined specifications, then it continues to be processed as described herein.
- a pharmaceutical composition provided herein can promote the colonization of an individual microbial strain or combinations of microbial strains from a mammalian microbiome, particularly microbial strain(s) that have been identified, characterized, or assessed as decreasing the severity or incidence of a mammalian disease or condition, in a mammal suffering from or at risk of the mammalian disease or condition.
- a pharmaceutical composition provided herein can attenuate the colonization of an individual microbial strain or combinations of microbial strains from a mammalian microbiome, particularly microbial strain(s) that have been identified, characterized, or assessed as increasing the severity or incidence of a mammalian disease or condition, in a mammal suffering from or at risk of the mammalian disease or condition.
- a pharmaceutical composition provided herein can promote the colonization of an individual microbial strain or combinations of microbial strains from a mammalian microbiome, particularly microbial strain(s) that have been identified, characterized, or assessed as not affecting the severity or incidence of the mammalian disease or condition but have been identified, characterized, or assessed as being capable of outcompeting one or more microbial strains that have been identified, characterized, or assessed as increasing the severity or incidence of a mammalian disease or condition, in a mammal suffering from or at risk of the mammalian disease or condition.
- each of the one or more microbial strains in a composition comprises 10 1 to 10 12 colony forming units (CFUs). In some embodiments, each of the one or more microbial strains in a composition comprises 10 6 to 10 12 CFUs. In some embodiments, each of the one or more microbial strains in a composition comprises the same number of CFUs. In some embodiments, some of the one or more microbial strains in a composition comprises a different number of CFUs.
- a composition comprises a total of 10 6 to 10 12 of CFUs.
- a pharmaceutical composition is tailored to a specific mammal (e.g., a specific human patient) based on that mammal's (e.g., human's) microbiome.
- a pharmaceutical composition is specific for a microbiome of an individual mammal (e.g., human).
- a pharmaceutical composition is specific for microbiomes of a population of mammals (e.g., humans). Populations of mammals can include, but are not limited to: families, mammals in the same regional location (e.g., neighborhood, city, state, or country), mammals with the same disease or condition, mammals of a particular age or age range, mammals that consume a particular diet (e.g., food, food source, or caloric intake).
- compositions described herein can be useful in the treatment of subjects.
- Methods provided by the present disclosure include methods for the treatment of certain diseases, disorders and conditions.
- relevant diseases, disorders and conditions may be or include a neurodegenerative disease, disorder, or condition.
- a neurodegenerative disease, disorder, or condition may be Alzheimer's disease.
- relevant diseases, disorders and conditions may be or include an ocular neovascular disease, disorder, or condition.
- a neurodegenerative disease, disorder, or condition may be diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
- methods of treatment provided by the present disclosure involve administering a therapeutically effective amount of a composition as described herein alone or in combination with other compositions and/or treatments to a subject who is in need of, or who has been determined to be in need of, such treatment.
- methods of treatment provided herein are prophylactic or preventative, e.g., may be administered to subjects prior to display of significant symptoms and/or to exposure to a particular expected inducement that is associated with neurodegenerative diseases, disorders, or conditions.
- methods of treatment provided herein are therapeutic, e.g., may be administered to subjects after development of significant symptoms associated with neurodegenerative diseases, disorders, or conditions.
- provided methods of treatment are administered to a subject that is a mammal, e.g., a mammal that experiences a disease, disorder, or condition as described herein; in some embodiments, a subject is a human or non-human veterinary subject, e.g., an ape, cat dog, monkey, or pig.
- treatment involves ameliorating at least one symptom of a disease, disorder, or condition associated with neurodegenerative diseases, disorders, or conditions.
- a method of treatment can be prophylactic.
- the methods can include administration of a therapeutically effective amount of compositions disclosed herein before, during (e.g., concurrently with), or after administration of a treatment that is expected to be associated with neurodegenerative diseases, disorders, or conditions.
- subjects who receive treatment as described herein may be receiving and/or may have received other treatment (e.g., pharmacological treatment/therapy, surgical, etc), for example that may be intended to treat one or more symptoms or features of a disease disorder or condition as described herein (e.g. neurodegenerative diseases, disorders, or conditions), so that provided compositions are administered in combination with such other therapy (i.e. treatment) to treat the relevant disease, disorder, or condition.
- other treatment e.g., pharmacological treatment/therapy, surgical, etc
- compositions described herein can be administered in a form containing one or more pharmaceutically acceptable carriers.
- suitable carriers have been described previously and vary with the desired form and mode of administration of a composition.
- pharmaceutically acceptable carriers can include diluents or excipients such as fillers, binders, wetting agents, disintegrators, surface-active agents, glidants, and lubricants.
- a carrier may be a solid (including powder), liquid, or any combination thereof.
- Each carrier is preferably “acceptable” in the sense of being compatible with other ingredients in the composition and not injurious to a subject.
- a carrier can be biologically acceptable and inert (e.g., it permits the composition to maintain viability of the biological material until delivered to the appropriate site).
- Tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, orange flavoring, or other suitable flavorings.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, primogel, or corn starch
- a lubricant such as magnesium stearate or sterotes
- a glidant such as colloidal silicon
- Oral compositions can include an inert diluent or an edible carrier.
- an active compound can be incorporated with excipients and used in the form of tablets, lozenges, pastilles, troches, or capsules, e.g., gelatin capsules.
- Oral compositions can also be prepared by combining a composition of the present disclosure with a food.
- microbes can be formulated in a food item.
- Some non-limiting examples of food items to be used with the methods and compositions described herein include: popsicles, cheeses, creams, chocolates, milk, meat, drinks, pickled vegetables, kefir, miso, sauerkraut, etc.
- food items can be juices, refreshing beverages, tea beverages, drink preparations, jelly beverages, and functional beverages; alcoholic beverages such as beers; carbohydrate-containing foods such as rice food products, noodles, breads, and pastas; paste products such as fish, hams, sausages, paste products of seafood; retort pouch products such as curries, food dressed with a thick starchy sauce, and Chinese soups; soups; dairy products such as milk, dairy beverages, ice creams, and yogurts; fermented products such as fermented soybean pastes, fermented beverages, and pickles; bean products; various confectionery products including biscuits, cookies, and the like, candies, chewing gums, gummies, cold desserts including jellies, cream caramels, and frozen desserts; instant foods such as instant soups and instant soy-bean soups; and the like.
- alcoholic beverages such as beers
- carbohydrate-containing foods such as rice food products, noodles, breads, and pastas
- paste products such as fish, hams, sausages,
- a food used for administration is chilled, for example, iced flavored water.
- the food item is not a potentially allergenic food item (e.g., not soy, wheat, peanut, tree nuts, dairy, eggs, shellfish or fish).
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- a composition described herein is administered to a subject according to a dosing regimen that achieves population of the subject's microbiome with administered cells.
- a composition is administered to a subject in a single dose.
- a composition is administered to a subject in a plurality of doses.
- a dose of a composition is administered to a subject twice a day, daily, weekly, or monthly.
- each of the one or more microbial strains in a dose comprises 10 1 to 10 12 colony forming units (CFUs). In some embodiments, each of the one or more microbial strains in a dose comprises 10 6 to 10 12 CFUs. In some embodiments, each of the one or more microbial strains in a dose comprises the same number of CFUs. In some embodiments, some of the one or more microbial strains in a dose comprises a different number of CFUs.
- a dose of one or more microbial strains comprises a total of 10 6 to 10 12 CFUs. In some embodiments, a dose of one or more microbial strains comprises a total of 10 7 to 10 10 CFUs. In some embodiments, a dose of one or more microbial strains comprises 5-200 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 5-50 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 5-20 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 50-100 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 100-200 billion CFUs.
- a signal sequence for secretion from C. elegans FLP-1 was included in the apoE4 sequence (“Worm 2”). In the other construct, no signal sequence was added to the a oE4 sequence (“Worm 1”).
- Extrachromosomal array strains were constructed by injecting the either Worm 1 or Worm 2 with an expression plasmid and co-injection marker (2 ng/ ⁇ l for pCFJ90, pmyo-2::mCherry). Sequences used for Worm 1 and Worm 2 are included in TABLE 2 below. Coding sequences are indicated by capital letters; non-coding sequences are indicated by small letters.
- AD Alzheimer's disease
- APP amyloid precursor protein
- PSEN1 and PSEN2 presenilins
- Soluble A ⁇ oligomers can also cause synaptic dysfunction leading to neurodegeneration and cognitive disabilities.
- the neurofibrillary tangles in AD can include hyperphosphorylated tau protein, which is a microtubule associated protein in neurons.
- hyperphosphorylated tau protein which is a microtubule associated protein in neurons.
- tau can be abnormally hyperphosphorylated and aggregate into filaments.
- AD cases While about 5% of AD cases appear to have a genetic cause, 95% of the cases are sporadic or late-onset AD with unknown etiology. Less than 1% of AD cases are caused by genetic mutations in genes including APP, PSEN1 and PSEN2. Though several other genes were implicated in AD, one of the strongest genetic risk factors in AD is apoe. (Lambert, J.-C., et al. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1099; Shen, L., and Jia, J. (2016). An Overview of Genome-Wide Association Studies in Alzheimer's Disease. Neurosci. Bull.
- a lipid/cholesterol carrier apolipoprotein E (APOE) is encoded by apoe.
- APOE2 lipid/cholesterol carrier apolipoprotein E
- APOE3 3 major protein variants, termed APOE2, APOE3, and APOE4, that differ from each other only at two amino acid residues.
- apoe4 People carrying polymorphism in apoe, specifically the apoe4 allele are significantly more likely develop AD, but also early-onset AD, compared to the people who carry either the apoe2 or apoe3 alleles.
- APOE2 is thought to be the protective form of APOE
- APOE4 is thought to be the “toxic” form.
- APOE4 exacerbates brain changes associated with AD including increased levels of amyloid deposits, brain dysfunction and neurodegeneration.
- APOE4 exacerbates brain changes associated with AD including increased levels of amyloid deposits, brain dysfunction and neurodegeneration.
- AD Alzheimer's Disease Genetic Risk Factor APOE- ⁇ 4 Also Affects Normal Brain Function. Curr. Alzheimer Res. 13, 1200-1207, which is incorporated herein by reference.
- APOE4 the molecular mechanisms of how APOE4 promotes AD pathogenesis is still not well-understood.
- ApoE and A ⁇ in Alzheimer's disease accidental encounters or partners?
- APOE4 is thought to contribute to AD pathogenesis via both loss-of-function and gain-of-function mechanisms. (DiBattista, 2016; Zepa, L., et al. (2011). ApoE4-Driven Accumulation of Intraneuronal Oligomerized A ⁇ 42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function. Int. J. Alzheimers Dis. 2011, each of which is incorporated herein by reference).
- APOE epsilon4 Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol. Aging 27, 285-292, each of which is incorporated herein by reference).
- therapies targeting APOE4 is lacking.
- APOE ⁇ 4 The most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimers Dement. J. Alzheimers Assoc. 10, 861-868; Holtzman, D. M., et al. (2012). Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2, each of which is incorporated herein by reference).
- tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50, 669-677; Risner, M. E., et al. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254; each of which is incorporated herein by reference).
- APOE4 is expressed in the brain, the peripheral tissue expression of APOE4 is high; this raises the possibility that peripheral APOE4 could contribute to AD pathogenesis.
- APOE protein is synthesized primarily in the liver and is involved in lipid transport and cholesterol homeostasis. (Safieh, M., et al. (2019). ApoE4: an emerging therapeutic target for Alzheimer's disease. BMC Med. 17, which is incorporated herein by reference). Liver is the primary site which encounters not only the nutrients but also gut microbiome-derived small molecules or metabolites or toxins through the enterohepatic circulation. Thus, dysbiosis in the gut will have profound effect on the liver.
- AD might have a gut-origin: “microbiome-derived materials” might leak into the enterohepatic circulation and reaches the liver. From liver, the APOE4 might transport these “microbiome-derived materials” to brain where they could either seed amyloid deposits and/or increase neuroinflammation.
- gut microbiome plays an important role in AD. Significant changes in the microbiome were observed in human AD patients compared to control populations. However, whether these changes are the cause or consequence of the disease is not known. Though many of the microbiome components are implicated in either susceptibility or pathogenesis of AD, the molecular mechanisms of such interactions remains unknown.
- Example 2.2 APOE4 Enhances a AP-Induced Paralysis Phenotype
- transgenic C. elegans strains expressing human APOE4 were developed. These transgenic C. elegans strains expressed human APOE4 in the gut of C. elegans under the control of an intestinal promoter along with a signal sequence that allows the human APOE4 to be secreted out of the cell [e.g., mbEx2(pvha-6::ssapoe4)], or without a signal sequence [e.g., mbEx1(pvha-6::apoe4)]. In C. elegans , there is no liver and the gut perform all the functions that liver typically does. Animals were administered with the E. coli OP50 standard laboratory strain.
- GFP aggregates in the anterior region of the animal were counted when the animals reached adulthood. For each assay, at least 17 animals were recorded. For each data point, mean ⁇ s.d is presented in the graph of FIG. 2 . Compared to animals expressing A ⁇ 3-42, animals expressing A ⁇ 3-42 and ssApoE4 had significantly increased GFP aggregates as analyzed using Student's t-test, P ⁇ 0.0001.
- Example 2.4 UbV-GFP is Stabilized in Animals Expressing Both Human ssAPOE4 and Human tau352 (PHP)
- Hyperphosphoryated tau has been reported to be associated with AD. Expression of pseudohyperphosphorylated tau, which mimics AD-relevant modification, was further reported to induce progressive age-dependent locomotion defects in C. elegans . (Brandt, R., Gergou, A., Wacker, I., Fath, T., and Hutter, H. (2009). A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol. Aging 30, 22-33, which is incorporated herein by reference).
- the number of animals expressing GFP in the gut were counted when the animals reached adulthood. For each assay, at least 30 animals were recorded. Data from three independent trials are presented in ( FIG. 3 ). For each data point, mean ⁇ s.d is presented in the graph. Compared to animals that expressed tau352(PHP), animals expressing ssAPOE4 and tau352(PHP) had significantly increased UbV-GFP expression, as analyzed using Student's t-test, P ⁇ 0.0001.
- UbV-GFP undergoes proteasomal-dependent degradation, while impaired proteostasis causes stabilization of the GFP (see, e.g., FIG. 3 ).
- Minimal or no GFP expression was observed in animals expressing human ssApoE4; however, the UbV-GFP was stabilized in animals expressing both human ssApoE4 and human pseudohyperphosphorylated human tau ( FIG. 3 ).
- Pseudohyperphosphorylated human tau expression itself did not induce proteasomal stress ( FIG. 3 ). This result suggested that expression of human ssApoE4 and human pseudohyperphosphorylated human tau induces proteasomal stress.
- Hyperphosphorylated Tau has previously been reported to be resistant to proteasomal degradation (Poppek, D., Keck, S., Ermak, G., Jung, T., Stolzing, A., Ullrich, O., Davies, K. J. A., and Grune, T. (2006). Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem. J. 400, 511-520, which is incorporated herein by reference) and tau phosphorylation was reported to modulate proteasomal activity (Ren, Q.-G., Liao, X.-M., Chen, X.-Q., Liu, G.-P., and Wang, J.-Z. (2007).
- mice of the appropriate genotypes were administered with either E. coli OP50 standard laboratory strain or individual microbiome strains. Number of paralyzed animals were recorded on day 4 of adulthood. Data from three independent trials are presented. For each data point, mean ⁇ s.d is presented in the graph. See Table 1 below for the raw data with number of animals analyzed for each condition.
- a novel transgenic C. elegans strain that expresses human ssApoE4, human A ⁇ 1-42, human pseudophosphorylated tau and UbV-GFP proteasomal marker was generated.
- This transgenic strain can be employed for not only identifying interventions that suppress paralysis, but also for agents that improve proteasomal function. Further, this model could be used for finding parameters or features of a biological pathway affect (enhance or decrease) paralysis. Parameters or features could be small molecules, metabolites, nucleic acids, proteins, lipids, or even microbiome components.
- Enhancement of paralysis was dependent on the presence of ssAPOE4 because administration of many of these bacteria to animals that express human A ⁇ 1-42, human pseudophosphorylated tau and UbV-GFP proteasomal marker did not enhance the paralysis phenotype (Table 7; FIG. 4 ).
- E. coli isolate 5 52.9 ⁇ 1.1 (295) 5.3 ⁇ 1.5 (300)
- E. coli isolate 12 71.9 ⁇ 1.8 (281) 5.1 ⁇ 2.1 (297)
- E. coli isolate 15 71.1 ⁇ 2.4 (301) 5.7 ⁇ 2.2 (297)
- E. coli isolate 8 63.6 ⁇ 1.0 (299) 6.0 ⁇ 1.0 (301)
- E. coli isolate 13 50.7 ⁇ 0.3 (302) 5.2 ⁇ 1.6 (286)
- Example 2.6 Microbial Strains Modulate A ⁇ 3-42::GFP Aggregation
- Porphyromonas gingivalis (Table 1).
- P. gingivalis was identified in AD patient brain and was implicated in neurotoxic tau and amyloid deposition. (Dominy, S. S., et al. (2019). Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 5, which is incorporated herein by reference). Further, P.
- gingivalis has been reported to increase ubiquitin load, suggesting a disruption of proteasomal function. (Dominy et al., 2019, which is incorporated herein by reference). Oral administration of P. gingivalis was previously shown to be sufficient to induce brain infection and induction of A ⁇ deposits (Dominy et al., 2019, which is incorporated herein by reference).
- E. coli isolates were found that increased a paralysis phenotype, as well as caused increased A ⁇ 3-42 ::GFP aggregates in a ssAPOE4 dependent fashion (TABLE 7; FIG. 4 ; FIG. 5 ).
- C. elegans are fed on a standard non-pathogenic E. coli OP50 strain in the lab.
- Previous studies have shown that gram-negative bacterial molecules especially from E. coli are associated with AD neuropathology. (Zhan, X., Stamova, B., Jin, L.-W., DeCarli, C., Phinney, B., and Sharp, F. R. (2016). Gram-negative bacterial molecules associate with Alzheimer disease pathology.
- E. fergusonii and E. albertii also showed similar trends to that of E. coli . While some isolates of E. fergusonii and E. albertii increased the paralysis phenotype, others strains had either mild or moderate effects (TABLE 7). This peculiar effect on paralysis was also observed in isolates of Klebsiella oxytoca, Klebsiella pnuemoniae and Alcaligenes faecalis . This might be a general tendency for other microbial populations as well, but because of the number of strains analyzed, this feature might be missed.
- the present disclosure teaches that individual strains of a particular microbe can have differential effects on biological phenotype(s), specifically including disease-associated phenotype(s).
- the present disclosure provides technologies for identifying and/or characterizing particular strains, and/or components or combinations thereof, which may achieve a particular impact on a biological phenotype.
- microbiome samples from apparently healthy donors were analyzed. It is possible that AD patient microbiome samples might produce a better trend in identifying strains that might have deleterious effects.
- a patient microbiome could be assessed for increased or decreased presence of microbial strains that are associated with or, alternatively affect, disease.
- metagenomic sequencing of patient population could identify the diversity of microbial species present in a particular patient or patient population, these methods cannot identify strain-level differences in patient samples compared to healthy population.
- the present system fills this gap in identifying strain-level differences in patient(s) and/or patient population(s), which may be important for a number of diseases or conditions, including AD.
- the present disclosure provides technologies for defining, assessing, and/or detecting, microbes, and/or components or combinations thereof (i.e., microbial signature(s)), that may be associated with a particular disease states; in some embodiments, such microbial signatures can be detected in patient sample(s) and, for example, may be useful to diagnose a disease state, to monitor impact of a particular therapy with respect to such disease state, etc.
- microbial signature(s) i.e., microbial signature(s)
- Example 2.7 Exemplary Microbial Strains That Affect ATP Production
- the Neuro2A cell line was purchased from ATCC and cultured in EMEM media supplemented with 10% FBS, and 1% L-glutamine. Cells were maintained at 37° C./5% CO 2 incubators. All experiments were carried out using only passage 3-7 cells. Neuro2A cells (5 ⁇ 10 4 cells per well) were plated onto a 96-well white-walled plate (Corning) and incubated overnight at 37° C./5% CO 2 . Each of the 10 bacteria or a combination of all bacteria (CT10) were grown in the following media: Reinforced Clostridial Broth, Peptone Yeast extract Glucose broth, MRS broth and Tryptic Soy Broth.
- the bacteria were resuspended to 10 8 CFU in PBS and stored at ⁇ 80° C. 10 8 CFU of each microbe (referred as samples) was added to 6 wells. The combination of all bacteria (CT10) was added to 6 wells at 10 9 CFU (i.e., 10 8 CFU of each bacteria). For the control wells, PBS with no bacteria were added. After 16 hours of incubation at 37° C./5% CO 2 , 2 ⁇ M of Human Amyloid ⁇ 1- 42 was added to all the wells except for control untreated wells. The cells were incubated for 24 hours at 37° C./5% CO 2 .
- the cells were washed with PBS three-times and 0.05 ml of Promega CellTiter-Glo and plate was incubated at room temperature shielded from light for 1 hour.
- the luminescence was measured using a microplate reader (Promega discoverer, Promega Corp), indicating the ATP levels.
- the ATP levels were normalized to protein content, as measured by the Bradford Protein Assay kit (ThermoFisher Scientific). 10 ⁇ l of samples was added to 150 ⁇ l of Bradford reagent in clear 96-well plates in duplicates and incubated for 5 min in dark at RT and the absorbance was measured at 600 nm using a microplate reader (Promega Discoverer, Promega Corp.).
- the normalized luminescence was calculated by dividing the luminescence value by OD protein absorbance value. The average of the triplicate wells for each condition was calculated % ATP compared to the control was calculated.
- treating Neuro2A cells with 2 ⁇ M of Human Amyloid ⁇ 1-42 (“Mock-treated”) caused significant decrease in ATP production. While treatment of Neuro2A cells with Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp. or Acidaminococcus sp. resulted in significant increase in ATP production compared to the Mock-treated cells, a combination of all the bacteria together (CT-10) resulted in further significant increase in the ATP production in the presence of Human Amyloid ⁇ 1-42 .
- CT-10 a combination of all the bacteria together
- ozaenae Bacillus cereus Klebsiella pneumoniae subsp. pneumoniae Bacillus coagulans Klebsiella pneumoniae subsp. rhinoscleromatis Bacillus licheniformis Klebsiella quasipneumoniae subsp.
- Hypoxia inducible factor (HIF) pathway mediates a diversity of metabolic and physiological adaptations to reduced oxygen levels in cells. Activation of the HIF pathway promotes erythropoiesis and angiogenesis to reduce the cellular requirement for oxygen. Though the HIF pathway is important for cellular stress response, constitutive activation of HIF-1 leads to neovascularization in conditions such as diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, and glaucoma. Thus, developing modulators of HIF pathway is essential for the treatment of ocular neovascular diseases.
- the HIF-1 pathway consists of the HIF transcription factor and the negative regulator, the prolyl hydroxylase EGLN.
- EGLN functions as oxygen sensor and in the presence of oxygen it hydroxylates the HIF ⁇ -subunit (HIF ⁇ ). Hydroxylation of HIF ⁇ leads to binding to von Hippel-Lindau (VHL) E3 ubiquitin ligase, among other factors, which promote HIF ⁇ degradation (see FIG. 7 ). Under low oxygen conditions, HIF ⁇ protein is stabilized and it promotes transcriptional activation of genes required for adaptation to low oxygen levels.
- VHL von Hippel-Lindau
- egl-9 encodes the EGLN homolog.
- HIF-1 which is the homolog of HIF1 ⁇
- protein levels are stabilized.
- the HIF1 protein is constitutively active leading to continuous activity of HIF-1 transcriptional target genes.
- egl-9 loss-of-function (egl-9 lf) C. elegans mutants were analyzed.
- egl-9 lf mutant C. elegans have constitutively active HIF-1, which results in them being defective in laying eggs. Therefore, they become bloated with eggs as adults.
- Example 3.3 Microbial Strains Affect HIF-1 Induced Egg Laying Defects
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Abstract
A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.
Description
- The present application is a continuation of U.S. application Ser. No. 17/019,183, filed Sep. 11, 2020, which claims priority to U.S. provisional patent application No. 62/988,132, filed Mar. 11, 2020, and U.S. provisional patent application No. 62/899,718, filed Sep. 12, 2019, the entire contents of all of which are hereby incorporated by reference in their entirety.
- The present specification makes reference to a Sequence Listing (submitted electronically as a .txt file named “2013404-0024_ST25.txt” on Apr. 29, 2022). The .txt file was generated on Oct. 7, 2020, and is 7,072 bytes in size. The entire contents of the Sequence Listing are herein incorporated by reference.
- Caenorhabditis elegans is a bacteriovorus nematode that is about 1 mm in length and lives in temperate soil environments.
- The present disclosure provides an insight that C. elegans can provide and/or represent surprisingly useful systems for assessing one or more features of a microbial preparation (e.g., of a microbiome sample). Among other things, the present disclosure describes technologies that can be useful for assessing microbiome samples to identify or characterize effects and/or modulation of microbial strains of such microbiome samples on certain diseases or conditions. In some embodiments, such technologies can be useful to discern strain-level differences in a particular patient or patient population. Accordingly, the present disclosure also provides technologies that can be useful to assess the nature of the microbial strains in patient-specific samples and thus provide patient-specific information on how individual patients' microbiomes differentially affect their health conditions. For example, in some embodiments, technologies provided herein can be useful to identify diseases or conditions to which a patient might be susceptible, based on the nature of the microbial strains in patient-specific samples. In some embodiments, technologies provided herein can be useful to identify microbial strains in patients that are beneficial, e.g., to protect patients from or confer resistance to certain diseases or conditions. Thus, technologies described herein are useful as diagnostic tools for screening microbiome samples (e.g., human microbiome samples) for disease modifiers (e.g., microbial strains that affect a disease or condition).
- Indeed, in certain embodiments, the use of transgenic C. elegans whole-animal model systems to identify or screen for microbiome strains (e.g., present in human microbiome) that can modulate or affect pathogenesis and/or development of a neurodegenerative disease or condition (e.g., Alzheimer's disease). Those skilled in the art reading the present disclosure will understand that technologies described herein are applicable for use not only relating to neurodegenerative diseases, such as Alzheimer's disease as exemplified, but also relating to various other diseases or conditions that may be associated with microbiomes, such as, but not limited to Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, type II diabetes, obesity, hyperglycemia, glucose intolerance, insulin resistance (i.e., hyperinsulinemia, metabolic syndrome, syndrome X), hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia (e.g., dyslipidemia), hypertriglyceridemia, cardiovascular disease, atherosclerosis, peripheral vascular disease, kidney disease, ketoacidosis, thrombotic disorders, nephropathy, diabetic neuropathy, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, glaucoma, sexual dysfunction, dermatopathy, dyspepsia, hypoglycemia, metabolic syndrome, cancer or edema.
- In some aspects, provided herein are systems comprising a plurality of C. elegans cultures, wherein each culture comprises a transgenic C. elegans strain that models a disease or condition (e.g., a mammalian disease or condition). In some embodiments, such a plurality of C. elegans cultures may comprise at least 5 or more (including, e.g., at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50 or more) C. elegans cultures.
- In some embodiments, one or more of C. elegans cultures in a provided system includes a transgenic C. elegans strain that models a disease or condition present in a target subject. In some embodiments, one or more of C. elegans cultures in a provided system may include a transgenic C. elegans strain that models a mammalian disease or condition (e.g., a human disease or condition). An exemplary human disease or condition to be modeled by C. elegans strains may include a neurodegenerative disease or disorder (e.g., Alzheimer's disease). In some embodiments, a disease or condition (e.g. human disease or condition) to be modeled by C. elegans strains may include a disease or condition associated with an altered or defective HIF-1 pathway (e.g. may comprise a cellular stress response). In some embodiments, for example, the disease or condition to be modeled by C. elegans may be an ocular neovascular disease or disorder (e.g., diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma). In some embodiments, one or more of C. elegans cultures in a provided system may include a transgenic C. elegans that models a non-human mammalian disease or conditions, e.g., a canine, a feline, an equine, a bovine, an ovine, a caprine, or a porcine disease or condition.
- In some embodiments, transgenic C. elegans strains provided in a system described herein may comprise a transgene comprising a characteristic sequence element associated with a target disease or condition (e.g., a mammalian disease or condition). Such a characteristic sequence element that is associated with a disease or condition (e.g., a mammalian disease or condition) may be or comprise a foreign gene (e.g., a mammalian gene), a DNA regulatory element (e.g., a mammalian DNA regulatory element), and/or a mammalian RNA regulatory element. Various DNA and RNA regulatory elements are known in the art; one skilled in the art will thus understand that in some embodiments, DNA regulatory elements that are associated with a disease or condition (e.g., a mammalian disease or condition) may be or comprise enhancers, promoters, silencers, insulators, locus control regions, and combination thereof. In some embodiments, RNA regulatory elements such as, e.g., untranslated regions, introns, splice sites, and combinations thereof, which are associated with a disease or condition (e.g., a mammalian disease or condition), may be used in accordance with the present disclosure.
- Additionally, or alternatively, transgenic C. elegans strains in a provided system may comprise a transgene comprising a reporter gene. Non-limiting examples of such a reporter gene may include, but are not limited to, fluorescent, phosphorescent, and/or bioluminescent proteins.
- In some embodiments involving C. elegans cultures, at least two or more of such cultures may each comprise a transgenic C. elegans strain that models the same disease or condition (e.g., a mammalian disease or condition). In some such embodiments, at least two or more of such cultures may each comprise a transgenic C. elegans strain that models a different biochemical or molecular pathway associated with the same disease or condition (e.g., a mammalian disease or condition). In some embodiments involving C. elegans cultures, all of such cultures may each comprise the same transgenic C. elegans strains that model the same disease or condition (e.g., a mammalian disease or condition).
- In some embodiments involving C. elegans cultures, at least two or more of such cultures may each comprise a transgenic C. elegans strain that models a different disease or condition (e.g., a mammalian disease or condition).
- Systems described herein can be used to characterize relationships and/or effects of microbial preparations (e.g., of a microbiome sample) with certain diseases or conditions in target subjects. Accordingly, in some embodiments, one or more C. elegans cultures in such a system comprise microbes of a mammalian microbiome (e.g., a human microbiome). In some embodiments, each of such C. elegans cultures may include microbes of a mammalian microbiome (e.g., a human microbiome). In some embodiments, one or more C. elegans cultures in such a system can comprise microbes of a canine, a feline, an equine, a bovine, an ovine, a caprine, or a porcine microbiome. Microbiomes used in accordance with the present disclosure may be obtained or derived from target anatomical locations of mammalian subjects. Examples of such microbiomes may include, but are not limited to cutaneous microbiomes, oral microbiomes, nasal microbiomes, gastrointestinal microbiomes, brain microbiomes, pulmonary microbiomes, and/or urogenital microbiomes.
- In some embodiments, microbes in each C. elegans culture can comprise one or more microbial strains. In some embodiments, microbes in each culture can comprise a single microbial strain.
- In some embodiments, one or more of C. elegans cultures can comprise a therapeutic or nutraceutical agent.
- Methods for using a plurality of C. elegans cultures to characterize a microbiome are also provided herein. In some embodiments, a method is for screening a microbiome of an individual (e.g., a mammal, e.g., a human) to determine if a microbial strain or a combination of microbial strains affects a mammalian disease or disorder. In some embodiments, a method is for diagnosing an individual (e.g., a mammal, e.g., a human) based on one or more microbial strains in a microbiome of the individual. In some embodiments, a method is for monitoring a disease or condition progression in an individual (e.g., a mammal, e.g., a human) based on one or more microbial strains in a microbiome of the individual.
- In some embodiments described herein, a is provided method comprising adding microbes obtained from a mammalian microbiome to each of C. elegans cultures of a system described herein. In some embodiments, microbes in each C. elegans culture can comprise one or more microbial strains. In some embodiments, microbes in each such culture can comprise a single microbial strain. Microbiomes used in methods described herein may be obtained or derived from target anatomical locations of mammalian subjects. Examples of such microbiomes may include, but are not limited to cutaneous microbiomes, oral microbiomes, nasal microbiomes, gastrointestinal microbiomes, brain microbiomes, pulmonary microbiomes, and/or urogenital microbiomes.
- In some embodiments, a method may comprise adding a plurality of microbial strains of a mammalian microbiome to a plurality of C. elegans cultures, wherein a different microbial strain is added to each C. elegans culture, and wherein each culture comprises the same transgenic C. elegans strain, and the transgenic C. elegans strain models a mammalian disease or condition.
- In some embodiments, one or more of C. elegans cultures can comprise a therapeutic or nutraceutical agent. Thus, in some embodiments, a method described can further comprise adding a therapeutic or nutraceutical agent to one or more of C. elegans cultures.
- In some embodiments, a method described herein can further comprise determining one or more parameter values of a transgenic C. elegans strain in each of C. elegans cultures. In some embodiments, such parameter(s) of a transgenic C. elegans is/are associated with a mammalian disease or condition that such a transgenic C. elegans strain models. Exemplary such parameters of transgenic C. elegans may include biological functions or phenotypes and/or levels and/or activity of molecules (e.g., small molecules, proteins, polypeptide, or transcripts) that are associated with a mammalian disease or condition.
- In some embodiments, a method may further comprise: (a) determining, before adding a microbial strain to a C. elegans culture, one or more parameter values of the transgenic C. elegans strain in such a culture, (b) determining, after adding the microbial strain to the C. elegans culture, the same one or more parameter values of the transgenic C. elegans strain in such a culture, and (c) comparing the one or more parameter values determined before adding the microbial strain with the one or more parameter values determined after adding the microbial strain.
- Technologies described herein, in some embodiments, can be used to characterize microbial strain of a human biome associated with a human disease or condition. Thus, in some such embodiments, a transgenic C. elegans strain involved in systems and methods described herein models a human disease or condition. An exemplary human disease or condition that a transgenic C. elegans strain model is Alzheimer's disease. In some embodiments, a disease or condition (e.g. human disease or condition) that a transgenic C. elegans strain models may include a disease or condition associated with an altered or defective HIF-1 pathway (e.g. may comprise a cellular stress response). In some embodiments, for example, a disease or condition that a transgenic C. elegans strain models may be an ocular neovascular disease or disorder (e.g., diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma). In some embodiments, a disease or condition that a transgenic C. elegans strain models is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
- Accordingly, certain aspects described herein relate to technologies for characterizing a microbial strain of a human biome. For example, one aspect provides a method, which comprises (a) adding a microbial strain to a C. elegans culture comprising a transgenic C. elegans strain that models Alzheimer's disease, and (b) determining whether the microbial strain affects one or more parameters of the transgenic C. elegans strain, wherein such one or more parameters are associated with Alzheimer's disease. In some embodiments, such a transgenic C. elegans strain may comprise a transgene encoding a human ssApoE4 protein, a human Aβ1-42 polypeptide, or a human pseudophosphorylated tau protein.
- In some embodiments, such a method further comprises: (a) determining, before adding a microbial strain to a C. elegans culture, one or more parameter values of the transgenic C. elegans strain in such a culture, (b) determining, after adding the microbial strain to the C. elegans culture, the same one or more parameter values of the transgenic C. elegans strain in such a culture, and (c) comparing the one or more parameter values determined before adding the microbial strain with the one or more parameter values determined after adding the microbial strain. Exemplary such one or more parameters include, but are not limited to, (i) a level of C. elegans paralysis; (ii) a level of amyloid plaques; (iii) a level of tau filaments; (iv) a level of neuroinflammation; (v) a level of proteasomal function; and/or (vi) a combination thereof.
- In another aspect, the present disclosure provides a method of characterizing a microbial strain of a human biome, comprising: (a) adding the microbial strain to a C. elegans culture comprising a transgenic C. elegans strain that models a disease or condition associated with an altered or defective HIF-1 pathway, and (b) determining whether the microbial strain affects one or more parameters of the transgenic C. elegans strain, wherein the one or more parameters are associated with an altered or defective HIF-1 pathway. In some embodiments, such a transgenic C. elegans strain may comprise a transgene encoding a human prolyl hydroxylase EGLN, a human HIF transcription factor, or a human HIFα protein.
- In some embodiments, such a method further comprises: (a) determining, before adding the microbial strain to a C. elegans culture, one or more parameter values of the transgenic C. elegans strain in the culture, (b) determining, after adding the microbial strain to the C. elegans culture, the same one or more parameter values of the transgenic C. elegans strain in the culture, and (c) comparing the one or more parameter values determined before adding the microbial strain with the one or more parameter values determined after adding the microbial strain.
- Exemplary such one or more parameters include, but are not limited to, (i) a level of neuroinflammation; (ii) a level of proteasomal function; (iii) a level of C. elegans egg-laying rate; and/or (iv) a combination thereof.
- A transgenic C. elegans strain that expresses two or more of (i) a human ssApoE4, (ii) a human Aβ1-42, (iii) a human pseudophosphorylated tau, and (iv) a UbV-GFP proteasomal marker is also within the scope of the present disclosure.
- The present disclosure, among other things, also describes uses of provided transgenic C. elegans strains, systems, and/or methods to screen a mammalian microbiome for microbial strains that affect a mammalian disease or condition. Also, within the scope of the present disclosure includes uses of provided C. elegans, systems, and/or methods to characterize the effect a microbial strain of a mammalian microbiome has on a mammalian disease or condition. For example, a human microbiome can be screened/characterized using technologies provided herein in accordance with the present disclosure.
- The present disclosure describes, among other things, compositions comprising one or more microbial strains. In some embodiments, a composition provided herein comprises one or more microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein. In some embodiments, a composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein.
- In some embodiments, a composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains listed in TABLE 8 below.
- In some embodiments, a composition provided herein comprises Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, Acidaminococcus sp., or a combination thereof. In some embodiments, a combination comprises at least two of, at least three of, at least four of, at least five of, at least six of, at least seven of, at least eight of, at least nine of, or all of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, and Acidaminococcus sp.
- In some embodiments, a composition is a pharmaceutical composition. In some embodiments, a composition is an ingestible item.
- The present disclosure describes, among other things, methods comprising administering a composition described herein.
- In some embodiments, a method of treating a disease or condition in a subject, comprising administering to a subject in need a composition as described herein. In some embodiments, a disease or condition is a neurodegenerative disease or disorder. In some embodiments, a disease or condition is Alzheimer's disease. In some embodiments, a disease or condition may be associated with an altered or defective HIF-1 pathway. In some embodiments, a disease or condition may be an ocular neovascular disease or disorder. In some embodiments, a disease or condition is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma. The present disclosure describes, among other things, uses of compositions described herein. In some embodiments, a use of a composition as described herein is in the treatment of a disease or condition in a subject. In some embodiments, a disease or condition is a neurodegenerative disease or disorder. In some embodiments, a disease or condition is Alzheimer's disease. In some embodiments, a disease or condition may be associated with an altered or defective HIF-1 pathway. In some embodiments, a disease or condition may be an ocular neovascular disease or disorder. In some embodiments, a disease or condition is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
- These, and other aspects encompassed by the present disclosure, are described in more detail below and in the claims.
- The scope of the present invention is defined by the claims appended hereto and is not limited by certain embodiments described herein. Those skilled in the art, reading the present specification, will be aware of various modifications that may be equivalent to such described embodiments, or otherwise within the scope of the claims. In general, terms used herein are in accordance with their understood meaning in the art, unless clearly indicated otherwise. Explicit definitions of certain terms are provided below; meanings of these and other terms in particular instances throughout this specification will be clear to those skilled in the art from context.
- Use of ordinal terms such as “first,” “second,” “third,” etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.
- The articles “a” and “an,” as used herein, should be understood to include the plural referents unless clearly indicated to the contrary. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. In some embodiments, exactly one member of a group is present in, employed in, or otherwise relevant to a given product or process. In some embodiments, more than one, or all group members are present in, employed in, or otherwise relevant to a given product or process. It is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim (or, as relevant, any other claim) unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. Where elements are presented as lists (e.g., in Markush group or similar format), it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where embodiments or aspects are referred to as “comprising” particular elements, features, etc., certain embodiments or aspects “consist,” or “consist essentially of,” such elements, features, etc. For purposes of simplicity, those embodiments have not in every case been specifically set forth in so many words herein. It should also be understood that any embodiment or aspect can be explicitly excluded from the claims, regardless of whether the specific exclusion is recited in the specification.
- Administration: As used herein, the term “administration” typically refers to the administration of a composition to a subject or system to achieve delivery of an agent to the subject or system. In some embodiments, the agent is, or is included in, the composition; in some embodiments, the agent is generated through metabolism of the composition or one or more components thereof. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some particular embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g. intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc. In many embodiments provided by the present disclosure, administration is oral administration. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve application of a fixed number of doses. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and/or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time. Administration of cells can be by any appropriate route that results in delivery to a desired location in a subject where at least a portion of the delivered cells or components of the cells remain viable. A period of viability of cells after administration to a subject can be as short as a few hours, e.g., twenty-four hours, to a few days, to as long as several years, i.e., long-term engraftment. In some embodiments, administration comprises delivery of a bacterial extract or preparation comprising one or more bacterial metabolites and/or byproducts but lacking fully viable bacterial cells.
- Analog: As used herein, the term “analog” refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an “analog” shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, an analog is a substance that can be generated from the reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance. In some embodiments, an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.
- Approximately: As applied to one or more values of interest, includes to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within ±10% (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
- Comparable: As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, subjects, etc., that may not be identical to one another but that are sufficiently similar to permit comparison therebetween so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.
- Conservative: As used herein, refers to instances when describing a conservative amino acid substitution, including a substitution of an amino acid residue by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of interest of a protein, for example, the ability of a receptor to bind to a ligand. Examples of groups of amino acids that have side chains with similar chemical properties include: aliphatic side chains such as glycine (Gly, G), alanine (Ala, A), valine (Val, V), leucine (Leu, L), and isoleucine (Ile, I); aliphatic-hydroxyl side chains such as serine (Ser, S) and threonine (Thr, T); amide-containing side chains such as asparagine (Asn, N) and glutamine (Gln, Q); aromatic side chains such as phenylalanine (Phe, F), tyrosine (Tyr, Y), and tryptophan (Trp, W); basic side chains such as lysine (Lys, K), arginine (Arg, R), and histidine (His, H); acidic side chains such as aspartic acid (Asp, D) and glutamic acid (Glu, E); and sulfur-containing side chains such as cysteine (Cys, C) and methionine (Met, M). Conservative amino acids substitution groups include, for example, valine/leucine/isoleucine (Val/Leu/Ile, V/L/I), phenylalanine/tyrosine (Phe/Tyr, F/Y), lysine/arginine (Lys/Arg, K/R), alanine/valine (Ala/Val, A/V), glutamate/aspartate (Glu/Asp, E/D), and asparagine/glutamine (Asn/Gln, N/Q). In some embodiments, a conservative amino acid substitution can be a substitution of any native residue in a protein with alanine, as used in, for example, alanine scanning mutagenesis. In some embodiments, a conservative substitution is made that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet, G. H. et al., 1992, Science 256:1443-1445, which is incorporated herein by reference in its entirety. In some embodiments, a substitution is a moderately conservative substitution wherein the substitution has a nonnegative value in the PAM250 log-likelihood matrix.
-
CONSERVATIVE AMINO ACID SUBSTITUTIONS For Amino Acid Code Replace With Alanine A D-ala, Gly, Aib, β-Ala, Acp, L-Cys, D-Cys Arginine R D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn Asparagine N D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln Aspartic Acid D D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln Cysteine C D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr Glutamine Q D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp Glutamic Acid E D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln Glycine G Ala, D-Ala, Pro, D-Pro, Aib, β-Ala, Acp Isoleucine I D-Ile, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met Leucine L D-Leu, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met Lysine K D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn Methionine M D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val Phenylalanine F D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4 or 5-phenylproline, AdaA, AdaG, cis-3,4 or 5-phenylproline, Bpa, D-Bpa Proline P D-Pro, L-I-thioazolidine-4-carboxylic acid, D-or-L-1-oxazolidine-4-carboxylic acid (Kauer, U.S. Pat. No. (4,511,390) Serine S D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met (O), D-Met (O), L-Cys, D-Cys Threonine T D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met (O), D-Met (O), Val, D-Val Tyrosine Y D-Tyr, Phe, D-Phe, L-Dopa, His, D-His Valine V D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met, AdaA, AdaG - Control: As used herein, refers to the art-understood meaning of a “control” being a standard against which results are compared. Typically, controls are used to augment integrity in experiments by isolating variables in order to make a conclusion about such variables. In some embodiments, a control is a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparator. A “control” also includes a “control animal.” A “control animal” may have a modification as described herein, a modification that is different as described herein, or no modification (i.e., a wild-type animal). In one experiment, a “test” (i.e., a variable being tested) is applied. In a second experiment, the “control,” the variable being tested is not applied. In some embodiments, a control is a historical control (i.e., of a test or assay performed previously, or an amount or result that is previously known). In some embodiments, a control is or comprises a printed or otherwise saved record. A control may be a positive control or a negative control.
- Determining, measuring, evaluating, assessing, assaying and analyzing: Determining, measuring, evaluating, assessing, assaying and analyzing are used interchangeably herein to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assaying may be relative or absolute. “Assaying for the presence of” can be determining the amount of something present and/or determining whether or not it is present or absent.
- Dosage form: Those skilled in the art will appreciate that the term “dosage form” may be used to refer to a physically discrete unit of an agent (e.g., a therapeutic agent) for administration to a subject. Typically, each such unit contains a predetermined quantity of agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen). Those of ordinary skill in the art appreciate that the total amount of a therapeutic composition or agent administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.
- Dosing regimen: Those skilled in the art will appreciate that the term “dosing regimen” may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population.
- Engineered: In general, the term “engineered” refers to the aspect of having been manipulated by the hand of man. For example, a cell or organism is considered to be “engineered” if it has been manipulated so that its genetic information is altered (e.g., new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or deletion mutation, or by mating protocols). As is common practice and is understood by those in the art, progeny of an engineered polynucleotide or cell are typically still referred to as “engineered” even though the actual manipulation was performed on a prior entity.
- Excipient: As used herein, refers to an inactive (e.g., non-therapeutic) agent that may be included in a pharmaceutical composition, for example to provide or contribute to a desired consistency or stabilizing effect. In some embodiments, suitable pharmaceutical excipients may include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- Functional: As used herein, a “functional” biological molecule is a biological molecule in a form in which it exhibits a property and/or activity by which it is characterized. A biological molecule may have two functions (i.e., bifunctional) or many functions (i.e., multifunctional).
- Gene: As used herein, refers to a DNA sequence in a chromosome that codes for a product (e.g., an RNA product and/or a polypeptide product). In some embodiments, a gene includes coding sequence (i.e., sequence that encodes a particular product). In some embodiments, a gene includes non-coding sequence. In some particular embodiments, a gene may include both coding (e.g., exonic) and non-coding (e.g., intronic) sequence. In some embodiments, a gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences that, for example, may control or impact one or more aspects of gene expression (e.g., cell-type-specific expression, inducible expression, etc.). For the purpose of clarity, we note that, as used in the present disclosure, the term “gene” generally refers to a portion of a nucleic acid that encodes a polypeptide or fragment thereof, the term may optionally encompass regulatory sequences, as will be clear from context to those of ordinary skill in the art. This definition is not intended to exclude application of the term “gene” to non-protein-coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a polypeptide-coding nucleic acid.
- Improve, increase, enhance, inhibit or reduce: As used herein, the terms “improve,” “increase,” “enhance,” “inhibit,” “reduce,” or grammatical equivalents thereof, indicate values that are relative to a baseline or other reference measurement. In some embodiments, a value is statistically significantly difference that a baseline or other reference measurement. In some embodiments, an appropriate reference measurement may be or comprise a measurement in a particular system (e.g., in a single individual) under otherwise comparable conditions absent presence of (e.g., prior to and/or after) a particular agent or treatment, or in presence of an appropriate comparable reference agent. In some embodiments, an appropriate reference measurement may be or comprise a measurement in comparable system known or expected to respond in a particular way, in presence of the relevant agent or treatment. In some embodiments, an appropriate reference is a negative reference; in some embodiments, an appropriate reference is a positive reference.
- Isolated: As used herein, refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man. In some embodiments, an isolated substance or entity may be enriched; in some embodiments, an isolated substance or entity may be pure. In some embodiments, isolated substances and/or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated. In some embodiments, isolated agents are about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is “pure” if it is substantially free of other components. In some embodiments, as will be understood by those skilled in the art, a substance may still be considered “enriched”, “isolated” or even “pure”, after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, percent isolation or purity of the substance is calculated without including such carriers or excipients. Those skilled in the art are aware of a variety of technologies for isolating (e.g., enriching or purifying) substances or agents (e.g., using one or more of fractionation, extraction, precipitation, or other separation).
- Pharmaceutical composition: As used herein, the term “pharmaceutical composition” refers to a composition in which an active agent is formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, the active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, a pharmaceutical composition may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue, capsules, powders, etc. In some embodiments, an active agent may be or comprise a cell or population of cells (e.g., a culture, for example of an EES microbe); in some embodiments, an active agent may be or comprise an extract or component of a cell or population (e.g., culture) of cells. In some embodiments, an active agent may be or comprise an isolated, purified, or pure compound. In some embodiments, an active agent may have been synthesized in vitro (e.g., via chemical and/or enzymatic synthesis). In some embodiments, an active agent may be or comprise a natural product (whether isolated from its natural source or synthesized in vitro).
- Pharmaceutically acceptable: As used herein, the term “pharmaceutically acceptable” which, for example, may be used in reference to a carrier, diluent, or excipient used to formulate a pharmaceutical composition as disclosed herein, means that the carrier, diluent, or excipient is compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
- Pharmaceutically acceptable carrier: As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be is “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.
- Prevention: The term “prevention”, as used herein, refers to a delay of onset, and/or reduction in frequency and/or severity of one or more symptoms of a particular disease, disorder or condition. In some embodiments, prevention is assessed on a population basis such that an agent is considered to “prevent” a particular disease, disorder or condition if a statistically significant decrease in the development, frequency, and/or intensity of one or more symptoms of the disease, disorder or condition is observed in a population susceptible to the disease, disorder, or condition. In some embodiments, prevention may be considered complete, for example, when onset of a disease, disorder or condition has been delayed for a predefined period of time.
- Reference: As used herein describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and/or comparison to a particular possible reference or control. In some embodiments, a reference is a negative control reference; in some embodiments, a reference is a positive control reference.
- Risk: As will be understood from context, “risk” of a disease, disorder, and/or condition refers to a likelihood that a particular individual will develop the disease, disorder, and/or condition. In some embodiments, risk is expressed as a percentage. In some embodiments, risk is from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or up to 100%. In some embodiments risk is expressed as a risk relative to a risk associated with a reference sample or group of reference samples. In some embodiments, a reference sample or group of reference samples have a known risk of a disease, disorder, condition and/or event. In some embodiments a reference sample or group of reference samples are from individuals comparable to a particular individual. In some embodiments, relative risk is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.
- Sample: As used herein, the term “sample” typically refers to an aliquot of material obtained or derived from a source of interest. In some embodiments, a source of interest is a biological or environmental source. In some embodiments, a source of interest may be or comprise a cell or an organism, such as a microbe, a plant, or an animal (e.g., a human). In some embodiments, a source of interest is or comprises biological tissue or fluid. In some embodiments, a biological tissue or fluid may be or comprise amniotic fluid, aqueous humor, ascites, bile, bone marrow, blood, breast milk, cerebrospinal fluid, cerumen, chyle, chime, ejaculate, endolymph, exudate, feces, gastric acid, gastric juice, lymph, mucus, pericardial fluid, perilymph, peritoneal fluid, pleural fluid, pus, rheum, saliva, sebum, semen, serum, smegma, sputum, synovial fluid, sweat, tears, urine, vaginal secretions, vitreous humour, vomit, and/or combinations or component(s) thereof. In some embodiments, a biological fluid may be or comprise an intracellular fluid, an extracellular fluid, an intravascular fluid (blood plasma), an interstitial fluid, a lymphatic fluid, and/or a transcellular fluid. In some embodiments, a biological fluid may be or comprise a plant exudate. In some embodiments, a biological tissue or sample may be obtained, for example, by aspirate, biopsy (e.g., fine needle or tissue biopsy), swab (e.g., oral, nasal, skin, or vaginal swab), scraping, surgery, washing or lavage (e.g., bronchioalveolar, ductal, nasal, ocular, oral, uterine, vaginal, or other washing or lavage). In some embodiments, a biological sample is or comprises cells obtained from an individual. In some embodiments, a sample is a “primary sample” obtained directly from a source of interest by any appropriate means. In some embodiments, as will be clear from context, the term “sample” refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane. Such a “processed sample” may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to one or more techniques such as amplification or reverse transcription of nucleic acid, isolation and/or purification of certain components, etc.
- Small molecule: As used herein, the term “small molecule” refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons. In general, small molecules may have a molecular weight of less than 3,000 Daltons (Da). Small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).
- Subject: As used herein, the term “subject” refers to an individual to which a provided treatment is administered. In some embodiments, a subject is animal. In some embodiments, a subject is a mammal, e.g., a mammal that experiences or is susceptible to a disease, disorder, or condition as described herein. In some embodiments, an animal is a vertebrate, e.g., a mammal, such as a non-human primate, (particularly a higher primate), a sheep, a dog, a rodent (e.g. a mouse or rat), a guinea pig, a goat, a pig, a cat, a rabbit, or a cow. In some embodiments, an animal is a non-mammal animal, such as a chicken, an amphibian, a reptile, or an invertebrate model C. elegans. In some embodiments, a subject is a human. In some embodiments, a patient is suffering from or susceptible to one or more diseases, disorders or conditions as described herein. In some embodiments, a patient displays one or more symptoms of a one or more diseases, disorders or conditions as described herein. In some embodiments, a patient has been diagnosed with one or more diseases, disorders or conditions as described herein. In some embodiments, the subject is receiving or has received certain therapy to diagnose and/or to treat a disease, disorder, or condition. In another embodiment, the subject is an experimental animal or animal substitute as a disease model.
- Substantially: As used herein, refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
- Therapeutic regimen: A “therapeutic regimen”, as that term is used herein, refers to a dosing regimen whose administration across a relevant population may be correlated with a desired or beneficial therapeutic outcome.
- Therapeutically effective amount: As used herein, is meant an amount that produces the desired effect for which it is administered. In some embodiments, the term refers to an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is one that reduces the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition. Those of ordinary skill in the art will appreciate that the term “therapeutically effective amount” does not in fact require successful treatment be achieved in a particular individual. Rather, a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. In some embodiments, reference to a therapeutically effective amount may be a reference to an amount as measured in one or more specific tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.). Those of ordinary skill in the art will appreciate that, in some embodiments, a therapeutically effective amount of a particular agent or therapy may be formulated and/or administered in a single dose. In some embodiments, a therapeutically effective agent may be formulated and/or administered in a plurality of doses, for example, as part of a dosing regimen.
- Treatment: As used herein, the term “treatment” (also “treat” or “treating”) refers to any administration of a therapy that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition. In some embodiments, such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition. Alternatively, or additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition. In some embodiments, treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
-
FIG. 1 shows data evidencing that APOE4 protein enhances the Aβ-induced paralysis phenotype in C. elegans. C. elegans animals having the indicated genotypes were administered an E. coli OP50 standard laboratory strain. Animals were monitored fromday 1 adulthood every alternative day until all were paralyzed. For each assay, at least 20 animals were recorded. Data from three independent trials are presented in a plot. For each data point, mean±s.d is presented in the graph. -
FIG. 2 shows data evidencing that expression of Aβ3-42 conjugated to green fluorescent protein (GFP) and human ssAPOE4 significantly increased the number of aggregates. C. elegans animals having the indicated genotypes were administered an E. coli OP50 standard laboratory strain. GFP aggregates in the anterior region of the animal were counted when the animals reached adulthood. For each assay, at least 17 animals were recorded. For each data point, mean±s.d is presented in a bar graph. Compared to animals expressing Aβ3-42, animals expressing Aβ3-42 and ssApoE4 had significantly increased GFP aggregates as analyzed using Student's t-test, P<0.0001. -
FIG. 3 shows data evidencing that UbV-GFP is stabilized in animals expressing both human ssAPOE4 and human tau352(PHP). C. elegans animals having the indicated genotypes were administered with the E. coli OP50 standard laboratory strain. The number of animals expressing GFP in the gut were counted when the animals reached adulthood. For each assay, at least 30 animals were recorded. Data from three independent trials are presented in a bar graph. For each data point, mean±s.d is presented in the graph. Compared to animals that expressed tau352(PHP), animals expressing ssAPOE4 and tau352(PHP) had significantly increased UbV-GFP expression as analyzed using Student's t-test, P<0.0001. -
FIG. 4 includes data evidencing that certain microbial strains of a microbiome increase Aβ mediated paralysis. C. elegans animals having the indicated genotypes were administered with either E. coli OP50 standard laboratory strain or individual microbiome strains. Number of paralyzed animals were recorded onday 4 of adulthood. Data from three independent trials are presented in a bar graph. For each data point, mean±s.d is presented in the graph. Table 1 includes the raw data with number of animals analyzed for each condition. -
FIG. 5 includes data evidencing certain microbial strains of a microbiome modulate Aβ3-42::GFP aggregation. C. elegans animals having the indicated genotypes were administered with either E. coli op50 standard laboratory strain or individual microbiome strains. The number of GFP aggregates in the anterior region of the animal were counted when the animals reached adulthood. GFP aggregates in three animals were counted for each condition. For each data point, mean±s.d is presented in the graph. -
FIG. 6 includes data showing that certain microbial strains altered ATP production. Neuro2A cells were either mock-treated or treated with 108 CFU of each bacterium or a combination of all bacteria (CT10) for 16 hours. 2 μM of Human Amyloid β1-42 was added to all the wells except for the untreated wells. Cells were incubated for 24 hours and ATP levels were measured and normalized. The percent ATP was calculated according to the following formula: % ATP=[(sample normalized luminescence value/control normalized luminescence) *100]. -
FIG. 7 includes a schematic of the exemplary HIF pathways. - Provided herein are transgenic C. elegans disease models and methods of using C. elegans disease models to rapidly identify, assess, or characterize one or more microbial strains from a mammalian microbiome as affecting (e.g., enhancing or minimizing) a phenotype associated with a mammalian disease or condition. In some embodiments, identification, assessment, or characterization can occur with or without chemical entities and/or biologics (e.g., antibodies).
- C. elegans is a bacteriovorus nematode that is fed on E. coli diet in the laboratory. C. elegans can provide reliable, effective, and efficient genotypic and phenotypic models for a number of mammalian diseases and conditions, including various human diseases and conditions, such as aging, diabetes, neurodegenerative disorders, metabolic diseases, and cancer. The present disclosure provides the insight that C. elegans models of mammalian diseases and conditions can be used to rapidly screen human microbiome for microbial strains that are affecting such mammalian diseases and conditions. It is improbable to conduct such studies in standard mammalian cell culture assays or animal models. For example, it would be economically unviable, time-consuming, and laborious to screen millions of microbial species and/or strains individually, or even in combinations using, e.g., mouse models of human diseases and conditions. While C. elegans may not include some of the complexities of mammalian systems, C. elegans models share features with mammalian systems, have quick response times, and are less expensive to produce and maintain than mammalian model systems. Accordingly, C. elegans models of mammalian diseases and conditions provide a powerful front line for examining the impacts microbial strains of mammalian biomes have on mammalian diseases and conditions and present a useful tool to prioritize lead microbial strains that impact specific and sensitive conserved therapeutic targets.
- Provided herein are methods of using C. elegans as a tool for rapidly screening human microbiome for disease modifiers. Microbial strains of samples from a healthy patient or a patient having a disease or condition can be cultured using standard microbiological techniques. These microbial strains can be fed to a transgenic C. elegans strain carrying a mammalian (e.g., human) disease marker, a mammalian (e.g., human) disease gene mutation, or a combination thereof. Microbial strains can be fed to a transgenic C. elegans strain either individually or in combination. In some cases, an individual microbial strain or a combination of microbial strains can be fed to transgenic C. elegans strains that have a mammalian (e.g., human) disease marker, a mammalian (e.g., human) disease gene mutation, or a combination thereof in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies).
- The present disclosure recognizes that multiple outcomes can arise from feeding an individual microbial strain or a combination of microbial strains can be fed to transgenic C. elegans strains that have a mammalian (e.g., human) disease marker, a mammalian (e.g., human) disease gene mutation, or a combination thereof in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies). In a first scenario, methods described here could be used to identify, define, assess, and/or detect individual microbial strains or combinations of microbial strains from a mammalian microbiome that increase the severity of a mammalian disease or condition phenotype in C. elegans. In a second scenario, methods described here could be used to identify, define, assess, and/or detect individual microbial strains or combinations of microbial strains from a mammalian microbiome that decrease the severity of a mammalian disease or condition phenotype in C. elegans. In a third scenario, methods described here could be used to identify, define, assess, and/or detect individual microbial strains or combinations of microbial strains from a mammalian microbiome that have no effect of a mammalian disease or condition phenotype in C. elegans. The present disclosure recognizes that each of these outcomes provides valuable information.
- For example, individual microbial strains or combinations of microbial strains from a mammalian microbiome that increase the severity of a mammalian disease or condition phenotype in C. elegans can be potential early diagnostic biomarkers for a mammalian disease or condition. In some embodiments, such individual microbial strains or combinations of microbial strains are correlated with a high occurrence or increased severity of the disease or condition in mammals (e.g., human). If such a correlation has not been previously found, transgenic C. elegans and methods of using transgenic C. elegans described herein could be used to rapidly screen and/or assess one or more microbial strains in a mammalian microbiome using genetic screening or chemical extraction or genomic data mining methods to identify the potential “toxic” metabolites or components of microbiome involved in an increase in disease severity or incidence. These identified microbial strains and/or components of a mammalian microbiome could be also used for developing diagnostics. Also, identification and/or characterization of “toxic” microbial strains or microbiome components could be used for developing modulators or therapeutics that could target microbial strains, microbiome components or biosynthetic pathways that produce them.
- In addition, the present disclosure recognizes that individual microbial strains or combinations of microbial strains from a mammalian microbiome that decrease the severity of a mammalian disease or condition phenotype in C. elegans can correlate with disease severity in human patients. In some embodiments, such individual microbial strains or combinations of microbial strains are correlated with a low occurrence or decreased severity of the disease or condition in mammals (e.g., human). If such a correlation has not been previously found, transgenic C. elegans and methods of using transgenic C. elegans described herein could be used to rapidly screen and/or assess one or more microbial strains in a mammalian microbiome using genetic screening or chemical extraction or genomic data mining methods to identify the potential “beneficial” microbial strains, microbiome components, or metabolites involved in an decrease in disease severity or incidence. These identified microbial strains and/or components of a mammalian microbiome could be also used for developing diagnostics. Also, identification and/or characterization of “beneficial” microbial strains or microbiome components could be used as modulators or therapeutics for disease.
- In some case, individual microbial strains or combinations of microbial strains from a mammalian microbiome can be also fed in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof to a transgenic C. elegans strain to identify potential biological or signaling or cellular target genes or pathways. Biological or signaling or cellular target genes or pathways can include, but are not limited to, inflammation, insulin receptor, cell death, mitochondria, endoplasmic reticulum, proteasome, lipogenesis, and detoxification.
- In some cases, individual microbial strains or combinations of microbial strains from a mammalian microbiome can be fed in combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof to C. elegans strain to identify a set of signaling or target genes or pathways (e.g., a comprehensive set) that could modulate or optimize functions of a particular subcellular organelle relevant for a particular disease. For example, there are multiple pathways or targets that could be modulated to achieve optimal mitochondrial function, which is a relevant and important target in several neurodegenerative diseases, including Alzheimer's disease (AD). Biological targets for improving mitochondrial function include: biogenesis, bioenergetics, hormesis, and/or repair. Using transgenic C. elegans disease models and/or methods of using C. elegans disease models described herein, it is possible to identify individual or combinatorial microbiome species and/or combination with chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof that could modify or improve or alter either mitochondrial biogenesis, bioenergetics, hormesis or repair or combinations thereof. Thus, it is possible to identify and combine individual microbial strains or combinations of microbial strains from a mammalian microbiome and/or chemical entities (e.g., small molecules, e.g., drugs) or biologics (e.g., monoclonal antibodies), or combinations thereof that able to target multiple pathways to, e.g., achieve optimal mitochondrial function.
- C. elegans
- The free-living nematode C. elegans has been used extensively as a model system. C. elegans are inexpensive to cultivate, easy to physically manipulate, and has a multitude of genetic and molecular tools available for study. C. elegans are simple multicellular organisms: adults contain approximately 1,000 somatic cells yet have a variety of tissue types such as muscles, nerves, and intestinal cells. C. elegans have a short generation time, which allows for rapid experimentation. C. elegans generally progress from egg to larva to fertile adult in 3 days at room temperature. A single adult C. elegans can have between 300 and 1,000 progenies, which allows for a significant number of animals to be used and then quickly replenished in a relatively short amount of time. Due to the sexual dimorphism, C. elegans are useful for genetics. Self-fertilizing hermaphrodites can be maintained as homozygous mutations without the need for mating and males can be used for genetic crosses. C. elegans are transparent at every stage of their life cycle, which provides the ability to see inside the organism. This permits the observation of cellular events. It also permits the use of phosphorescent, luminescent, and fluorescent reporters. Manipulation of protein expression in C. elegans can also be performed using RNA-mediated interference (RNAi), which can allow for rapid assessment of gene function. Another advantage of using C. elegans a model system is the ability to freeze and recover the animals, thereby allowing long-term storage.
- C. elegans can be genetically modified using a number of techniques to generate transgenic C. elegans strains. The sexual dimorphism of C. elegans allows for genetic manipulations to be performed with relative ease and according to know procedures. For example, if a strain needs to be propagated, single hermaphrodites can be used to self-fertilize and generate a population of offspring. Even if a mutation renders an animal unable to mate, it remains possible for a hermaphrodite to produce progeny. Another aspect of C. elegans reproduction that makes C. elegans an effective genetic tool is the animal's ability to cross males with hermaphrodites. For example, mating experiments allow genetic markers such as mutations causing visible phenotypes to be placed together in a single organism along with an unknown mutation in order to facilitate mapping of that mutation. Hermaphrodites make only a limited number of sperm and can typically have approximately 300 self progeny. Mating increases the number of offspring produced by a single hermaphrodite to approximately 1,000 due to the addition of the male-produced sperm. The relatively large number of progeny coupled with the short life span of C. elegans allows for rapid and inexpensive analyses to be performed on the animals.
- In addition to genetic modifications via reproduction, C. elegans can be genetically modified via injection of transgenes. Microinjection is an effective method for creating transgenic animals and for introducing various types of molecules directly to cells. For DNA transformation, one approach is to inject DNA into a distal arm of a C. elegans gonad. A distal germline of C. elegans contains a central core of cytoplasm that is shared by many germ cell nuclei. Therefore, DNA injected into a distal arm of a C. elegans gonad can be delivered to many progeny. Microinjection directly into oocyte nuclei can induce chromosomal integration of transgenes, but this technique can be more difficult to perform. C. elegans can also incorporate genetic material that is fed to them.
- C. elegans are relatively simple to culture. C. elegans can be cultivated in either liquid culture or on the Nematode Growth Medium (NGM) agar plates in the presence of bacteria. It is possible to grow the animals in a chemically defined medium without the addition of bacteria, which can be useful because the components of a medium can be altered in order to study the nutrient or other chemical requirements of the animals. In some embodiments, C. elegans are grown on the agar plates. C. elegans can be grown on Nematode Growth Medium (NGM) agar plates. Bacteria can be spread on the NGM plates as a food source for the animals. For example, OP50, a leaky E. coli uracil auxotroph can be used. OP50 will grow slowly and provide nutrients for the animals without overgrowing them. Once the animals have eaten all of the food on a plate they will burrow into the agar and can be maintained on the “starved” plate for weeks at a time in a 15° C. incubator. The animals can be transferred to an agar plate with fresh bacteria by either cutting and moving a small block of agar from the starved plate with a sterile instrument such as a micropipette tip, or washing the worms off the surface of the plate with sterile water, or by picking one or more individuals onto a fresh plate, which will cause the C. elegans to reemerge. At any time, C. elegans can be cryogenically preserved. C. elegans prefer to grow between 15° C. and 25° C., but the temperature can vary depending on the strain of C. elegans and conditions being tested. In some embodiments, a C. elegans culture can be cultured at a temperature of at least 5° C., at least 10° C., at least 15° C., at least 20° C., at least 25° C., at least 30° C., at least 35° C., or at least 40° C. In some embodiments, a C. elegans culture can be cultured at a temperature of at most 65° C., at most 60° C., at most 55° C., at most 50° C., at most 55° C., at most 40° C., at most 35° C., at most 30° C., at most 25° C., or at most 20° C. Standard protocols for C. elegans manipulation and culture are known, e.g., as described by Stiernagle T. Maintenance of C. elegans. Wormbook, ed. The C. elegans Research Community, WormBook. (Feb. 11, 2006), which is incorporated herein by reference.
- Microbial Preparation(s) and/or Component(s)
- The present disclosure provides systems and methods for assessing, characterizing, and identifying one or more microbial strains of a microbiome. Such systems and methods can be useful for assessing, characterizing, and identifying one or more microbial strains that affect the health of humans, livestock, and/or pets. In some embodiments, assessing, characterizing, and identifying one or more microbial strains from a microbiome of a snake, lizard, fish, or bird. In some embodiments, assessing, characterizing, and identifying one or more microbial strains from a mammalian microbiome. A mammalian microbiome can be a canine, a feline, an equine, a bovine, an ovine, a caprine, or a porcine microbiome. Generally, a microbiome used in a system or method described herein will correspond with the disease or condition modeled by a transgenic C. elegans used in the system or method. For example, if a transgenic C. elegans models a human disease, a human microbiome will be assessed, characterized, or identified.
- A microbiome can be isolated from any system or tissue of an organism that supports microbial growth. For example, a microbiome can be a cutaneous microbiome, an oral microbiome, a nasal microbiome, a gastrointestinal microbiome, a brain microbiome, a pulmonary microbiome, or a urogenital microbiome. A list of exemplary microbial strains found in a gastrointestinal microbiome is included below in TABLE 8. A person skilled in the art would understand that a microbiome sample can be obtained by various ways known in the art. For example, a cutaneous, oral, nasal, pulmonary, or urogenital microbiome sample could be obtained using a swab or tissue scrapping. In some embodiments, a gastrointestinal microbiome could be sampled from feces. A cutaneous microbiome, an oral microbiome, a nasal microbiome, a gastrointestinal microbiome, a brain microbiome, a pulmonary microbiome, or a urogenital microbiome sample could be obtained via a biopsy.
- In some embodiments, a microbiome is a microbiome of a healthy individual or an individual who does not suffer from or is not at risk of developing a particular disease or disorder. In some embodiments, a microbiome is a microbiome of an individual that suffers from or is at risk of developing a particular disease or disorder. In some embodiments, a microbiome is a microbiome of an individual who is known to suffer from a particular disease or disorder. In some embodiments, a human microbiome is a microbiome of a human with an unknown risk for one or more diseases or conditions.
- In some embodiments, a microbiome is a reference microbiome. A reference microbiome can be a microbiome of a healthy individual or an individual who does not suffer from or is not at risk of developing a particular disease or disorder. In some instances, a reference microbiome may be from the same individual as a microbiome to be assessed or characterized, but was obtained at a different time. In some instances, a reference microbiome may be from the same individual as a microbiome to be assessed or characterized, but was obtained from a different system or tissue.
- In some embodiments, an individual microbial strain or a combination of microbial strains may be assessed, characterized, or identified in a different relative amount than such strain or strains are found in a microbiome. For example, a single strain may be assessed, characterized, or identified using transgenic C. elegans or methods using transgenic C. elegans described herein, even though it is naturally present in a microbiome with other microbial strains. As another example, two microbial strains may be assessed, characterized, or identified together transgenic C. elegans or methods using transgenic C. elegans described herein, even though they are naturally present in a microbiome with additional microbial strains.
- An extract, component, or compound of a microbial strain may also be assessed, characterized, or identified using transgenic C. elegans or methods using transgenic C. elegans described herein. In some cases, an extract, component, or compound of a microbial strain that has been determined to affect a transgenic C. elegans model of a disease or condition may be assessed, characterized, or identified. Assessing, characterizing or identifying an extract, component, or compound of a microbial strain that affect a transgenic C. elegans model of a disease or condition may provide additional information about potential biomarkers, targets, or protective agents in a microbiome.
- A variety of technologies are known in the art that can be used to prepare extracts of microbial strains, and/or to isolate extracts, components, or compounds therefrom, or to process (e.g., to isolate and/or purify one or more components or compounds from). To give but a few examples, such technologies may include, for example, one or more of organic extraction, vacuum concentration, chromatography, and so on.
- Assessing Biological Impact
- The present disclosure provides the insight that C. elegans can be used to identify, characterize, or assess microbial strain(s) of a mammalian microbiome by contacting the microbial strain(s) (e.g., feeding the microbial strain(s) to, administering to) transgenic C. elegans that model a mammalian disease or condition. To determine whether a microbial strain or combination of microbial strains affects a transgenic C. elegans that model a mammalian disease or condition, parameters of the transgenic C. elegans can be observed, measured, or assessed in different samples that have been contacted with the microbial strain or combination of microbial strains. Various parameters of transgenic C. elegans can be observed, measured, or assessed to determine whether a microbial strain or combination of microbial strains affects a transgenic C. elegans that model a mammalian disease or condition. As just a few examples, transgenic C. elegans behaviors (e.g., mating, feeding, food aversion, or locomotion), genetic mutations (e.g., the presence of SNPs, deletions, additions, inversions, or repeats in DNA), transcript levels, protein levels, metabolite levels, lipid levels, carbohydrate levels, protein (e.g., enzyme) activity levels can be observed, measured, or assessed to determine whether a microbial strain or combination of microbial strains affects a transgenic C. elegans that model a mammalian disease or condition.
- In some embodiments, methods described herein utilize a first sample and a second sample. In some embodiments, a first sample is a reference sample. In some embodiments, a reference sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed), e.g., OP50. In some embodiments, a reference sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) a microbial strain or combination of microbial strains from a microbiome of a healthy individual. In some embodiments, a reference sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) a microbial strain or combination of microbial strains from a microbiome of an individual obtained at a first time point.
- In some embodiments, a second sample can be a test sample. In some embodiments, a test sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) an individual microbial strain or a combination of microbial strains from a mammalian microbiome, e.g., a human microbiome. In some instances, a human microbiome is a microbiome of a human suffering from or at risk of a disease or condition. In some instances, a human microbiome is a microbiome of a human with an unknown risk for one or more diseases or conditions. In some embodiments, a test sample can be a culture of transgenic C. elegans contacted with (e.g., administered or fed) a microbial strain or combination of microbial strains from a microbiome of an individual obtained at a second time point.
- In some embodiments, methods described herein comprise comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample. In some embodiments, by comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample, it can be determined that an individual microbial strain or a combination of microbial strains from a microbiome increase the severity or incidence of a disease or condition phenotype modeled by the cultured transgenic C. elegans. In some embodiments, by comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample, it can be determined that an individual microbial strain or a combination of microbial strains from a microbiome decrease the severity or incidence of a disease or condition phenotype modeled by the cultured transgenic C. elegans. In some embodiments, by comparing one or more parameters obtained from a test sample with one or more parameters obtained from a reference sample, it can be determined that an individual microbial strain or a combination of microbial strains from a microbiome have no effect on the severity or incidence of a disease or condition phenotype modeled by the cultured transgenic C. elegans.
- Transgenic C. elegans and methods using transgenic C. elegans provided herein can be useful in assessing, characterizing, or identifying microbial strains of a microbiome that affect a mammalian disease or condition. The present disclosure also provides the recognition that transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to define and/or characterize a microbial signature associated with a disease or condition. Further, the present disclosure provides the recognition that transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to define and/or characterize a microbial signature associated with one or more features of a disease or condition (e.g., severity, responsiveness to therapy, etc.). For example, if multiple microbial strains are determined to be associated with an increased severity of a disease or disorder, e.g., across multiple individuals, the microbial strains, as well as their relative amounts, could be used as a signature to identify individuals who are at risk of developing an increased severity of the disease or disorder. As another example, if multiple microbial strains are determined to be associated with an increased severity of a disease or disorder, e.g., in a single individual, at certain times (e.g., after removal from a treatment), the microbial strains, as well as their relative amounts, could be used as a signature to identify when that individual is at risk of developing an increased severity of the disease or disorder.
- The present disclosure also provides the recognition that transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to diagnose an individual with a disease or condition. In fact, using a microbial signature associated with a disease or condition determined through the use of transgenic C. elegans and methods using transgenic C. elegans provided herein, an individual can be diagnosed early and/or identified as an individual at risk.
- The present disclosure also provides the recognition that transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to monitor progression of a disease or condition in an individual. For example, if microbial strains determined to increase the severity of a disease or condition decrease in relative amount within a microbiome, it may indicate that the disease or condition is being attenuated, e.g., by treatment or immune response.
- The present disclosure also provides the insight that transgenic C. elegans and methods using transgenic C. elegans provided herein can be used to tailor treatments (e.g., therapies, nutraceuticals, and/or probiotics) to an individual patient. In some embodiments, transgenic C. elegans and methods using transgenic C. elegans provided herein can provide “personalized” therapy. In some cases, microbial strains within an individual can be assessed, characterized, or identified to determine if they have an effect on a disease or disorder. Based on the results, the individual can be treated with one or more microbial strains to adjust the microbial strains (and/or component or compound thereof) in their microbiome. In some instances, this will affect the disease or condition the individual is suffering from or at risk of developing. For example, if an individual is determined to have a relatively low amount of one or more microbial strains that have been determined to decrease the severity of a disease or condition, administration of the one or more microbial strains that have been determined to decrease the severity of a disease or condition to the individual (or an extract, component, or compound thereof) may attenuate the severity of the individual's disease or condition.
- Pharmaceutical Compositions
- Provided herein are compositions comprising individual microbial strains or combinations of microbial strains. In some embodiments, a composition comprises individual microbial strains or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein. In some embodiments, a composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof, which have been assessed, identified, characterized or assayed using transgenic C. elegans or methods as described herein.
- In some embodiments, a composition provided herein comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains listed in TABLE 8 below.
- In some embodiments, a composition provided herein comprises Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, Acidaminococcus sp., or a combination thereof. In some embodiments, a combination comprises at least two of, at least three of, at least four of, at least five of, at least six of, at least seven of, at least eight of, at least nine of, or all of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, and Acidaminococcus sp.
- In some embodiments, an individual microbial strain or combinations of microbial strains from a mammalian microbiome that have been killed (e.g., heat killed). Alternatively, in some embodiments, an individual microbial strain or combinations of microbial strains from a mammalian microbiome may include cells that are viable or alive.
- In some embodiments, one or more microbial strains comprise a viable or living individual microbial strain or combinations of microbial strains, e.g., from a mammalian microbiome.
- In some embodiments, one or more microbial strains comprise a viable or living individual microbial strain or combinations of microbial strains, e.g., from a mammalian microbiome, as described herein comprises and/or is formulated through use of one or more cell cultures and/or supernatants or pellets thereof, and/or a powder formed therefrom.
- In some embodiments, compositions for use in accordance with the present disclosure are pharmaceutical compositions, e.g., for administration (e.g., oral administration) to a mammal (e.g., a human). Pharmaceutical compositions typically include an active agent (e.g., individual microbial strains or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof), and a pharmaceutically acceptable carrier. Certain exemplary pharmaceutically acceptable carriers include, for instance saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- In some embodiments, a pharmaceutical composition for use in accordance with the present disclosure may include and/or may be administered in conjunction with, one or more supplementary active compounds; in certain embodiments, such supplementary active agents can include ginger, curcumin, probiotics (e.g, probiotic strains of one or more of the following genera: Lactobacillus, Bifidobacterium, Saccharomyces, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus, and/or Escherichia coli (see Fijan, Int J Environ Res Public Health. 2014 May; 11(5): 4745-4767, which is incorporated herein by reference); prebiotics (nondigestible food ingredients that help support growth of probiotic bacteria, e.g., fructans such as fructooligosaccharides (FOS) and inulins, galactans such as galactooligosaccharides (GOS), dietary fibers such as resistant starch, pectin, beta-glucans, and xylooligosaccharides (Hutkins et al., Curr Opin Biotechnol. 2016 February; 37: 1-7, which is incorporated herein by reference) and combinations thereof.
- Pharmaceutical compositions are typically formulated to be compatible with its intended route of administration. Examples of routes of administration include oral administration. Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, N.Y.). Oral compositions generally include an inert diluent or an edible carrier. To give but a few examples, in some embodiments, an oral formulation may be or comprise a syrup, a liquid, a tablet, a troche, a gummy, a capsule, e.g., gelatin capsules, a powder, a gel, a film, etc.
- In some embodiments, pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of a pharmaceutical composition. In some particular embodiments, a pharmaceutical composition can contain, e.g., any one or more of the following inactive ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. In some embodiments, the compositions can be taken as-is or sprinkled onto or mixed into a food or liquid (such as water). In some embodiments, a composition that may be administered to mammals as described herein may be or comprise an ingestible item (e.g., a food or drink) that comprises (e.g., is supplemented) with an individual microbial strain or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof.
- In some embodiments, a food can be or comprise one or more of bars, candies, baked goods, cereals, salty snacks, pastas, chocolates, and other solid foods, as well as liquid or semi-solid foods including yogurt, soups and stews, and beverages such as smoothies, shakes, juices, and other carbonated or non-carbonated beverages. In some embodiments, foods are prepared by a subject by mixing in individual microbial strains or combinations of microbial strains from a mammalian microbiome, extracts thereof, and/or components thereof.
- Compositions can be included in a kit, container, pack, or dispenser, together with instructions for administration or for use in a method described herein.
- Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, a composition (e.g., a pharmaceutical composition) as described herein may be or comprise one or more cells, tissues, or organisms (e.g., plant or microbe cells, tissues, or organisms) that produce (e.g., have produced, and/or are producing) a relevant compound.
- Those skilled in the art will appreciate that, in some embodiments, technologies for preparing compositions and/or preparations, and/or for preparing (and particularly for preparing pharmaceutical compositions) may include one or more steps of assessing or characterizing a compound, preparation, or composition, e.g., as part of quality control. In some embodiments, if an assayed material does not meet pre-determined specifications for the relevant assessment, it is discarded. In some embodiments, if such assayed material does meet the pre-determined specifications, then it continues to be processed as described herein.
- In some embodiments, a pharmaceutical composition provided herein can promote the colonization of an individual microbial strain or combinations of microbial strains from a mammalian microbiome, particularly microbial strain(s) that have been identified, characterized, or assessed as decreasing the severity or incidence of a mammalian disease or condition, in a mammal suffering from or at risk of the mammalian disease or condition. In some embodiments, a pharmaceutical composition provided herein can attenuate the colonization of an individual microbial strain or combinations of microbial strains from a mammalian microbiome, particularly microbial strain(s) that have been identified, characterized, or assessed as increasing the severity or incidence of a mammalian disease or condition, in a mammal suffering from or at risk of the mammalian disease or condition. In some embodiments, a pharmaceutical composition provided herein can promote the colonization of an individual microbial strain or combinations of microbial strains from a mammalian microbiome, particularly microbial strain(s) that have been identified, characterized, or assessed as not affecting the severity or incidence of the mammalian disease or condition but have been identified, characterized, or assessed as being capable of outcompeting one or more microbial strains that have been identified, characterized, or assessed as increasing the severity or incidence of a mammalian disease or condition, in a mammal suffering from or at risk of the mammalian disease or condition.
- In some embodiments, each of the one or more microbial strains in a composition comprises 101 to 1012 colony forming units (CFUs). In some embodiments, each of the one or more microbial strains in a composition comprises 106 to 1012 CFUs. In some embodiments, each of the one or more microbial strains in a composition comprises the same number of CFUs. In some embodiments, some of the one or more microbial strains in a composition comprises a different number of CFUs.
- In some embodiments, a composition comprises a total of 106 to 1012 of CFUs.
- In some embodiments, a pharmaceutical composition is tailored to a specific mammal (e.g., a specific human patient) based on that mammal's (e.g., human's) microbiome. In some embodiments, a pharmaceutical composition is specific for a microbiome of an individual mammal (e.g., human). In some embodiments, a pharmaceutical composition is specific for microbiomes of a population of mammals (e.g., humans). Populations of mammals can include, but are not limited to: families, mammals in the same regional location (e.g., neighborhood, city, state, or country), mammals with the same disease or condition, mammals of a particular age or age range, mammals that consume a particular diet (e.g., food, food source, or caloric intake).
- Methods of Treatment
- The present disclosure recognizes that compositions described herein can be useful in the treatment of subjects. Methods provided by the present disclosure include methods for the treatment of certain diseases, disorders and conditions. In some embodiments, relevant diseases, disorders and conditions may be or include a neurodegenerative disease, disorder, or condition. In some embodiments, a neurodegenerative disease, disorder, or condition may be Alzheimer's disease. In some embodiments, relevant diseases, disorders and conditions may be or include an ocular neovascular disease, disorder, or condition. In some embodiments, a neurodegenerative disease, disorder, or condition may be diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
- Generally, methods of treatment provided by the present disclosure involve administering a therapeutically effective amount of a composition as described herein alone or in combination with other compositions and/or treatments to a subject who is in need of, or who has been determined to be in need of, such treatment.
- In some embodiments, methods of treatment provided herein are prophylactic or preventative, e.g., may be administered to subjects prior to display of significant symptoms and/or to exposure to a particular expected inducement that is associated with neurodegenerative diseases, disorders, or conditions. In some embodiments, methods of treatment provided herein are therapeutic, e.g., may be administered to subjects after development of significant symptoms associated with neurodegenerative diseases, disorders, or conditions.
- In some embodiments, provided methods of treatment are administered to a subject that is a mammal, e.g., a mammal that experiences a disease, disorder, or condition as described herein; in some embodiments, a subject is a human or non-human veterinary subject, e.g., an ape, cat dog, monkey, or pig.
- In many embodiments, treatment involves ameliorating at least one symptom of a disease, disorder, or condition associated with neurodegenerative diseases, disorders, or conditions. In some embodiments, a method of treatment can be prophylactic.
- In some embodiments, the methods can include administration of a therapeutically effective amount of compositions disclosed herein before, during (e.g., concurrently with), or after administration of a treatment that is expected to be associated with neurodegenerative diseases, disorders, or conditions.
- In some embodiments, subjects who receive treatment as described herein may be receiving and/or may have received other treatment (e.g., pharmacological treatment/therapy, surgical, etc), for example that may be intended to treat one or more symptoms or features of a disease disorder or condition as described herein (e.g. neurodegenerative diseases, disorders, or conditions), so that provided compositions are administered in combination with such other therapy (i.e. treatment) to treat the relevant disease, disorder, or condition.
- In some embodiments, the compositions described herein can be administered in a form containing one or more pharmaceutically acceptable carriers. Suitable carriers have been described previously and vary with the desired form and mode of administration of a composition. For example, pharmaceutically acceptable carriers can include diluents or excipients such as fillers, binders, wetting agents, disintegrators, surface-active agents, glidants, and lubricants. Typically, a carrier may be a solid (including powder), liquid, or any combination thereof. Each carrier is preferably “acceptable” in the sense of being compatible with other ingredients in the composition and not injurious to a subject. A carrier can be biologically acceptable and inert (e.g., it permits the composition to maintain viability of the biological material until delivered to the appropriate site).
- Tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, orange flavoring, or other suitable flavorings. These are for purposes of example only and are not intended to be limiting.
- Oral compositions can include an inert diluent or an edible carrier. For purposes of oral therapeutic administration, an active compound can be incorporated with excipients and used in the form of tablets, lozenges, pastilles, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared by combining a composition of the present disclosure with a food. In some embodiments, microbes can be formulated in a food item. Some non-limiting examples of food items to be used with the methods and compositions described herein include: popsicles, cheeses, creams, chocolates, milk, meat, drinks, pickled vegetables, kefir, miso, sauerkraut, etc. In other embodiments, food items can be juices, refreshing beverages, tea beverages, drink preparations, jelly beverages, and functional beverages; alcoholic beverages such as beers; carbohydrate-containing foods such as rice food products, noodles, breads, and pastas; paste products such as fish, hams, sausages, paste products of seafood; retort pouch products such as curries, food dressed with a thick starchy sauce, and Chinese soups; soups; dairy products such as milk, dairy beverages, ice creams, and yogurts; fermented products such as fermented soybean pastes, fermented beverages, and pickles; bean products; various confectionery products including biscuits, cookies, and the like, candies, chewing gums, gummies, cold desserts including jellies, cream caramels, and frozen desserts; instant foods such as instant soups and instant soy-bean soups; and the like. It is preferred that food preparations not require cooking after admixture with microbial strain(s) to avoid killing any microbes. In one embodiment a food used for administration is chilled, for example, iced flavored water. In certain embodiments, the food item is not a potentially allergenic food item (e.g., not soy, wheat, peanut, tree nuts, dairy, eggs, shellfish or fish). Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- In some such embodiments, a composition described herein is administered to a subject according to a dosing regimen that achieves population of the subject's microbiome with administered cells. In some embodiments, a composition is administered to a subject in a single dose. In some embodiments, a composition is administered to a subject in a plurality of doses. In some embodiments, a dose of a composition is administered to a subject twice a day, daily, weekly, or monthly.
- In some embodiments, each of the one or more microbial strains in a dose comprises 101 to 1012 colony forming units (CFUs). In some embodiments, each of the one or more microbial strains in a dose comprises 106 to 1012 CFUs. In some embodiments, each of the one or more microbial strains in a dose comprises the same number of CFUs. In some embodiments, some of the one or more microbial strains in a dose comprises a different number of CFUs.
- In some embodiments, a dose of one or more microbial strains comprises a total of 106 to 1012 CFUs. In some embodiments, a dose of one or more microbial strains comprises a total of 107 to 1010 CFUs. In some embodiments, a dose of one or more microbial strains comprises 5-200 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 5-50 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 5-20 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 50-100 billion CFUs. In some embodiments, a dose of one or more microbial strains comprises 100-200 billion CFUs.
- The following examples are provided so as to describe to the skilled artisan how to make and use methods and compositions described herein, and are not intended to limit the scope of the present disclosure.
- Two different constructs for a human APOE4 transgene under the control of an intestinal promoter (pvha-6::apoE4::tbb-2 UTR) were generated by gene synthesis. The constructs were cloned into the KpnI/SalI restriction enzyme site of pUC57 plasmid. Human APOE4 protein sequence was codon optimized for optimal expression in C. elegans. Three synthetic introns were included within the apoE4 sequence in both constructs to avoid gene silencing and optimum expression in C. elegans. The nucleotide sequences of the introns are included in TABLE 1 below.
- In one construct, a signal sequence for secretion from C. elegans FLP-1 was included in the apoE4 sequence (“
Worm 2”). In the other construct, no signal sequence was added to the a oE4 sequence (“Worm 1”). -
TABLE 1 Element Sequence Intron 1 gtaagtttaaacatatatatactaactaaccctgattatt taaattttcag (SEQ ID NO.: 1) Intron 2gtaagtttaaacagtteggtactaactaaccatacatatt taaattttcag (SEQ ID NO.: 2) Intron 3gtaagtttaaacatgattttactaactaactaatctgatt taaattttcag (SEQ ID NO.: 3) FLP-1 atgactctgctctaccaagtagggttattactecttgtgg Signal cagctacttataaggtgtcggca (SEQ ID NO.: 4) Sequence - Extrachromosomal array strains were constructed by injecting the either
Worm 1 orWorm 2 with an expression plasmid and co-injection marker (2 ng/μl for pCFJ90, pmyo-2::mCherry). Sequences used forWorm 1 andWorm 2 are included in TABLE 2 below. Coding sequences are indicated by capital letters; non-coding sequences are indicated by small letters. -
TABLE 2 WORM 1vha-6 promoter: actaactgacattaggtgtcacacaaaagaaatcacacactatacatca aaatatacatcacaagtgagtcaatacaatccgggtgaagctcaagaat ggatttcgcagacttettctgctcattggctgcttcgaaaacctgaata gtttatattaaactagtgaaatcgaattcatacaaacctgtttcgattc actacttttcaatcgatggtcaaacgtagaatcaaaaacacgtgtcaga aacacttccaatcatcaaaatgatccatcaattccacteggagcaacaa tttcgaagcctgggaatgtgtgtggtgagcacttttggctctggtagag catgtacctttataggtgcgctctacgcaattcaccagctgaacaatgg agttgagcctaatgtaactaaaaatttatttgaatgctttacaaaaata ttatttcagatcttcgagatcatgaaaactatcaaacagcagcgccctg gagcaatcgagtcgttcccacaatattcaggtgtatatgcaatcgtttt agactacatttcggtaagttgctacttcagagataaactgtaattattt taaatttcagcgcaaacgcggaggaaagtctgatcctgttaacaaatac ataaatcgtttcctcgctgatctcacggagatattgccagcatgctcaa cgttgccagtgatgaatccaagcacagaactgcattaagtatactattt attactcgatacttttgttcacataggttttttaaatcatattttatgc atcatttatcatattcaatgcatcattcatatcatagtcaataaaaagg ttgatttctcatgttctggtttcaaatgctgactttggtaaaaagaacg cgtgcctgcctattgcctatcttggcattttctcgataaattttaaaat gtaggttcgatcttatgagatttgtagtcaaaagagctcatatgtattc aggtaggtctggtagcgagaccaacttaatagcatgacaagcattttca atttgccctggagcgcaattggtifittattcgaaaatcgcacatttct gtttccccataatataaaatttccaggacgatatatattacattettca caaaatattgcattacagacaccgacaaagaatctccacctgatatgaa aacaatgagccaacaatgttatctgtattgccaccacccacatttccta gtcattcagtatatattgtttcaattgaatcattgcaggtatatatcga attgaacttgtaaggettcatcttcatttctcaatacatcatccatcat tccagagcagctccggccacacaaaaattggtggeggtctgatattgat aatcgacttctttgacgtgcctgacggagcagcaaagcggagcactgat aagacaatgaagaactaaaaaattgtetteggttttcagtetttagttc tgcagcactttatttifigtttctcctatttttccgcattttectaact ttctgatgtccatttcaaatgattifigttataaaattgtttaatttca gggcgactaaaacctaccaaaacccataaaaa (SEQ ID NO.: 5) human apoE4: atgAAGGTCCTTTGGGCCGCCCTTCTTGTCACCTTCCTTGCTGGATGCC AAGCTAAGGTTGAGCAAGCTGTTGAAACTGAGCCAGAGCCAGAGCTTCG TCAACAAACTGAGTGGCAATCTGGACAACGTTGGGAGCTTGCTCTTGGA CGTTTCTGGGACTACCTTCGTTGGGTTCAAACCCTTTCCGAGCAAGTTC AAGAGGAGCTTCTTTCTTCCCAAGTTACCCAAGAGCTTCGTGCTCTTAT GGATGAGACTATGAAGgtaagtttaaacatatatatactaactaaccct gattatttaaattttcagGAGCTTAAGGCTTACAAGTCTGAGCTTGAGG AGCAACTTACCCCAGTTGCTGAGGAGACCCGTGCTCGTCTTTCCAAGgt aagtttaaacagttcggtactaactaaccatacatatttaaattttcag GAGCTTCAAGCTGCTCAAGCTCGTCTTGGAGCTGATATGGAGGATGTTC GTGGACGTCTTGTTCAATACCGTGGAGAGGTTCAAGCTATGCTTGGACA ATCTACCGAGGAGCTTCGTGTTCGTCTTGCCTCCCACCTTCGTAAGCTT CGTAAGCGTCTTCTTCGTGACGCTGACGACCTTCAAAAGCGTCTTGCTG TCTACCAAGCTGGAGCTCGTGAGGGAGCTGAGCGTGGACTTTCCGCTAT CCGTGAGCGTCTTGGACCACTTGTTGAGCAAGGACGTGTTCGTGCTGCT ACCGTCGGATCCCTTGCTGGACAACCACTTCAAGAGCGCGCTCAAGCTT GGGGAGAGCGTCTTCGTGCTCGCATGGAGGAGATGGGATCTCGCACCCG TGATCGTCTTGATGAGGTTAAGgtaagtttaaacatgattttactaact aactaatctgatttaaattttcagGAGCAAGTTGCTGAGGTCCGTGCTA AGCTTGAAGAGCAAGCTCAACAAATCCGTCTTCAAGCTGAGGCTTTCCA AGCTCGTCTTAAGTCTTGGTTCGAGCCACTTGTTGAGGATATGCAACGT CAATGGGCTGGACTTGTTGAGAAGGTCCAAGCCGCTGTCGGAACCTCCG CTGCTCCAGTTCCATCCGATAACCACTAA (SEQ ID NO.: 6) tbb-2 3'UTR: atgcaagatcctttcaagcattcccttcttctctatcactcttctttct ttttgtcaaaaaattctctcgctaatttatttgcttttttaatgttatt attttatgactifitatagtcactgaaaagtttgcatctgagtgaagtg aatgctatcaaaatgtgattctgtctgatgtactttcacaatctctctt caattccattttgaagtgctttaaacccgaaaggttgagaaaaatgcga gcgctcaaatatttgtattgtgttcgttgagtgacccaacaaaaagagg aaa (SEQ ID NO.: 7) WORM 2vha-6 promoter: actaactgacattaggtgtcacacaaaagaaatcacacactatacatca aaatatacatcacaagtgagtcaatacaatccgggtgaagctcaagaat ggatttcgcagacttettctgctcattggctgcttcgaaaacctgaata gtttatattaaactagtgaaatcgaattcatacaaacctgtttcgattc actacttttcaatcgatggtcaaacgtagaatcaaaaacacgtgtcaga aacacttccaatcatcaaaatgatccatcaattccacteggagcaacaa tttcgaagcctgggaatgtgtgtggtgagcacttttggctctggtagag catgtacctttataggtgcgctctacgcaattcaccagctgaacaatgg agttgagcctaatgtaactaaaaatttatttgaatgctttacaaaaata ttatttcagatcttcgagatcatgaaaactatcaaacagcagcgccctg gagcaatcgagtcgttcccacaatattcaggtgtatatgcaatcgtttt agactacatttcggtaagttgctacttcagagataaactgtaattattt taaatttcagcgcaaacgcggaggaaagtctgatcctgttaacaaatac ataaatcgtttcctcgctgatctcacggagatattgccagcatgctcaa cgttgccagtgatgaatccaagcacagaactgcattaagtatactattt attactcgatacttttgttcacataggttttttaaatcatattttatgc atcatttatcatattcaatgcatcattcatatcatagtcaataaaaagg ttgatttctcatgttctggtttcaaatgctgactttggtaaaaagaacg cgtgcctgcctattgcctatcttggcattttctcgataaattttaaaat gtaggttcgatcttatgagatttgtagtcaaaagagctcatatgtattc aggtaggtctggtagcgagaccaacttaatagcatgacaagcattttca atttgccctggagcgcaattggtifittattcgaaaatcgcacatttct gtttccccataatataaaatttccaggacgatatatattacattettca caaaatattgcattacagacaccgacaaagaatctccacctgatatgaa aacaatgagccaacaatgttatctgtattgccaccacccacatttccta gtcattcagtatatattgtttcaattgaatcattgcaggtatatatcga attgaacttgtaaggettcatcttcatttctcaatacatcatccatcat tccagagcagctccggccacacaaaaattggtggeggtctgatattgat aatcgacttctttgacgtgcctgacggagcagcaaagcggagcactgat aagacaatgaagaactaaaaaattgtetteggttttcagtetttagttc tgcagcactttatttifigtttctcctatttttccgcattttectaact ttctgatgtccatttcaaatgattifigttataaaattgtttaatttca gggcgactaaaacctaccaaaacccataaaaa (SEQ ID NO.: 5) human ssapoE4: atgactctgctctaccaagtagggttattactccttgtggcagctactt ataaggtgtcggcaAAGGTCCTTTGGGCCGCCCTTCTTGTCACCTTCCT TGCTGGATGCCAAGCTAAGGTTGAGCAAGCTGTTGAAACTGAGCCAGAG CCAGAGCTTCGTCAACAAACTGAGTGGCAATCTGGACAACGTTGGGAGC TTGCTCTTGGACGTTTCTGGGACTACCTTCGTTGGGTTCAAACCCTTTC CGAGCAAGTTCAAGAGGAGCTTCTTTCTTCCCAAGTTACCCAAGAGCTT CGTGCTCTTATGGATGAGACTATGAAGgtaagtttaaacatatatatac taactaaccctgattatttaaattttcagGAGCTTAAGGCTTACAAGTC TGAGCTTGAGGAGCAACTTACCCCAGTTGCTGAGGAGACCCGTGCTCGT CTTTCCAAGgtaagtttaaacagtteggtactaactaaccatacatatt taaattttcagGAGCTTCAAGCTGCTCAAGCTCGTCTTGGAGCTGATAT GGAGGATGTTCGTGGACGTCTTGTTCAATACCGTGGAGAGGTTCAAGCT ATGCTTGGACAATCTACCGAGGAGCTTCGTGTTCGTCTTGCCTCCCACC TTCGTAAGCTTCGTAAGCGTCTTCTTCGTGACGCTGACGACCTTCAAAA GCGTCTTGCTGTCTACCAAGCTGGAGCTCGTGAGGGAGCTGAGCGTGGA CTTTCCGCTATCCGTGAGCGTCTTGGACCACTTGTTGAGCAAGGACGTG TTCGTGCTGCTACCGTCGGATCCCTTGCTGGACAACCACTTCAAGAGCG CGCTCAAGCTTGGGGAGAGCGTCTTCGTGCTCGCATGGAGGAGATGGGA TCTCGCACCCGTGATCGTCTTGATGAGGTTAAGgtaagtttaaacatga ttttactaactaactaatctgatttaaattttcagGAGCAAGTTGCTGA GGTCCGTGCTAAGCTTGAAGAGCAAGCTCAACAAATCCGTCTTCAAGCT GAGGCTTTCCAAGCTCGTCTTAAGTCTTGGTTCGAGCCACTTGTTGAGG ATATGCAACGTCAATGGGCTGGACTTGTTGAGAAGGTCCAAGCCGCTGT CGGAACCTCCGCTGCTCCAGTTCCATCCGATAACCACTAA (SEQ ID NO.: 8) tbb-2 3'UTR: atgcaagatcctttcaagcattcccttcttctctatcactcttctttct ttttgtcaaaaaattctctcgctaatttatttgcttttttaatgttatt attttatgactifitatagtcactgaaaagtttgcatctgagtgaagtg aatgctatcaaaatgtgattctgtctgatgtactttcacaatctctctt caattccattttgaagtgctttaaacccgaaaggttgagaaaaatgcga gcgctcaaatatttgtattgtgttcgttgagtgacccaacaaaaagagg aaa (SEQ ID NO.: 7) -
TABLE 3 Strain Genotype PD1074 C. elegans wild-type MB1 mbEx1(pvha-6::apoE4::tbb-2 UTR + pmyo-2:mCherry) MB2 mbEx2(pvha-6::ssapoE4::tbb-2 UTR + pmyo-2:mCherry); SS is signal sequence MB3 mbEx1(pvha-6::apoE4::tbb-2 UTR + pmyo-2:mCherry); dvIs37 [myo-3p::GFP::Aβ(3-42) + rol-6(su1006)] MB4 mbEx2(pvha-6::ssapoE4::tbb-2 UTR + pmyo-2:mCherry); dvIs37 [myo-3p::GFP::Aβ (3-42) + rol-6(su1006)] CL2331 dvIs37 [myo-3p::GFP::Aβ (3-42) + rol-6(su1006)] MB5 mbEx1(pvha-6::apoE4::tbb-2 UTR + pmyo-2:mCherry); dvIs2 [pCL12(unc-54/human Aβ peptide 1-42 minigene) + pRF4] MB6 mbEx2(pvha-6::ssapoE4::tbb-2 UTR + pmyo-2:mCherry); dvIs2 [pCL12(unc-54/human Aβ peptide 1-42 minigene) + pRF4] CL2006 dvIs2 [pCL12 (unc-54/human Aβ peptide 1-42 minigene) + pRF4] MB7 mbEx3 [unc-119(+);sur-5::UbV-GFP] MB8 mbIs1[F25B3.3::tau352(PHP) + pha-1(+)] MB9 mbEx3 [unc-119(+);sur-5::UbV-GFP]; mbIs1[F25B3.3::tau352(PHP) + pha-1(+)] MB10 mbEx2(pvha-6::ssapoE4::tbb-2 UTR + pmyo-2:mCherry); mbIs1[F25B3.3::tau352(PHP) + pha-1(+)] MB11 mbEx2(pvha-6::ssapoE4::tbb-2 UTR + pmyo-2:mCherry); mbEx3 [unc-119(+); sur-5::UbV-GFP] MB12 mbEx2(pvha-6::ssapoE4::tbb-2 UTR + pmyo-2:mCherry); mbEx3 [unc-119(+); sur-5::UbV-GFP]; mbIs1[F25B3.3::tau352(PHP) + pha-1(+)] MB13 mbEx2(pvha-6::ssapoE4::tbb-2 UTR + pmyo-2:mCherry); mbEx3 [unc-119(+); sur-5::UbV-GFP]; mbIs1[F25B3.3::tau352(PHP) + pha-1(+)]; dvIs2 [pCL12(unc-54/human Aβ peptide 1-42 minigene) + pRF4] - Alzheimer's disease (AD) is the most common cause of dementia. AD is characterized by a progressive decline in cognitive functions, including memory, language, and cognitive skills. Senile plaques and intracellular neurofibrillary tangles are generally considered hallmark features of AD pathology. Plaques can comprise of aggregates of amyloid-β(Aβ) peptides of either 40 or 42 amino acids, which can be formed by abnormal processing of amyloid precursor protein (APP) by presenilins (PSEN1 and PSEN2). Soluble Aβ oligomers can also cause synaptic dysfunction leading to neurodegeneration and cognitive disabilities. (Mucke, L., and Selkoe, D. J. (2012). Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338, which is incorporated herein by reference). The neurofibrillary tangles in AD can include hyperphosphorylated tau protein, which is a microtubule associated protein in neurons. (Iqbal, K., et al. (2010). Tau in Alzheimer Disease and Related Tauopathies. Curr. Alzheimer Res. 7, 656-664, which is incorporated herein by reference). In AD, tau can be abnormally hyperphosphorylated and aggregate into filaments. (Grundke-Iqbal, I., et al. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A 83, 4913-4917, which is incorporated herein by reference). Because of the strong evidence of involvement of Aβ in AD, several monoclonal antibody-based therapeutics were developed and tested to target the amyloid plaques. (van Dyck, C. H. (2018). Anti-Amyloid-O Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biol. Psychiatry 83, 311-319, which is incorporated by reference in its entirety). Though studies in standard mammalian animal models showed that interventions that effectively prevent or removed Aβ accumulation in animal models, did not improve cognition in human clinical trials.
- While about 5% of AD cases appear to have a genetic cause, 95% of the cases are sporadic or late-onset AD with unknown etiology. Less than 1% of AD cases are caused by genetic mutations in genes including APP, PSEN1 and PSEN2. Though several other genes were implicated in AD, one of the strongest genetic risk factors in AD is apoe. (Lambert, J.-C., et al. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1099; Shen, L., and Jia, J. (2016). An Overview of Genome-Wide Association Studies in Alzheimer's Disease. Neurosci. Bull. 32, 183-190, each of which is incorporated herein by reference). A lipid/cholesterol carrier apolipoprotein E (APOE) is encoded by apoe. In humans, there are 3 major protein variants, termed APOE2, APOE3, and APOE4, that differ from each other only at two amino acid residues. (Mahley, R. W. (2016). Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J. Mol. Med. Berl. Ger. 94, 739-746, which is incorporated herein by reference). People carrying polymorphism in apoe, specifically the apoe4 allele are significantly more likely develop AD, but also early-onset AD, compared to the people who carry either the apoe2 or apoe3 alleles. (Roses, A. D. (1996). Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-400; Strittmatter, W. J., and Roses, A. D. (1996). Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19, 53-77, each of which is incorporated herein by reference). While APOE2 is thought to be the protective form of APOE, APOE4 is thought to be the “toxic” form. (Strittmatter and Roses, 1996, which is incorporated herein by reference). APOE4 exacerbates brain changes associated with AD including increased levels of amyloid deposits, brain dysfunction and neurodegeneration. (DiBattista, A. M., et al. (2016). Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function. Curr. Alzheimer Res. 13, 1200-1207, which is incorporated herein by reference). Despite the importance of APOE4 in AD, the molecular mechanisms of how APOE4 promotes AD pathogenesis is still not well-understood. (Kanekiyo, T., et al. (2014). ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron 81, 740-754, which is incorporated by reference in its entirety). APOE4 is thought to contribute to AD pathogenesis via both loss-of-function and gain-of-function mechanisms. (DiBattista, 2016; Zepa, L., et al. (2011). ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function. Int. J. Alzheimers Dis. 2011, each of which is incorporated herein by reference).
- Earlier studies suggested that APOE isoforms binds and helps to clear Aβ. (Kim, J., et al. (2009). The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303, which is incorporated herein by reference). Compared to APOE2 and APOE3, APOE4 was suggested to be less efficient in clearing Aβ (Kim, 2009, which is incorporated herein by reference). However, recent studies suggest that APOE compete with Aβ for uptake through apoE receptors. (Verghese, P. B., et al. (2013). APOE influences amyloid-β (Aβ) clearance despite minimal APOE/Aβ association in physiological conditions. Proc. Natl. Acad. Sci. U.S.A 110, E1807-1816; Yajima, R., et al. (2015). APOE-isoform-dependent cellular uptake of amyloid-β is mediated by lipoprotein receptor LR11/SorLA. Biochem. Biophys. Res. Commun. 456, 482-488, each of which is incorporated herein by reference). While all the isoforms were able to compete for binding to APOE receptor, APOE4 expressing cells were less efficient in clearing Ap. (Verghese, 2013, which is incorporated herein by reference).
- Though, the role of APOE4 in Aβ brain pathology has been well-documented, the influence of APOE4 in tau pathology has been only recently explored. Using a tauopathy model that overexpress 1N4R human tau containing the P301S mutation, it was shown that ApoE4 exacerbates tau induced neuroinflammation and neurodegeneration phenotypes independent of Aβ pathology. (Shi, Y., et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523-527, which is incorporated herein by reference). The Tau P301S mutation was originally found in human cases with frontotemporal dementia and degeneration. (Bugiani, O., et al. (1999). Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. J. Neuropathol. Exp. Neurol. 58, 667-677, which is incorporated herein by reference). Further, the tau P301S mutant proteins are more favorable substrates for phosphorylation compared to the wild-type tau. (Alonso, A. del C., et al. (2004). Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 279, 34873-34881, which is incorporated herein by reference). Interestingly, the neurofibrillary tangles found in AD are composed primarily of hyperphosphorylated tau. (Iqbal, 2010, which is incorporated herein by reference). Also, in frontotemporal dementia patients, the frequency of APOE4 allele is significantly higher (Stevens, M., et al. (1997). Apolipoprotein E gene and sporadic frontal lobe dementia. Neurology 48, 1526-1529, which is incorporated herein by reference) and APOE4 carriers also have increased disease severity (Agosta, F., et al. (2009). Apolipoprotein ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc. Natl. Acad. Sci. 106, 2018-2022; Engelborghs, S., et al. (2006). Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol. Aging 27, 285-292, each of which is incorporated herein by reference). Despite the importance of APOE4 in AD, therapies targeting APOE4 is lacking. (Michaelson, D. M. (2014). APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimers Dement. J. Alzheimers Assoc. 10, 861-868; Holtzman, D. M., et al. (2012). Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2, each of which is incorporated herein by reference). Moreover, despite being identified in more than half of all AD patients, ApoE4 carriers are often excluded in the clinical trials for AD because of the unpredictability of their response. (Qiu, W. Q., et al. (2013). Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J. Alzheimers Dis. JAD 37, 421-428; Sperling, R., et al. (2012). Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241-249; Farlow, M. R., et al. (1998). Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
Neurology 50, 669-677; Risner, M. E., et al. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254; each of which is incorporated herein by reference). - Interestingly, although APOE4 is expressed in the brain, the peripheral tissue expression of APOE4 is high; this raises the possibility that peripheral APOE4 could contribute to AD pathogenesis. Apart from brain, APOE protein is synthesized primarily in the liver and is involved in lipid transport and cholesterol homeostasis. (Safieh, M., et al. (2019). ApoE4: an emerging therapeutic target for Alzheimer's disease. BMC Med. 17, which is incorporated herein by reference). Liver is the primary site which encounters not only the nutrients but also gut microbiome-derived small molecules or metabolites or toxins through the enterohepatic circulation. Thus, dysbiosis in the gut will have profound effect on the liver. One possibility is that AD might have a gut-origin: “microbiome-derived materials” might leak into the enterohepatic circulation and reaches the liver. From liver, the APOE4 might transport these “microbiome-derived materials” to brain where they could either seed amyloid deposits and/or increase neuroinflammation. Recent studies have suggested that the gut microbiome plays an important role in AD. Significant changes in the microbiome were observed in human AD patients compared to control populations. However, whether these changes are the cause or consequence of the disease is not known. Though many of the microbiome components are implicated in either susceptibility or pathogenesis of AD, the molecular mechanisms of such interactions remains unknown.
- To test whether microbes modulate AD pathogenesis, transgenic C. elegans strains expressing human APOE4 were developed. These transgenic C. elegans strains expressed human APOE4 in the gut of C. elegans under the control of an intestinal promoter along with a signal sequence that allows the human APOE4 to be secreted out of the cell [e.g., mbEx2(pvha-6::ssapoe4)], or without a signal sequence [e.g., mbEx1(pvha-6::apoe4)]. In C. elegans, there is no liver and the gut perform all the functions that liver typically does. Animals were administered with the E. coli OP50 standard laboratory strain. Animals were monitored from day1 adulthood every alternative day until all were paralyzed. For each assay, at least 20 animals (as listed in TABLE 4) were recorded. Data from three independent trials was obtained. For each data point, mean±s.d is presented in the graph of
FIG. 1 . Transgenic animals expressing human APOE4 with or without the signal sequence did not show any apparent phenotypes (FIG. 1 ). - Expression of human Aβ1-42 in the C. elegans muscles has been reported to induce paralysis phenotype. (Link, C. D. (1995). Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A 92, 9368-9372, which is incorporated herein by reference). To determine whether human APOE4 modulates a paralysis phenotype induced by human Aβ1-42 in the muscles, animals listed in TABLE 4 were analyzed.
-
TABLE 4 C. elegans Expressed mbEx1(pvha-6::apoe4) APOE4 without signal sequence mbEx2(pvha-6::ssapoe4) APOE4 with signal sequence dvls2(punc-54::Abeta1-42) Aβ1-42 mbEx1(pvha-6::apoe4); APOE4 without signal sequence; Aβ1-42 dvls2(punc-54::Abeta1-42) mbEx2(pvha-6::ssapoe4); APOE4 with signal sequence; Aβ1-42 dvls2(punc-54::Abeta1-42) - Expression of APOE4 with a signal sequence enhanced the Aβ-induced paralysis phenotype. While ˜40% of animals that expressed Aβ were paralyzed, >90% of animals that expressed both Aβ and APOE4 with a signal sequence were paralyzed by
day 8 of adulthood (FIG. 1 ). However, the paralysis phenotype of animals that expressed Aβ and APOE4 without a signal sequence was similar to that of animals that expressed Aβ by itself (FIG. 1 ). In contrast, expressing APOE4 by itself, with or without the signal sequence, in the absence of Aβ expression did not induce paralysis phenotype adulthood (FIG. 1 ). - For the remainder of the studies described herein, a strain that expressed APOE4 with a signal sequence, which will be referred to ssApoE4, was analyzed.
- Expression of human Aβ3-42 conjugated with GFP in C. elegans muscles has been reported to cause aggregate formation. (Link, C. D., Fonte, V., Roberts, C. M., Hiester, B., Silverman, M. A., and Stein, G. H. (2008). The beta amyloid peptide can act as a modular aggregation domain. Neurobiol. Dis. 32, 420-425, which is incorporated herein by reference). To determine whether expression of human ssApoE4 affects Aβ aggregate formation in C. elegans, animals that express human ssApoE4 along with human Aβ3-42 conjugated to GFP were generated. Animals listed in TABLE 5 below were administered with the E. coli OP50 standard laboratory strain.
-
TABLE 5 C. elegans Expressed GFP::A-Beta (3-42) Aβ3-42 ssApoE4::GFP::A-Beta (3-42) APOE4 with signal sequence; Aβ3-42 - GFP aggregates in the anterior region of the animal were counted when the animals reached adulthood. For each assay, at least 17 animals were recorded. For each data point, mean±s.d is presented in the graph of
FIG. 2 . Compared to animals expressing Aβ3-42, animals expressing Aβ3-42 and ssApoE4 had significantly increased GFP aggregates as analyzed using Student's t-test, P<0.0001. - Compared to the number of aggregates in the anterior area of animals that expressed human Aβ3-42 conjugated to GFP, the number of aggregates in animals that expressed both Aβ3-42 conjugated to GFP and human ssApoE4 was significantly increased (
FIG. 2 ). Interestingly, Aβ deposition in AD patients has been reported to be higher in APOE4 carriers in comparison with non-carriers. (Dorey, E., Chang, N., Liu, Q. Y., Yang, Z., and Zhang, W. (2014). Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. Neurosci. Bull. 30, 317-330, which is incorporated herein by reference). - Hyperphosphoryated tau has been reported to be associated with AD. Expression of pseudohyperphosphorylated tau, which mimics AD-relevant modification, was further reported to induce progressive age-dependent locomotion defects in C. elegans. (Brandt, R., Gergou, A., Wacker, I., Fath, T., and Hutter, H. (2009). A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol. Aging 30, 22-33, which is incorporated herein by reference).
- To analyze whether ssAPOE4 modulates tau-induced defects in C. elegans, a transgenic strain that expressed pseudohyperphosphorylated human tau and human ssAPOE4 was generated. Animals of the appropriate genotypes were administered with the E. coli op50 standard laboratory strain. No apparent differences locomotion was observed in between the strain that expressed pseudohyperphosphorylated human tau and human ssAPOE4 compared to the strain that expressed the pseudohyperphosphorylated human tau strain alone (data not shown).
- Proper proteasomal function is important for cellular function and previous studies in the field have shown that proteasomal function is impaired in human AD (Bonet-Costa, V., et al. (2016). The Proteasome and Oxidative Stress in Alzheimer's Disease. Antioxid. Redox Signal. 25, 886-901; Upadhya, S. C., and Hegde, A. N. (2007). Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem. 8, S12; Oddo, S. (2008). The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med. 12, 363-373; Zheng, Q., et al. (2016). Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. Front. Aging Neurosci. 8, each of which is incorporated herein by reference). To determine whether ssApoE4 expression affects proteasomal function, animals that carry human ssApoE4 and a marker for impaired proteasomal function were generated (TABLE 6). The proteasomal dysfunction marker consists of a noncleavable ubiquitin that is N-terminally fused to GFP (UbV-GFP).
-
TABLE 6 C. elegans Expressed UbV-GFP ubiquitin N-terminally fused to GFP ssapoe4; APOE4 with signal sequence; ubiquitin N-terminally UbV-GFP fused to GFP Tau352(PHP); Pseudohyperphosphorylated tau protein; ubiquitin N- UbV-GFP terminally fused to GFP ssapoe4; APOE4 with signal sequence; Tau352(PHP); Pseudohyperphosphorylated tau protein; ubiquitin N- UbV-GFP terminally fused to GFP - The number of animals expressing GFP in the gut were counted when the animals reached adulthood. For each assay, at least 30 animals were recorded. Data from three independent trials are presented in (
FIG. 3 ). For each data point, mean±s.d is presented in the graph. Compared to animals that expressed tau352(PHP), animals expressing ssAPOE4 and tau352(PHP) had significantly increased UbV-GFP expression, as analyzed using Student's t-test, P<0.0001. - Generally, UbV-GFP undergoes proteasomal-dependent degradation, while impaired proteostasis causes stabilization of the GFP (see, e.g.,
FIG. 3 ). Minimal or no GFP expression was observed in animals expressing human ssApoE4; however, the UbV-GFP was stabilized in animals expressing both human ssApoE4 and human pseudohyperphosphorylated human tau (FIG. 3 ). Pseudohyperphosphorylated human tau expression itself did not induce proteasomal stress (FIG. 3 ). This result suggested that expression of human ssApoE4 and human pseudohyperphosphorylated human tau induces proteasomal stress. - Hyperphosphorylated Tau has previously been reported to be resistant to proteasomal degradation (Poppek, D., Keck, S., Ermak, G., Jung, T., Stolzing, A., Ullrich, O., Davies, K. J. A., and Grune, T. (2006). Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem. J. 400, 511-520, which is incorporated herein by reference) and tau phosphorylation was reported to modulate proteasomal activity (Ren, Q.-G., Liao, X.-M., Chen, X.-Q., Liu, G.-P., and Wang, J.-Z. (2007). Effects of tau phosphorylation on proteasome activity. FEBS Lett. 581, 1521-1528; Johnson, G. V. W. (2006). Tau phosphorylation and proteolysis: insights and perspectives. J. Alzheimers Dis.
JAD 9, 243-250, which is incorporated herein by reference). In the C. elegans transgenic strain, human pseudohyperphosphorylated human tau was expressed in the neurons, while human ssApoE4 was expressed under the control of intestinal promoter along with signal sequences, which allowed it be secreted out of the cell. The induction of UbV-GFP was primarily observed in the intestine of the animals (not shown). The intestine is large prominent tissue in C. elegans, which may mask the induction of UbV-GFP in other tissues. However, induction of UbV-GFP in the intestine provided an easy visual screening for interventions that might modify the proteasomal function. - Animals of the appropriate genotypes were administered with either E. coli OP50 standard laboratory strain or individual microbiome strains. Number of paralyzed animals were recorded on
day 4 of adulthood. Data from three independent trials are presented. For each data point, mean±s.d is presented in the graph. See Table 1 below for the raw data with number of animals analyzed for each condition. - To facilitate rapid screening of a microbiome for modulators, a novel transgenic C. elegans strain that expresses human ssApoE4, human Aβ1-42, human pseudophosphorylated tau and UbV-GFP proteasomal marker was generated. This transgenic strain can be employed for not only identifying interventions that suppress paralysis, but also for agents that improve proteasomal function. Further, this model could be used for finding parameters or features of a biological pathway affect (enhance or decrease) paralysis. Parameters or features could be small molecules, metabolites, nucleic acids, proteins, lipids, or even microbiome components. Approximately 1400 individual microbial strains from a human microbiome were administered to animals carrying human ssApoE4, human Aβ1-42, human pseudophosphorylated tau and UbV-GFP proteasomal marker. A degree of paralysis was observed. A group of microbial populations were found to enhance a paralysis phenotype of animals expressing human ssApoE4, human Aβ1-42, human pseudophosphorylated tau and UbV-GFP proteasomal marker (Table 7;
FIG. 4 ). Enhancement of paralysis was dependent on the presence of ssAPOE4 because administration of many of these bacteria to animals that express human Aβ1-42, human pseudophosphorylated tau and UbV-GFP proteasomal marker did not enhance the paralysis phenotype (Table 7;FIG. 4 ). -
TABLE 7 % animal paralyzed (n) in strain expressing % animals paralyzed ssAPOE4, Tau352(PHP) (n) in strain expressing Microbial isolate and Aβ Tau352(PHP) and Aβ E. coli OP50 40.6 ± 1.8 (305) 5.5 ± 2.1 (288) E. coli isolate 2 91.6 ± 1.1 (297) 6.3 ± 3.7 (298) E. coli isolate 6 85.6 ± 2.1 (298) 5.6 ± 2.9 (305) E. coli isolate 7 83.9 ± 7.1 (299) 5.0 ± 1.7 (301) E. coli isolate 3 51.2 ± 1.1 (299) 5.4 ± 1.6 (299) E. coli isolate 5 52.9 ± 1.1 (295) 5.3 ± 1.5 (300) E. coli isolate 12 71.9 ± 1.8 (281) 5.1 ± 2.1 (297) E. coli isolate 15 71.1 ± 2.4 (301) 5.7 ± 2.2 (297) E. coli isolate 8 63.6 ± 1.0 (299) 6.0 ± 1.0 (301) E. coli isolate 21 68.2 ± 2.7 (285) 6.0 ± 1.9 (300) E. coli isolate 13 50.7 ± 0.3 (302) 5.2 ± 1.6 (286) E. coli isolate 11 51.7 ± 1.8 (302) 5.5 ± 1.4 (289) Escherichia fergusonii isolate 2 68.3 ± 2.4 (297) 5.2 ± 0.2 (290) Escherichia fergusonii isolate 4 76.0 ± 4.2 (304) 5.8 ± 2.0 (292) Escherichia fergusonii isolate 5 82.7 ± 4.4 (304) 5.4 ± 0.7 (299) Escherichia fergusonii isolate 8 63.5 ± 1.8 (296) 6.3 ± 0.6 (304) Escherichia albertii isolate 5 57.1 ± 6.1 (291) 5.6 ± 2.1 (302) Escherichia albertii isolate 3 56.0 ± 8.1 (300) 5.5 ± 0.5 (292) Escherichia albertii isolate 8 57.7 ± 10.0 (299) 5.5 ± 1.4 (290) Escherichia albertii isolate 4 67.6 ± 5.3 (297) 5.5 ± 0.8 (293) Klebsiella oxytoca isolate 1 75.5 ± 5.3 (295) 8.7 ± 1.2 (299) Klebsiella oxytoca isolate 8 55.6 ± 4.3 (300) 8.1 ± 0.6 (308) Klebsiella oxytoca isolate 4 51.7 ± 1.3 (302) 7.5 ± 1.3 (305) Klebsiella oxytoca isolate 5 86.7 ± 1.2 (293) 7.6 ± 2.8 (284) Klebsiella pneumoniae isolate 1 70.8 ± 8.6 (300) 9.4 ± 1.6 (299) Klebsiella pneumoniae isolate 3 58.4 ± 3.4 (303) 12.2 ± 0.5 (296) Streptococcus downei 64.8 ± 2.0 (301) 11.6 ± 0.4 (301) Streptococcus sanguinis 90.3 ± 2.0 (299) 13.8 ± 1.2 (297) Streptococcus vestibularis 75.1 ± 4.4 (297) 13.9 ± 1.4 (297) Streptococcus mitis 80.4 ± 1.4 (305) 13.5 ± 0.7 (303) Streptococcus gallolyticus 60.5 ± 5.4 (296) 14.7 ± 0.5 (305) Streptococcus anginosus 56.3 ± 3.1 (297) 14.4 ± 1.5 (300) Streptococcus caprinus 77.5 ± 2.9 (298) 12.9 ± 2.2 (302) Streptococcus intermedius 60.8 ± 9.1 (303) 11.9 ± 1.2 (302) Staphylococcus aureus 70.3 ± 4.0 (303) 13.0 ± 0.3 (307) Staphylococcus epidermis 79.0 ± 1.6 (300) 13.0 ± 0.3 (301) Staphylococcus hominis 57.1 ± 8.2 (305) 11.9 ± 1.0 (287) Paenisporosarcina sp 69.8 ± 0.4 (288) 12.5 ± 0.6 (296) Paenibacillus sp. 78.1 ± 4.1 (309) 12.5 ± 0.5 (305) Sporosarcina sp. 66.8 ± 0.8 (301) 11.7 ± 1.4 (308) Paenibacillus Sp. 64.7 ± 3.1 (287) 13.0 ± 0.4 (293) Alcaligenes faecalis isolate 1 74.7 ± 9.9 (297) 7.5 ± 3.2 (294) Alcaligenes faecalis isolate 2 57.7 ± 4.1 (297) 6.3 ± 1.1 (285) Enterococcus faecium 75.7 ± 6.9 (296) 12.0 ± 1.0 (300) Enterococcus faecalis 73.3 ± 5.6 (304) 13.3 ± 0.5 (309) Deinococcus grandis 52.9 ± 0.9 (310) 12.5 ± 1.2 (312) Neisseria sp 52.7 ± 3.9 (302) 12.6 ± 1.8 (302) Rhodococcus erythropolis 44.6 ± 1.3 (316) 13.3 ± 1.2 (316) Corynebacterium amycolatum 56.2 ± 1.5 (301) 11.7 ± 4.3 (292) Actinomyces sp 58.0 ± 2.0 (300) 11.0 ± 0.1 (301) Rothia dentocariosa 92.3 ± 1.1 (299) 11.0 ± 3.7 (300) Arcobacter butzlerei 58.3 ± 2.1 (292) 13.5 ± 0.7 (304) Citrobacter freundii 58.2 ± 3.9 (301) 11.9 ± 1.5 (301) Acinetobacter baumanni 68.7 ± 1.4 (310) 8.5 ± 2.1 (299) Porphyromonas gingivalis 87.9 ± 5.1 (297) 11.4 ± 0.6 (298) Fusobacterium nucleatum 84.4 ± 4.6 (300) 10.9 ± 5.2 (302) Salmonella enterica 64.9 ± 5.0 (291) 12.9 ± 1.4 (295) Shigella flexneri 64.5 ± 6.7 (303) 9.8 ± 4.4 (306) Pseudomonas sp. 73.3 ± 8.3 (292) 11.3 ± 4.2 (292) Cardiobacterium vulvarum 57.9 ± 1.7 (302) 12.9 ± 1.9 (302) Achromabacter oxlosoxidans 61.5 ± 3.0 (296) 12.2 ± 1.1 (296) - Included in microbial populations that were observed to enhance paralysis in C. elegans animals expressing human ssApoE4, human Aβ1-42, human pseudophosphorylated tau and UbV-GFP proteasomal marker was Porphyromonas gingivalis (Table 1). P. gingivalis was identified in AD patient brain and was implicated in neurotoxic tau and amyloid deposition. (Dominy, S. S., et al. (2019). Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 5, which is incorporated herein by reference). Further, P. gingivalis has been reported to increase ubiquitin load, suggesting a disruption of proteasomal function. (Dominy et al., 2019, which is incorporated herein by reference). Oral administration of P. gingivalis was previously shown to be sufficient to induce brain infection and induction of Aβ deposits (Dominy et al., 2019, which is incorporated herein by reference).
- Animals were administered with either E. coli OP50 standard laboratory strain or individual microbiome strains. GFP aggregates in the anterior region of the animal were counted when the animals reached adulthood. GFP aggregates in three animals were counted for each condition. For each data point, mean±s.d is presented in the graph.
- Administration of P. gingivalis induced increased Aβ3-42::GFP aggregates; however, the Aβ3-42::GFP aggregates were increased significantly higher in animals expressing human ssApoE4 and Aβ3-42::GFP together (
FIG. 5 ). This result suggested that the ssApoE4 genotype has a deleterious effect in increasing the incidence AD associated symptoms. Thus, identification of a known microbial population that was previously implicated in AD validates that a transgenic human ssApoE4, pseudophosphorylated tau and Aβ expressing C. elegans platform assay. The results confirm that other microbial populations discovered might be factors that affect AD risk in humans. - Interestingly, several E. coli isolates were found that increased a paralysis phenotype, as well as caused increased Aβ3-42::GFP aggregates in a ssAPOE4 dependent fashion (TABLE 7;
FIG. 4 ;FIG. 5 ). This is interesting at least because C. elegans are fed on a standard non-pathogenic E. coli OP50 strain in the lab. Previous studies have shown that gram-negative bacterial molecules especially from E. coli are associated with AD neuropathology. (Zhan, X., Stamova, B., Jin, L.-W., DeCarli, C., Phinney, B., and Sharp, F. R. (2016). Gram-negative bacterial molecules associate with Alzheimer disease pathology. Neurology 87, 2324-2332, which is incorporated herein by reference). It is possible that these factors are not expressed or weakly expressed in E. coli OP50 strain or this could suggest strain-specific difference. The 11 strains of E. coli tested were classified into strains that had either mild, moderate or severe effect on the paralysis (TABLE 7;FIG. 4 ) or Aβ3-42::GFP aggregate phenotype (FIG. 5 ). These data suggest that strain specific differences in microbial populations could contribute the occurrence or severity of AD. - E. fergusonii and E. albertii also showed similar trends to that of E. coli. While some isolates of E. fergusonii and E. albertii increased the paralysis phenotype, others strains had either mild or moderate effects (TABLE 7). This peculiar effect on paralysis was also observed in isolates of Klebsiella oxytoca, Klebsiella pnuemoniae and Alcaligenes faecalis. This might be a general tendency for other microbial populations as well, but because of the number of strains analyzed, this feature might be missed. Thus, among other things, the present disclosure teaches that individual strains of a particular microbe can have differential effects on biological phenotype(s), specifically including disease-associated phenotype(s). In some embodiments, the present disclosure provides technologies for identifying and/or characterizing particular strains, and/or components or combinations thereof, which may achieve a particular impact on a biological phenotype.
- Further, microbiome samples from apparently healthy donors were analyzed. It is possible that AD patient microbiome samples might produce a better trend in identifying strains that might have deleterious effects. However, using this C. elegans characterization system, a patient microbiome could be assessed for increased or decreased presence of microbial strains that are associated with or, alternatively affect, disease. Though metagenomic sequencing of patient population could identify the diversity of microbial species present in a particular patient or patient population, these methods cannot identify strain-level differences in patient samples compared to healthy population. The present system fills this gap in identifying strain-level differences in patient(s) and/or patient population(s), which may be important for a number of diseases or conditions, including AD. Thus, this platform could serve us a potential early diagnostic disease predictor. Thus, among other things, the present disclosure provides technologies for defining, assessing, and/or detecting, microbes, and/or components or combinations thereof (i.e., microbial signature(s)), that may be associated with a particular disease states; in some embodiments, such microbial signatures can be detected in patient sample(s) and, for example, may be useful to diagnose a disease state, to monitor impact of a particular therapy with respect to such disease state, etc.
- The Neuro2A cell line was purchased from ATCC and cultured in EMEM media supplemented with 10% FBS, and 1% L-glutamine. Cells were maintained at 37° C./5% CO2 incubators. All experiments were carried out using only passage 3-7 cells. Neuro2A cells (5×104 cells per well) were plated onto a 96-well white-walled plate (Corning) and incubated overnight at 37° C./5% CO2. Each of the 10 bacteria or a combination of all bacteria (CT10) were grown in the following media: Reinforced Clostridial Broth, Peptone Yeast extract Glucose broth, MRS broth and Tryptic Soy Broth. The bacteria were resuspended to 108 CFU in PBS and stored at −80° C. 108 CFU of each microbe (referred as samples) was added to 6 wells. The combination of all bacteria (CT10) was added to 6 wells at 109 CFU (i.e., 108 CFU of each bacteria). For the control wells, PBS with no bacteria were added. After 16 hours of incubation at 37° C./5% CO2, 2 μM of Human Amyloid β1-42 was added to all the wells except for control untreated wells. The cells were incubated for 24 hours at 37° C./5% CO2. The cells were washed with PBS three-times and 0.05 ml of Promega CellTiter-Glo and plate was incubated at room temperature shielded from light for 1 hour. The luminescence was measured using a microplate reader (Promega discoverer, Promega Corp), indicating the ATP levels. The ATP levels were normalized to protein content, as measured by the Bradford Protein Assay kit (ThermoFisher Scientific). 10 μl of samples was added to 150 μl of Bradford reagent in clear 96-well plates in duplicates and incubated for 5 min in dark at RT and the absorbance was measured at 600 nm using a microplate reader (Promega Discoverer, Promega Corp.). The normalized luminescence was calculated by dividing the luminescence value by OD protein absorbance value. The average of the triplicate wells for each condition was calculated % ATP compared to the control was calculated.
- As shown in
FIG. 6 , treating Neuro2A cells with 2 μM of Human Amyloid β1-42 (“Mock-treated”) caused significant decrease in ATP production. While treatment of Neuro2A cells with Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp. or Acidaminococcus sp. resulted in significant increase in ATP production compared to the Mock-treated cells, a combination of all the bacteria together (CT-10) resulted in further significant increase in the ATP production in the presence of Human Amyloid β1-42. -
TABLE 8 Exemplary Microbial Strains Found in Human Gut Microbiome Bacteroides pectinophilus Exiguobacterium mexicanum Acetobacter sp Faecalibacterium prausnitzii Acetobacterium tundrae Faecalitalea cylindroides Achromobacter aegrifaciens Finegoldia magna Achromobacter insuavis Flavonifractor plautii Achromobacter piechaudii Flintibacter butyricus Achromobacter xylosoxidans Fusicatenibacter saccharivorans Acidaminococcus fermentans Fusobacterium gonidiaformans Acidaminococcus intestini Fusobacterium mortiferum Acinetobacter baumannii Fusobacterium nucleatum Acinetobacter junii Fusobacterium ulcerans Actinomyces sp. Fusobacterium varium Agathobacter rectalis Gardnerella vaginalis Agathobaculum butyriciproducens Gemella haemolysans Aggregatibacter segnis Gemella sanguinis Akkermansia muciniphila Gemmiger formicilis Alistipes finegoldii Gluconacetobacter sp Alistipes indistinctus Gluconobacter sp Alistipes onderdonkii Gordonibacter pamelaeae Alistipes putredinis Granulicatella adiacens Alistipes shahii Grimontia hollisae Allisonella histaminiformans Haemophilus parainfluenzae Anaerobaculum hydrogeniformans Harryflintia acetispora Anaerococcus hydrogenalis Helicobacter bilis Anaerococcus octavius Helicobacter bizzozeronii Anaerococcus prevotii Helicobacter canadensis Anaerococcus tetradius Helicobacter cinaedi Anaerococcus vaginalis Helicobacter pullorum Anaerofilum agile Helicobacter pylori Anaerofustis stercorihominis Helicobacter winghamensis Anaerosporobacter mobilis Holdemanella biformis Anaerostipes caccae Holdemania filiformis Anaerostipes hadrus Holdemania massiliensis Anaerostipes rhamnosivorans Hungatella effluvii Anaerotruncus colihominis Hungatella hathewayi Anaerovorax odorimutans Intestinimonas butyriciproducens Arcobacter butzleri Kineothrix alysoides Asaccharobacter celatus Kingella oralis Atopobium parvulum Klebsiella pneumoniae Atopobium vaginae Klebsiella pneumoniae subsp. ozaenae Bacillus cereus Klebsiella pneumoniae subsp. pneumoniae Bacillus coagulans Klebsiella pneumoniae subsp. rhinoscleromatis Bacillus licheniformis Klebsiella quasipneumoniae subsp. quasipneumoniae Bacillus pseudomycoides Klebsiella singaporensis Bacillus sonorensis Klebsiella variicola Bacillus toyonensis Lachnobacterium bovis Bacillus wiedmannii Lachnospira multipara Bacteroides caccae Lachnospira pectinoschiza Bacteroides cellulosilyticus Lactobacillus acidophilus Bacteroides clarus Lactobacillus amylolyticus Bacteroides coprocola Lactobacillus amylovorus Bacteroides coprophilus Lactobacillus antri Bacteroides dorei Lactobacillus brevis subsp. Gravesensis Bacteroides eggerthii Lactobacillus buchneri Bacteroides faecis Lactobacillus casei Bacteroides finegoldii Lactobacillus coryniformis subsp. Coryniformis Bacteroides fluxus Lactobacillus crispatus Bacteroides fragilis Lactobacillus delbrueckii subsp. Bulgaricus Bacteroides intestinalis Lactobacillus delbrueckii subsp. indicus Bacteroides massiliensis Lactobacillus delbrueckii subsp. Lactis Bacteroides nordii Lactobacillus fermentum Bacteroides oleiciplenus Lactobacillus fructivorans Bacteroides ovatus Lactobacillus gasseri Bacteroides plebeius Lactobacillus helveticus Bacteroides salanitronis Lactobacillus hilgardii Bacteroides salyersiae Lactobacillus iners Bacteroides stercoris Lactobacillus jensenii Bacteroides thetaiotaomicron Lactobacillus johnsonii Bacteroides uniformis Lactobacillus mucosae Bacteroides vulgatus Lactobacillus oris Bacteroides xylanisolvens Lactobacillus paracasei Bacteroides xylanolyticus Lactobacillus paracasei subsp. tolerans Barnesiella intestinihominis Lactobacillus pentosus Bartonella clarridgeiae Lactobacillus plantarum subsp. plantarum Bartonella quintana str. Toulouse Lactobacillus reuteri Bifidobacterium adolescentis Lactobacillus rhamnosus Bifidobacterium angulatum Lactobacillus rogosae Bifidobacterium animalis Lactobacillus ruminis Bifidobacterium bifidum Lactobacillus salivarius Bifidobacterium breve Lactobacillus ultunensis Bifidobacterium catenulatum Lactobacillus vaginalis Bifidobacterium coryneforme Lactococcus formosensis Bifidobacterium dentium Lactococcus garvieae Bifidobacterium faecale Lactococcus lactis subsp. Cremoris Bifidobacterium gallicum Lactococcus lactis subsp. lactis Bifidobacterium longum Lactonifactor longoviformis Bifidobacterium longum subsp. infantis Laribacter hongkongensis Bifidobacterium longum subsp. longum Lautropia mirabilis Bifidobacterium longum subsp. suis Leptotrichia buccalis Bifidobacterium pseudocatenulatum Leptotrichia hofstadii Bifidobacterium pseudolongum Leuconostoc lactis Bifidobacterium stercoris Leuconostoc mesenteroides subsp. Cremoris Bilophila wadsworthia Listeria grayi Bittarella massiliensis Listeria monocytogenes Blautia coccoides Longicatena caecimuris Blautia faecis Marvinbryantia formatexigens Blautia glucerasea Megamonas funiformis Blautia hansenii Megamonas rupellensis Blautia hydrogenotrophica Megasphaera elsdenii Blautia luti Megasphaera indica Blautia obeum Megasphaera micronuciformis Blautia producta Megasphaera paucivorans Blautia schinkii Methanobrevibacter smithii Blautia stercoris Methanomassiliicoccus luminyensis Blautia wexlerae Methanosphaera stadtmanae Bradyrhizobium japonicum Methylobacterium radiotolerans Burkholderia ambifaria Mitsuokella jalaludinii Burkholderia cenocepacia Mitsuokella multacida Burkholderia glumae Mobiluncus mulieris Burkholderia multivorans Mogibacterium timidum Burkholderia plantarii Mogibacterium vescum Butyricicoccus faecihominis Moraxella catarrhalis Butyricicoccus pullicaecorum Morganella morganii subsp. morganii Butyricimonas faecihominis Murdochiella asaccharolytica Butyricimonas paravirosa Mycobacterium abscessus Butyricimonas virosa Mycobacterium tuberculosis Butyrivibrio crossotus Mycoplasma hominis Campylobacter coli Neisseria cinerea Campylobacter concisus Neisseria flavescens Campylobacter curvus Neisseria macacae Campylobacter gracilis Neisseria mucosa Campylobacter hominis Neisseria sicca Campylobacter jejuni subsp. Jejuni Neisseria subflava Campylobacter showae Nitrobacter hamburgensis Campylobacter upsaliensis Nitrobacter winogradskyi Candidatus Dorea massiliensis Odoribacter laneus Candidatus Stoquefichus massiliensis Odoribacter splanchnicus Capnocytophaga gingivalis Olsenella profusa Capnocytophaga sputigena Olsenella scatoligenes Cardiobacterium hominis Olsenella uli Catenibacterium mitsuokai Oribacterium sinus Catonella morbi Oscillibacter ruminantium Cedecea lapagei Oscillibacter valericigenes Citrobacter amalonaticus Oscillospira guilliermondii Citrobacter freundii Oxalobacter formigenes Citrobacter koseri Paenibacillus jamilae Citrobacter youngae Paenibacillus kribbensis Clostridium acetobutryicum Paenibacillus riograndensis Clostridium aerotolerans Paeniclostridium sordellii Clostridium aldenense Parabacteroides distasonis Clostridium aminophilum Parabacteroides goldsteinii Clostridium aminovalericum Parabacteroides gordonii Clostridium amygdalinum Parabacteroides johnsonii Clostridium asparagiforme Parabacteroides merdae Clostridium baratii Paraprevotella clara Clostridium bartlettii Paraprevotella xylaniphila Clostridium beijerinckii Parasutterella excrementihominis Clostridium bifermentans Parasutterella secunda Clostridium bolteae Parvimonas micra Clostridium butyricum Pediococcus acidilactici Clostridium celerecrescens Pediococcus pentosaceus Clostridium cf. saccharolyticum Peptoniphilus duerdenii Clostridium citroniae Peptoniphilus grossensis Clostridium clariflavum Peptoniphilus harei Clostridium clostridioforme Peptoniphilus indolicus Clostridium cocleatum Peptostreptococcus anaerobius Clostridium colinum Phascolarctobacterium faecium Clostridium difficile Phascolarctobacterium succinatutens Clostridium glycyrrhizinilyticum Porphyromonas asaccharolytica Clostridium hathewayi Porphyromonas endodontalis Clostridium herbivorans Porphyromonas gingivalis Clostridium hiranonis Prevotella bivia Clostridium hylemonae Prevotella buccae Clostridium innocuum Prevotella copri Clostridium lactatifermentans Prevotella disiens Clostridium lavalense Prevotella marshii Clostridium leptum Prevotella melaninogenica Clostridium methoxybenzovorans Prevotella nigrescens Clostridium methylpentosum Prevotella pallens Clostridium nexile Prevotella salivae Clostridium orbiscindens Prevotella stercorea Clostridium oroticum Prevotella tannerae Clostridium perfringens Prevotella timonensis Clostridium polysaccharolyticum Propionibacterium acnes Clostridium propionicum Propionibacterium avidum Clostridium ramosum Propionibacterium namnetense Clostridium rectum Proteus mirabilis Clostridium saccharogumia Proteus penneri Clostridium saccharolyticum Providencia alcalifaciens Clostridium sardiniense Providencia rettgeri Clostridium saudii Providencia rustigianii Clostridium scindens Providencia stuartii Clostridium sordellii Pseudoflavonifractor capillosus Clostridium sphenoides Ralstonia sp. Clostridium spiroforme Robinsoniella peoriensis Clostridium sporogenes Roseburia cecicola Clostridium sticklandii Roseburia faecis Clostridium straminisolvens Roseburia hominis Clostridium symbiosum Roseburia intestinalis Clostridium tertium Roseburia inulinivorans Clostridium thermocellum Rothia dentocariosa Clostridium xylanolyticum Ruminococcus albus Clostridium xylanovorans Ruminococcus bromii Collinsella aerofaciens Ruminococcus callidus Collinsella intestinalis Ruminococcus faecis Collinsella stercoris Ruminococcus gnavus Collinsella tanakaei Ruminococcus lactaris Coprobacillus cateniformis Ruminococcus obeum Coprobacter fastidiosus Ruminococcus torques Coprococcus catus Ruthenibacterium lactatiformans Coprococcus comes Sarcina ventriculi Coprococcus eutactus Sellimonas intestinalis Corynebacterium ammoniagenes Senegalimassiiia anaerobia Corynebacterium matruchotii Shigella boydii Corynebacterium pseudogenitalium Shigella dysenteriae Corynebacterium tuberculostearicum Shigella flexneri Deinococcus radiodurans Shigella sonnei Dermabacter hominis Slackia faecicanis Desuifotomaculum guttoideum Slackia isoflavoniconvertens Desulfovibrio legallis Slackia piriformis Desulfovibrio piger Solobacterium moorei Dialister invisus Staphylococcus caprae Dialister microaerophilus Staphylococcus epidermidis Dialister succinatiphilus Staphylococcus hominis subsp. Hominis Dielma fastidiosa Staphylococcus lugdunensis Dorea formicigenerans Staphylococcus warneri Dorea longicatena Streptococcus agalactiae Dysgonomonas mossii Streptococcus anginosus Edwardsiella tarda Streptococcus anginosus subsp. whileyi Eggerthella lenta Streptococcus australis Eggerthella sinensis Streptococcus bovis Eikenella corrodens Streptococcus constellatus subsp. constellatus Eisenbergiella tayi Streptococcus equinus Enhydrobacter aerosaccus Streptococcus gallolyticus subsp. pasteuri Enterobacter aerogenes Streptococcus gallolyticus subsp. pasteurianus Enterobacter asburiae Streptococcus gordonii Enterobacter cancerogenus Streptococcus gordonii str. Challis Enterobacter cloacae Streptococcus infantarius Enterobacter hormaechei Streptococcus infantarius subsp. coli Enterobacter kobei Streptococcus infantarius subsp. Infantarius Enterobacter ludwigii Streptococcus infantis Enterobacter xiangfangensis Streptococcus lactarius Enterococcus asini Streptococcus lutetiensis Enterococcus avium Streptococcus mutans Enterococcus casseliflavus Streptococcus parasanguinis Enterococcus durans Streptococcus pasteurianus Enterococcus faecalis Streptococcus pleomorphus Enterococcus faecium Streptococcus rubneri Enterococcus gallinarum Streptococcus salivarius Enterococcus hirae Streptococcus salivarius subsp. salivarius Enterococcus mundtii Streptococcus sanguinis Enterococcus raffinosus Streptococcus thermophilus Enterococcus raffinosus Streptococcus vestibularis Erysipelotrichaceae bacterium Subdoligranulum variabile Escherichia albertii Succinatimonas hippei Escherichia coli Sutterella parvirubra Escherichia fergusonii Sutterella stercoricanis Eubacterium biforme Sutterella wadsworthensis Eubacterium callanderi Terrisporobacter glycolicus Eubacterium contortum Turicibacter sanguinis Eubacterium cylindroides Ureaplasma parvum Eubacterium desmolans Vagococcus penaei Eubacterium dolichum Varibaculum cambriense Eubacterium eligens Veillonella sp. Eubacterium hadrum Veillonella dispar Eubacterium hallii Veillonella parvula Eubacterium infirmum Veillonella rogosae Eubacterium limosum Veillonella tobetsuensis Eubacterium oxidoreducens Vibrio cholerae Eubacterium ramulus Vibrio furnissii Eubacterium rectale Vibrio mimicus Eubacterium ruminantium Victivallis vadensis Eubacterium saburreum Weissella cibaria Eubacterium siraeum Weissella confusa Eubacterium sulci Weissella paramesenteroides Eubacterium tortuosum Xenorhabdus nematophila Eubacterium ventriosum Yersinia enterocolitica subsp. Palearctica Eubacterium xylanophilum Yersinia pseudotuberculosis Eubacterium yurii subsp. Margaretiae - Hypoxia inducible factor (HIF) pathway mediates a diversity of metabolic and physiological adaptations to reduced oxygen levels in cells. Activation of the HIF pathway promotes erythropoiesis and angiogenesis to reduce the cellular requirement for oxygen. Though the HIF pathway is important for cellular stress response, constitutive activation of HIF-1 leads to neovascularization in conditions such as diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, and glaucoma. Thus, developing modulators of HIF pathway is essential for the treatment of ocular neovascular diseases.
- The HIF-1 pathway consists of the HIF transcription factor and the negative regulator, the prolyl hydroxylase EGLN. EGLN functions as oxygen sensor and in the presence of oxygen it hydroxylates the HIF α-subunit (HIFα). Hydroxylation of HIFα leads to binding to von Hippel-Lindau (VHL) E3 ubiquitin ligase, among other factors, which promote HIFα degradation (see
FIG. 7 ). Under low oxygen conditions, HIFα protein is stabilized and it promotes transcriptional activation of genes required for adaptation to low oxygen levels. - In C. elegans, egl-9 encodes the EGLN homolog. In egl-9 loss-of-function (egl-9 lf) C. elegans mutants, HIF-1, which is the homolog of HIF1α, protein levels are stabilized. Thus, the HIF1 protein is constitutively active leading to continuous activity of HIF-1 transcriptional target genes. To identify microbes that regulate HIF-1 pathway, egl-9 loss-of-function (egl-9 lf) C. elegans mutants were analyzed. egl-9 lf mutant C. elegans have constitutively active HIF-1, which results in them being defective in laying eggs. Therefore, they become bloated with eggs as adults.
- HIF-1 modulators were identified by screening individual bacterial strains for the ability to suppress the egg laying defect of egl-9 lf mutant. While wildtype animals lay 8±2 (n=30) eggs per hour, egl-9 lf mutants lay 2±1 (n=30) eggs/hour. The egl-9 lf C. elegans mutants were administered with each individual microbe and the respective egg-laying rate was measured. In this assay, it was found that Gluconacetobacter spp and Bifidobacterium spp significantly enhanced the egg-laying rate of egl-9 lf C. elegans mutants to 11±2 (n=25) and 8±2 (n=29) respectively (see Table 9). This example demonstrates that microbial strains, such as those in Table 9, can modulate HIF-1 and a HIF-1 pathway, and can be used to ameliorate conditions and diseases associated with an alteration of a HIF-1 pathway.
-
TABLE 9 egl-9 lf C. elegans Egg-laying Number of administered with rate animals tested E. coli OP50-1 2 ± 1 30 Gluconacetobacter hansenii 11 ± 2 25 Terrisporobacter glycolicus 3 ± 1 32 Coprococcus sp. 1 ± 1 28 L. plantarum 2 ± 2 29 Clostridium butyricum 3 ± 1 31 Paenibacillus barengoltzii 1 ± 2 27 Veillonella atypica 1 ± 1 30 Bifidobacterium 8 ± 2 29 Bacillus subtilis 4 ± 2 28 Acidaminococcus sp 3 ± 2 31 - It is to be appreciated by those skilled in the art that various alterations, modifications, and improvements to the present disclosure will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of the present disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawing are by way of example only and any invention described in the present disclosure if further described in detail by the claims that follow.
- Those skilled in the art will appreciate typical standards of deviation or error attributable to values obtained in assays or other processes as described herein. The publications, websites and other reference materials referenced herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference in their entireties.
- It is to be understood that while embodiments of the invention have been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (23)
1.-62. (canceled)
63. A composition comprising one or more microbial strains listed in TABLE 8.
64. The composition of claim 63 , comprising two or more microbial strains listed in TABLE 8.
65. The composition of claim 63 , comprising five or more microbial strains listed in TABLE 8.
66. The composition of claim 63 , comprising 10 or more microbial strains listed in TABLE 8.
67. A composition comprising Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or a combination thereof.
68. The composition of claim 67 , comprising at least two microbial strains selected from the group consisting of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, and Acidaminococcus sp.
69. The composition of claim 67 , comprising at least five microbial strains selected from the group consisting of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium, Bacillus subtilis, and Acidaminococcus sp.
70. The composition of claim 67 , comprising Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., L. plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, and Acidaminococcus sp.
71. The composition of claim 67 , wherein the composition is a pharmaceutical composition.
72. The composition of claim 67 , wherein the composition is an ingestible item.
73. A method of treating a disease or condition in a subject, comprising administering to a subject in need a composition comprising the composition of claim 67 .
74. The method of claim 73 , wherein the disease or condition is a neurodegenerative disease or disorder.
75. The method of claim 73 , wherein the disease or condition is Alzheimer's disease.
76. The method of claim 73 , wherein the disease or condition is associated with an altered or defective HIF-1 pathway.
77. The method of claim 73 , wherein the disease or condition is an ocular neovascular disease or disorder.
78. The method of claim 73 , wherein the disease or condition is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
79. Use of a composition of claim 67 in the treatment of a disease or condition in a subject.
80. The use of claim 79 , wherein the disease or condition is a neurodegenerative disease or disorder.
81. The use of claim 79 , wherein the disease or condition is Alzheimer's disease.
82. The use of claim 79 , wherein the disease or condition is associated with an altered or defective HIF-1 pathway.
83. The use of claim 79 , wherein the disease or condition is an ocular neovascular disease or disorder.
84. The use of claim 79 , wherein the disease or condition is diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, or glaucoma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/673,581 US20220256823A1 (en) | 2019-09-12 | 2022-02-16 | Compositions and methods for characterizing a microbiome |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962899718P | 2019-09-12 | 2019-09-12 | |
US202062988132P | 2020-03-11 | 2020-03-11 | |
US17/019,183 US11284609B2 (en) | 2019-09-12 | 2020-09-11 | Compositions and methods for characterizing a microbiome |
US17/673,581 US20220256823A1 (en) | 2019-09-12 | 2022-02-16 | Compositions and methods for characterizing a microbiome |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/019,183 Continuation US11284609B2 (en) | 2019-09-12 | 2020-09-11 | Compositions and methods for characterizing a microbiome |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220256823A1 true US20220256823A1 (en) | 2022-08-18 |
Family
ID=74868862
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/019,183 Active US11284609B2 (en) | 2019-09-12 | 2020-09-11 | Compositions and methods for characterizing a microbiome |
US17/673,581 Pending US20220256823A1 (en) | 2019-09-12 | 2022-02-16 | Compositions and methods for characterizing a microbiome |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/019,183 Active US11284609B2 (en) | 2019-09-12 | 2020-09-11 | Compositions and methods for characterizing a microbiome |
Country Status (10)
Country | Link |
---|---|
US (2) | US11284609B2 (en) |
EP (1) | EP4028558A4 (en) |
JP (1) | JP2022547601A (en) |
KR (1) | KR20220065793A (en) |
CN (1) | CN114585752A (en) |
AU (1) | AU2020346072A1 (en) |
BR (1) | BR112022004335A2 (en) |
CA (1) | CA3153020A1 (en) |
IL (1) | IL291202A (en) |
WO (1) | WO2021051020A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021051020A2 (en) | 2019-09-12 | 2021-03-18 | MarvelBiome, Inc. | Compositions and methods for characterizing a microbiome |
CA3153779A1 (en) * | 2019-10-01 | 2021-04-08 | Jothi Amaranath GOVINDAN | Compositions and methods for extending lifespan |
KR20230175194A (en) * | 2021-03-12 | 2023-12-29 | 마블바이옴 인코포레이티드 | Methods and uses of microbiome compositions, ingredients, or metabolites for the treatment of eye disorders |
WO2023281335A1 (en) * | 2021-07-09 | 2023-01-12 | Claudio De Simone | SPECIES, STRAINS AND COMPOSITIONS OF LACTIC ACID BACTERIA CAPABLE OF MODULATING BODY OXYGENATION BY INCREASING HIF-1α LEVELS |
WO2024026339A2 (en) * | 2022-07-28 | 2024-02-01 | Resbiotic Nutrition, Inc. | Probiotic blend supplement with micronutrients for infant and children's health |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040250299A1 (en) * | 1999-04-15 | 2004-12-09 | Devgen Nv | Compound screening method |
US6540996B1 (en) * | 1999-04-15 | 2003-04-01 | Devgen Nv | Compound screening methods |
US7399900B2 (en) * | 2000-03-22 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can used in the treatment of the above disease states and identification of anematode gene |
US6894205B2 (en) | 2001-06-22 | 2005-05-17 | Vanderbilt University | Assay for toxin induced neuronal degeneration and viability in C. elegans |
US8809617B2 (en) * | 2009-11-05 | 2014-08-19 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Automated high-content live animal drug screening using C. elegans |
CN103857402A (en) * | 2011-10-11 | 2014-06-11 | 阿基姆医药公司 | Composition comprising anaerobically cultured human intestinal microbiota |
WO2021051020A2 (en) | 2019-09-12 | 2021-03-18 | MarvelBiome, Inc. | Compositions and methods for characterizing a microbiome |
-
2020
- 2020-09-11 WO PCT/US2020/050585 patent/WO2021051020A2/en active Application Filing
- 2020-09-11 JP JP2022516215A patent/JP2022547601A/en active Pending
- 2020-09-11 AU AU2020346072A patent/AU2020346072A1/en active Pending
- 2020-09-11 CA CA3153020A patent/CA3153020A1/en active Pending
- 2020-09-11 CN CN202080071998.8A patent/CN114585752A/en active Pending
- 2020-09-11 KR KR1020227011753A patent/KR20220065793A/en unknown
- 2020-09-11 EP EP20863710.8A patent/EP4028558A4/en active Pending
- 2020-09-11 US US17/019,183 patent/US11284609B2/en active Active
- 2020-09-11 BR BR112022004335A patent/BR112022004335A2/en unknown
-
2022
- 2022-02-16 US US17/673,581 patent/US20220256823A1/en active Pending
- 2022-03-08 IL IL291202A patent/IL291202A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US11284609B2 (en) | 2022-03-29 |
WO2021051020A2 (en) | 2021-03-18 |
CA3153020A1 (en) | 2021-03-18 |
AU2020346072A1 (en) | 2022-04-07 |
EP4028558A4 (en) | 2024-01-03 |
IL291202A (en) | 2022-05-01 |
KR20220065793A (en) | 2022-05-20 |
US20210076649A1 (en) | 2021-03-18 |
CN114585752A (en) | 2022-06-03 |
WO2021051020A3 (en) | 2021-04-22 |
EP4028558A2 (en) | 2022-07-20 |
BR112022004335A2 (en) | 2022-06-07 |
JP2022547601A (en) | 2022-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11284609B2 (en) | Compositions and methods for characterizing a microbiome | |
KR102682981B1 (en) | Microbial compositions containing ellagitannins and methods of use | |
US11957723B2 (en) | Methods and uses of microbiome compositions, components, or metabolites for treating neurodegenerative diseases | |
Yang et al. | Could a swimming creature inform us on intestinal diseases? Lessons from zebrafish | |
US11738056B2 (en) | Compositions and methods for improving mitochondrial function | |
US20220082552A1 (en) | Methods and uses of microbiome compositions | |
US20220330597A1 (en) | Compositions and methods for extending lifespan | |
KR20240113585A (en) | Microbial compositions comprising ellagitannin and methods of use | |
US20210230660A1 (en) | Carotenoids for treating or preventing nausea | |
Abbedissen | Characterization of the CEL-MODY mouse–A new disease model for chronic pancreatitis | |
Fu et al. | An FXR-Casp6 Axis Mediated Bile Acid/Gut Microbiota Sensing Modulates Neonatal β-Cell Mass Expansion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MARVELBIOME, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOVINDAN, JOTHI AMARANATH;JAYAMANI, ELAMPARITHI;CHATTER, PRITI H.;AND OTHERS;SIGNING DATES FROM 20201019 TO 20201023;REEL/FRAME:059047/0394 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |